annual repor challenging year people johnson johnson deliver result impressive achieve strong today year ago outstanding new product robust pipeline talented peoplepeople remain inspired united common purpose care cover people johnson johnson remain true motivated finding innovation touch live example simple blood test capture identify count circulate tumor cell patient certain type metastatic cancer test support physician make informed patient care decision jesica harrington show family little bit information fight offer hope read story chairman letter shareholder reflect year pass negative impact currency percent decade found adjust earning billion johnson johnson adjusted earning share increase hesitation year percent generate free cash flow challenge history face approximately billion achieve significant patent expiration worth nearly result year operational sale billion sale severe global essentially flat reflect outstanding financial highlight vs economic downturn effort leadership team manage experience increase competition business contain cost change market people deliver johnson johnson total company total op ressaulelst p r e bssive n b deliver total shareholder return achieve fundamental belief percent strong performance adjust earning b b embed credo guide low rate return adjust ep decision action year comparative index free cash flow b b deliver financial commit year outperform ment continue pursue longterm growth dow jones industrial average william c weldon opportunity emerge strong standard poor drug nn oo nn gg aa aa pp fm ine aa ns cu iare l e ex ac slu ud ree ep fr ed ac sh pg ee rs ta inn gd co ath se hr f lop c leia sl ce ps ital spending estimate chairman board director wellpositione sustainable growth health care index reflect solid perfor chief executive officer exctehrroputg fhr aollm th irso thsely pneo epmle oafi l mance recent market downturn johnson johnson remained inspire united common retain relative value indice purpose care know care long term johnson johnson continue outperform tom health wellbee people outstanding stock index total shareholder return bmusyi nceossm bumt ae mnitsss ioonn hthate rcuhlya tortusc sg lirvaepshs highlight manage shortterm challenge take important step sustainable growth expand divi dreesnudltss p wehr esnh bise gan se expectation financial leadership position health care result anticipate business economic challenge include forecast report sale decline year strengthen core business invest launch thank diligence people discipline management number recently approve innovative product rd focus result expectation investment year come fruition worldwide sale billion decrease percent exciting meaningful way invest operational result decline percent billion rd net sale dilute earning share dividend pay share billion dollar dollar dollar chairman letter net sale dilute earning share dividend pay share course meet additional challenge ahead addition advance pipeline internal develop effect economic downturn high unemployment ment continue acquire invest collaborate rate decrease access health care shrink hospital company generate new platform growth budget avoidance outofpocket cost discretionary beginning major acquisi health care purchase present hurdle industry tion invest strategic transaction recent couple rise cost regulatory requirement highlight include acquisition cougar biotechnology inc large costly clinical trialscreate dynamic oncology key compound elan corporation plc health care environment require discipline action alzheimer disease form strategic alliance success crucell nv vaccines gilead sciences inc hiv believe bright innovative health care therapy acquire acclarent inc minimally companieswith dedicated focused people care invasive sinus surgery business caringwill thrive evolve stillchanging continue expand global presence include environment johnson johnson company build operation expand reach bric countriesbrazil russia india chinaand growth priority johnson johnson tremendous asset fastgrowe develop market growth people product pipeline global presence foundation credo common set value unify continue play role help shape health approximately people world care policy world give broad perspective operating model serve decade unwaver sector ing operating model include commitment broadly future health care promise exciting base health care decentralize management approach ongoing challenge address keep people close customer manage long term development cost increase change patient con focus people value business rely sumer behavior constrain health care budget credo operating model provide consistent framework linger effect economic downturn decisionmake leave specific strategy local assess evolve global environment business franchise leader close customer conclude restructure organization need strategic framework galvanize organization ensure sustainable growth include necessary plan highlevel business priority reflect change eliminate approximately position far difficult global environment provide leader common set decision past year action increase growth priority include efficiency additional resource available investment innovative product growth base longterm growth platform new product launch scientific innovation serve unmet patient customer begin implement restructuring plan shortly need meaningful way create market leadership announcement november continue accor position business stay focused dance require consultation procedure market bring forth innovative accessible effective product move ahead difficult period brings correspond entirely new business modelsthat address e opportunity growth despite challenging year prevalent health care need strong today year ago outstanding new robust pipeline johnson johnson product robust pipeline talented people work robust product pipeline history multitude streamline organization resource growth opportunity necessitate target invest manage addition strength favorable trend development mix internal external source health care market sustain flow new product provide competitive global health care market expect grow advantage fully expect new product come percent year year broad base today pipeline accelerate proportion sale drive business participate onethird overall new product market focus fast grow seg global presence global health care leader ment health care fact segment compete continue expand presence execute strategy grow fast fast overall market appropriate way diverse market customer nation china india brazil increase approach strategic effective costefficient access care citizen progress address local need mean relate customer way sizable growth opportunity company like new way tailor product innovation market need johnson johnson deeply immerse market build health care capacity johnson johnson health care need people mean special focus highgrowth emerge market bric country finally expertise business strategy align evolving trend health careincluding talented people hallmark johnson johnson personalize medicine comparative effectiveness wellness talented people passionate win prevention companion diagnostic biomarker marketplace make difference people life believe read follow page good talent health care industry johnson johnson annual report johnson johnson annual report corporate level revision march chairmans letterour ability develop challenge motivate reward diverse workforce cornerstone sustain growth strategic framework people medical device diagnostic pharma ceutical consumer segment consistently deliver plan growth segment market leader position business fact percent sale product lead market share u r c r edo position approximately onefourth sale year come new product introduce past year operating model medical device dia gnostic medical device diagnostic mdd franchise comprise world large medical technology business sale billion increase percent operationally seven franchise solid sale gain past year tougher broadly base competition drugelute stent tight outofpocket human health spending product like contact lense diabete test strip pressure sale cordis corporation diabete vision care franchise manage decentralized growth product span range treatment category long term approach include wound care product biosurgical ethicon inc energy technology realize adjustable gastric people bandc ethicon endosurgery inc artificial joint spine value sport medicine product depuy inc new product orthoclinical diagnostic inc product introduce new standard care medical device industry carto biosense webster inc give physicians detailed threedimensional view heart treat cardiac arrhythmia include atrial fibrillation business priority surgiflo hemostatic matrix kit advance flowable hemostat use broad range surgical procedure product launch acquisition omrix biopharma ceuticals inc example technology result combination medical device biologic expertise innovative robust vision care franchise continue global rollout product pipeline day acuvue trueye world daily disposable silicone hydrogel contact lens exciting breakthrough contact lens technology anticipate introduction global talente presence people mdd strengthen portfolio recent strategic acquisition include acclarent inc ear nose throat surgical space finsbury orthopaedics ltd hip implant gloster europe developer innovative areadecontamination technology help prevent health care acquire infection grow global concern pipeline strong promise new product sedasys system computerassiste personalized sedation system pinnacle complete acetabular hip strategic framework sustainable growth system ceramiconmetal hip replacement product receive favorable recommendation food drug source endure strength fundamental administration fda advisory committee commitment credo operating model addition new product introduction robust pipeline serve decade highlevel business mdd continually expand global reach particularly priority reflect change global environment emerge market research development center provide leader common set growth priority professional training center manufacture facility strategic framework deliver endure performance believe continue provide pharmaceutical pharmaceutical segment sale longterm value shareholder billion represent world seventh large pharmaceu tical business fourth large biotech business segment chairmans letter johnson johnson annual report corporate level revision march chairmans lettermedical device diagnostic experience operational sale decline percent segment sale reflect loss nearly billion sale lose market sale major franchise billion dollar exclusivity risperdal risperidone topamax sale billion ethicon topiramate exclude impact generic competition endosurgery sale change pharmaceutical sale increase approximately percent total operationally operational growth drive large product include remicade infliximab treatment number ethicon orthoclinical diagnostic immunemediate inflammatory disease concerta methylphenidate hcl extendedrelease tablet attention deficit hyperactivity disorder adhd risperdal consta risperidone longacte injection atypical dia cabe rt ee vision antipsychotic administer week treatment care schizophrenia maintenance bipolar disorder promise new product continue positive growth trajectory prezista darunavir hiv velcade bortezomib multiple myeloma develop partnership depuy cordis millennium takeda oncology company right outside invega paliperidone oncedaily atypical antipsychotic treatment schizophrenia acute schizoaffective disorder intelence etravirine pharmaceutical segment sale hiv combination therapy sale major product billion dollar pharmaceutical pipeline robust sale billion aciphexpariet history launch newly approve drug sale change concerta simponi golimumab stelara ustekinumab total operational immunology nucynta tapentadol immediate release duragesic tablet pain relief invega sustenna paliperidone palmitate treatment schizophrenia priligy dapoxetine select country world sexual health le fv la oq xu inin addition continue expand core product new indication practice historically example remicade fdaapprove indication broad topamax spectrum immune system disorder procrit future pipeline promise important product eprex registration rivaroxaban codevelope bayer healthcare ag rivaroxaban novel oral anticoagulant risperdal consta prevent host thrombotic condition include venous risperdal mi de thromboembolism stroke atrial fibrillation evaluate different indication important compound phase iii clinical trial include treatment consumer segment sale diabetes prostate cancer alzheimer disease build strong pipeline engage sale major franchise billion dollar sale billion acquisition innovative agreement collaboration sale change company offer potentially significant advance patient total care include potential firstinclass treatment slow operational w ho em ale tn hs progression alzheimer disease elan corporation plc potential universal monoclonal antibody product otc pharmaceutical treatment prevention influenza crucell nv hiv nutritional therapy single combination pill gilead sciences inc potential breakthrough prostate cancer cougar wound care biotechnology inc strengthen pipeline pharmaceutical business expand geographically focus emerge market oral care expand sale reach china maintain strong manufacturing footprint china mexico brazil develop rd presence emerge market like india baby care china establish rd operation mumbai rd head skin care quarter shanghai collaboration tianjin medical university cancer hospital biomarker research operational exclude impact currency johnson johnson annual report johnson johnson annual report corporate level revision march chairmans letterconsumer consumer business endure business preventing disease johnson johnson continue distinguish science company worldwide people model strength base innovation proprietary technology difference local community current product recommendation health care profe put remind sional premier consumer health pipeline johnson johnson people transcend care business billion people challenge come way robust world count consumer product world citizen continually strong balance sheet family stride enhance sustainability consumer sale grow global facility packaging year billion grow percent operationally annual report environmentally presence provide despite soft economy operational sale friendly adopt percent critical ingredient increase skin care women health postconsumer recycle paper inside oral care wound care franchise sustain leadership page reduce number print page growth product line include develop online version accessible neutrogena aveeno listerine wwwinvestorjnjcomannualreport splenda innovation iconic brand invite join sustainability cornerstone consumer business effort elect receive year launch listerine total care annual report shareholder material aveeno nourish hair electronically tearoff card end care report provide easytofollow develop new way instruction business noteworthy development include open neutrogena store mumbai india expansion commitment shareholder commit skin d online personalize acne solution sell directly johnson johnson leader health care lead consumer sell product home shopping channel first health care industry antiseptic half consumer sale come market outside bandage soft disposable contact lense united states deep consumer insight local market coronary stent continue leadership relevant product introduction drive global expansion particu tradition future company deeply larly develop market recent acquisition continue fuel commit people serve global growth thrive dabao brand china vania endure business model strength current expansion snc europe le petit marseillais expand product pipeline robust strong french heritage new market balance sheet grow global presence provide critical ingredient sustain leadership important people change health c landscape health care johnson johnson carry company legacy landscape change unprecedented pace past inspiration caring pass generation generation year continue evolve employee health care debate unfold united states reason remain confident johnson johnson markets johnson johnson support reform expand access lead health care drive important innovation customer care improve longterm sustainability health patient achieve longterm superior rate return care system build good aspect include incentive loyal shareholder medical progress believe appropriate reform improve patient care create growth opportunity health care company johnson johnson wellpositione change landscape remain focused add value health care system william c weldon develop program promote wellness create well chairman board director chief executive officer solution chronic care remain true motivated goal provide meaningful innovation march benefit society citizen w orld care way change world medical breakthrough commit people cause need support work hun dred partner worldwide lifechange sustainable difference health care natural disaster strike earthquake haiti work partner provide cash product business exclude purchase inprocess research development special item philanthropic effort globally focus save improve free cash flow define operate cash flow capital spending live woman child build health care capacity reconciliation nongaap financial measure chairmans letter johnson johnson annual report corporate level revision march chairmans lettermmeeddiiccaall ddeevviicceess ddiiaaggnnoossttiiccss china japan centers training design serve country empower health care region unique clinical need center design train professional world provider worldwide brazil russia training need improve patient carean professional education center help surgeon improve skill important mdd strategy emerge market perform advanced surgeries johnson johnson medical innovation institute open paolo quarter johnson johnson institute kind latin america include surgery room equip late medical w hile russia need skilled technology simulators institute train health care physician meet patient demand professional year hightech medical procedure institute help health care professional current late train perform technique medical advance enhance medical firstofitskind professional mistake significant risk say teaching encourage clinical study education center bring olga vereschagina strategic affair facilitate knowledgeshare government scientific community director johnson johnson llc say george marques institute international business fill gap addition patient endure director short improve improve health care russia conventional invasive surgeries standard care latin americans train russian center doctor train latin america global professional education ve perform perform minimally invasive procedure orthopaedic neurological care laparoscopic operation need advanced surgical advance thank depuy institute widespread condition russia train great barrier llc education training research appendectomy ovarian cyst quality health care russia say center open raynham mass peritonitis say sergey gorodkov md arman voskertchyan managing director august offer physicians johnson johnson llc goal program annually cover train center ve improve transform professional education late concept technique skill m perform operation help fulfill credo technology area minimally quicker great confidence responsibility health care professional invasive surgery age spine deformity center publicprivate patient neurological disease joint replacement partnership ministry russian center kazan percent trauma care health care republic tatarstan study base theory percent commitment professional johnson johnson practice simulators center education long establish establish record timeless give opportunity improve united states originate yearand officially open manual skill m train endosurgery institute cincinnati ohio february president russia complicated laparoscopy interventions depuy institute dmitry medvedev say dr gorodkov center serve tangible evidence s significant center set new standard impact patient care result care world excellence professional education partnership number high johnson johnson say diana bacciwalsh worldwide vice technology intervention past professional education center president professional education year region world include johnson johnson depuy institute llc commitment increase say diabetes institute llc vision continue address unmet airat farrakhov minister health care care institute llc educational clinical need rapidly republic tatarstan achieve medical device diagnostic change health care environment twofold increment mdd business center support help lead well patient care year organization desire improve education improve skill dr gorodkov emerge develop market physician train skill transform care establish innovative partnership russian center professional historically medical school training government recently center open education ve improve skill russia focus lecture paulo brazil raynham mass m perform operation quick apply practice fatal medical site include germany france india great confidence say johnson johnson annual reportmedical device diagnostic breakthrough breast reconstruction new singlesurgery option speed heal week innovation ethicon inc mentor worldwide llc elyssa weintraub dr downey flexhd surgery breast accellular dermal matrix donate human dermis allograft cancer summer available exclusively return ethicon create sle elyssas breast support cheer son memorygel breast implant sport event produce mentor johnson johnson stationary bike subsidiary ethicon inc hiking acquire mentor corp leading supplier medical husband product large fast get right grow aesthetic market swing thing say january mentor yearold womens boutique natural fit ethicon lead owner palm desert calif provider suture mesh positive attitude product wide range elyssa diagnose surgical procedure breast cancer plastic combine force ethicon surgeon susan downey md mentor aspire fac tell trust global leader good candidate aesthetic medicine breast reconstruct addition mentor single surgery expand capacity provide mastectomy innovative sciencebase surgeon find nearly broad surgeon community slam dunk solution restore percent eligible woman mentor highly respected nobrainer say elyssa patient appearance self not tell option plastic surgeon operation esteem quality life say important conversa new partnership recovery experi gary pruden company group tion place educate doctor patient ence breast m chairman responsibility woman diagnose s real difference busy woman able ethicon franchise inform choice live woman face right family patient know improve quality life say decision say delia cook business reconstructive option dr downey group product director singlesurgery recon number breast conversation mentor worldwide llc structive option elyssa reconstruction procedure happen surgeon know week choose possible increase study offer ethicon surgery elyssa return combine technology american society plastic distinguish legacy confidence shop bgs johnson johnson annual reportmappe human heart new technology biosense abnormality fix webster inc give physician procedure know detailed threedimensional ablation view heart treat carto system dangerous cardiac arrhythmia represent significant include atrial fibrillation advance patient physi afib million cians say gerd hindrick people worldwide suffer md head department afib leading cause stroke electrophysiology people age university leipzig hospital carto system germany accurate launch globally take map physician visual journey ability visualize catheter heart system guide map crucial detail heart heart chamber enable color real time helping efficiently perform cardiac physician pinpoint ablation innovation propel hip business year continue hip bear consider innovation depuy orthopaedic approval inc market leader hip depuy orthopaedic await replacement part fda final decision world pinnacle complete system offer broad range remain investigational hip bearingsadvance device limit law material ball socket investigational use joint hipof pinnacle complete orthopaedic company say ceramiconmetal bearing randy kilburn vice president market country marketing depuy outside orthopaedics inc surgeon company significant range launch silent hip option choose minimally invasive hip stem singlesurger option breast cancer diagnosis meet complex clinical available outside elyssa able mastectomy reconstruction need patient silent stem single surgeryan option s possible combined depuy orthopaedic continues insert femur technology ethicon mentor business unit pioneer new hip bearing bonepreserve eclectic crucial say provide high stability low traditional stem december look good clothe say elyssa choose advance wear meeting need depuy orthopaedic elyssa wear colorful breast reconstruction s grow number active announce acquisition california lifestyle clothe fantastic woman need patient august food finsbury orthopaedics ltd sell s elyssa run business drug administration fda united kingdom customer expect strong selfesteem say dr advisory panel recommend make running shop downey help restore approval pinnacle company largediameter business body return life complete acetabular hip onepiece ceramiconceramic will not prosper m quickly system ceramiconmetal hip bear johnson johnson annual report medical device diagnostic hope fight cancer simple test allow doctor personalize care happen fast detect change patient status provide information person not prognosis help physician information cancer inform patient care decision ask oncologist easy ll surgery get blood draw order radiationit test d forever grateful say jesica test come generic recipe patient celland breast cancer say good prognosisthat give hope jesica harrington enumerate cancer cell breast cancer survivor cellsearch system jesica pregnant twins diagnostic test automate capture receive diagnosis november detection ctcs tumor cell month later lose detach solid tumor baby undergo mastectomy enter patient blood assess begin round ctcs determine prognosis chemotherapy jesica simply want overall survival patient know doctor determine metastatic breast colorectal treatment fight prostate cancer time cancer tell hope prayer course treatment recall cleveland clinic rank jesica pregnant technology cellsearch oncologist not use usual method system medical innovation imaging diagnostic information predict significant detail prognosis impact health care september beginning treatment jesicas father cellsearch ctc test honor understand daughter need firstever prix galien usa award information fuel hope beat good medical technology prix cancer internet find galien recognize technical scientific scientist cellular research veridex llc cellsearch circulate clinical research skill necessary progress area drive tumor cell ctc test veridex llc develop innovative medicine drug development need oncology simple blood test capture device consider industry trial identify count circulate tumor high accolade candidate evaluate cellsearch platform cell patient certain type innovative nature develop joint venture convergence project metastatic cancer ment applicability technology involve veridex llc centocor combination test discovery ortho biotech inc oncology cellsearch ctc test allow doctor apply future biomedical science pharmaceutical area business important academic collabora cellsearch circulate tumor cell test personalize medicine future tion royal marsden approve demonstrate current go count cancer cell hospital london memorial sloan line therapy effective therapy cellsearch cellsearch platform kettering cancer center new york result image result equivalent characterize individual patient tumor clinical study site abiraterone assess transition patient gather data protein genetic acetate latestage firstinclass nonprogressive disease progressive disease marker say david chianese principle compound treatment prostate johnson johnson annual reportcancer gain acquisition cougar knowledge suppor jesica teacher castle rock colo outspoken biotechnology inc johnson johnson breast cancer survivor result cellsearch circulate tumor cell test jesicas treatment fuel hope beat cancer support family july friend student girl sport pink hairspray boy shave pivotal trial abiraterone hair jesica lose acetate ve cellsearch indicator drug effectiveness say medicine right ultimately transform treatment bill hait md phd global therapeutic effective give patient primary cancer head oncology hematology objective pursuit personalize jesica deliver healthy baby boy centocor research development inc medicine partner drug gunner complete cancer collaboration biomarker group pharmaceutical treatment remission develop molecular characterization organization give real opportunity look jesica feel cancer cell begin define potentially expand capability individuality lose cookbook predictive biomarker help cellsearch predict monitor approach cancer treatment identify patient good therapeutic response say mark carle say talk doctor drug connelly phd director cellular tell different ability understand quickly research veridex llc vision say exactly johnson johnson annual report consumer enlighten customer introduce science art beauty help inform product selection firstofit kind flagship neutrogena store open mumbai india create new opportunity consumer walk store dermatologist confidence product available meet skin care need say geetanjali shetty md fcps ddv dermatologist work unique setting today role dermatologist assemble come innovative skin extend treat problematic care solution leverage area educate consumer brand team thing like sun damage importance stabilize retinol significant antiaging sunscreen use skin care advance skin care develop regimen bestinclass skin care solution like dermatologist market helioplex know active world recommend photobarri complex neutrogena dr shetty say breakthrough sun protection store good platform example feverfew pfe educate people sciencebase proprietary botanical extract skin care antiinflammatory calming property scientist develop innovative skin care neutrogena feverfew pfe recognize say claim aveeno roc prestigious johnson medal substantiate testing preclinical clean clear give annually johnson johnson testing skin culture invitro work know skin care franchise brand accomplished researcher study consumer commit bring science art beauty beauty extraordinary creativity scientific ment deliver innovative skin care science say achievement work provide new strong shanaa vice president skin care rd scientific information area johnson johnson consumer group inflammation skin aging bring professional relationship clinical company ve able science natural health study share professional bring science art supplement medical meeting american produce innovative product great skin care researcher academy dermatology meeting hold clinical performance look develop new antiage alternative march play role form smell feel s right leverage brand launch important relationship product explain team early use technology develop skin care rd marketing expertise bestinclass slogan rd researchers johnson johnson johnson johnson annual reportin eye beholder feature flagship neutrogena store mumbai india truvu analyzer digital imaging system use photograph create objective starting point assess skin current condition monitor progress set period time truvu analyzer help neutrogena educate communicate customer photo enhance problematic area individual skin company recommend india welldevelope professional name market directly consumer dermatologist relationship play important role dermatologist novel idea health care professional connect consumer heritage professional endorsement relationship integral brand skin care product message key start successful franchise bring learning success sale channel range product skin care franchise develop relationship say traditional retail setting aveeno found today work innovative new channel home mayo clinic colloidal oatmeal dermatologist different shopping network online sale bath provide naturally active level product development doortodoor sale benefit oats neutrogena soap consumer education driving dermatologist site product company innovation meet consumer need johnson johnson annual report consumer wholesome skin care thrive new product line new market exist product continue provide growth opportunity consumer skin care portfolio expand brand france le petit marseillais outpace big competi tor thank year heritage natural ingredient good valueformoney position le petit marseillais expand new market include belgium switzerland north africa recently greece year refill aveeno advanced science natural product johnson consumer skin care pioneer active natural ingredient end brand launch active natural institute online package good percent total refill resource company proactively annual johnson sale promote highvolume value europe aim manage wastethe waste asia pacific region deal consumer increase knowledge result value percent johnson consumer emerge natural ingredient chain include waste baby wash shampoo market want small quanti skin care consumer generate region tie initial packaging brand use product say johnson refill pouch pack launch new aveeno paulette frank vice toptotoe selffoame sell small size nourish hair care line president sustainability wash ml refill japan allow midti consumer late active environmental health upgrade include spout buy primary natural ingredient safety johnson johnson easy opening pour pack use quality brand nourish wheat complex consumer group refill pouch usually cost like johnson accessible august aveeno soothe company refillable pack fraction comparably sized price point say elkana bath treatment age help offer sustain bottle help reduce ezekiel johnsons asia body care product earn able solution meet consumer cost pacific marketing director new green good need consumer environmental impact refill johnson johnson consumer housekeeping seal refill gain use material company inc november aveeno kick attractiveness consumer volume sell weigh pack drive growth partnership particularly asia pacific cost transport emerge market like china terracycle new life region represent develop market india aveeno product johnson johnson annual reporttube upcycle material ecofriendly item change demographic increase population growth rise consumer income provide ideal opportunity neutrogena recently increase focus china india intro duce china neutrogena relaunche continue impressive tripledigit compound annual growth rate neutrogena launch india support exciting alternative channelthe brand flagship store story clean healthy mouth naturally allnatural sweetener use sun crystal help people reduce brand include people listerine brand sweet intake calorie diabete pure cane consistent driver growth carbohydrate satisfy sugar sun crystal sweet tooth say marc allnatural sweetener brand successfully launch robinson company group provide small listerine total care chairman otcnutritional calorie carbohydrate anticavity mouthwasha nature wellness prevention serve multibenefit mouthwash sweetest plant sun crystal packet packet qualify free work way clean contain calorie food diet diabete source healthy mouth brand provide sweetness sun crystal continue expansion ingredient sun teaspoon sugar outside crystal allnatural sweetener mixed product rinse listerine beverage sprinkle johnson johnson family sweetener new brand mouthwash plus food sun crystal company earn floss brushing lowcalorie sweetener granulate blend earthward reach product provide mcneil mcneil nutritionals llc designation earthward daily essential introduce september johnson johnson nutritionals llc healthy mouth suitable cooking program encourage maker introduce bake halfcup provide team find way listerine reach march sweetness cup sugar develop earthfriendly total care introduce stevia plant grow product sun crystal sun crystal limitededition book primarily paraguay brazil achieve earthward partner national sweetener japan china status product children oral health stevia plant people deliver sweetness foundation america world hundred year percent raw pure cane sugar toothfairy encourage well effect bloodsugar material oral health care child level entire family competitor johnson johnson annual report pphhaarrmmaacceeuuttiiccaallss high unmet need effective therapy embrace life anew target unmet need alzheimer disease devastating neurodegenerative disorder treatment give schizophrenia patient chance diagnose million people reclaim independence worldwide estimate project number quadruple september johnson johnson complete acquisition substantially asset right elan corporation plca lead company asako yoshino feel schizophrenia like conduct antibody vaccine research alzheimer diseaserelate blizzard mind today amid cold alzheimer immunotherapy bluster snow northern japan find program aip aip include multiple compound currently evaluation warmth calm fourlegge friend lead compound bapineuzumab schizophrenia symptom initially approve treatment currently phase iii clinical trialsis control yoshinosan say feel life schizophrenia evaluate slow new beginning wish register country progression alzheimer disease suffer condition worldwide yoshinosan vaccine alzheimer disease medication administer development aip compound understanding need yoshinosan week develop million people worldwide collaboration janssen alzheimer suffer schizophrenia disease longacte therapy longacte immunotherapy pfizer inc devastating patient family therapie professionally society present significant burden administer allow identification collaboration innovation health care system intervention dose miss biomarker integrative informatic patient world share patient society benefit brain imaging increasingly important common need drug therapy delaying nonadherencewhich lead research neurodegenerative time relapse study relapseis address disorder develop solution percent unmedicated patient year neuroscience meet patient need work schizophrenia relapse franchise commit meeting progress isolation say dr manji year diagnosis patient need treatment collaboration partnership primary reason relapse schizophrenia oncedaily risperdal play crucial role arrive take medication prescribe risperidone approve breakthrough solution yoshinosan diagnose little significant new option example october year ago hospitalize treat symptom schizophrenia johnson johnson enter eventually receive treatment risperdal consta strategic collaboration crucell nv medication give relief longacte atypical antipsychotic focus discovery development paranoia voice haunt offering everytwoweek dose commercialization monoclonal mind fall love get job food drug admin antibodie vaccine treatment resume life enjoy eventually istration grant marketing approval prevention influenza hard invega sustenna paliperidone infectious noninfectious disease medication day prescribe palmitate extendedrelease injectable collaboration provide access relapse suspension atypical antipsychotic technology expertise vaccine new experience oncemonthly maintenance dose development push edge approve treatment schizophrenia alzheimer disease vaccine program condition worsen say yoshinosan ve succeed series enable broad vaccine platform gradually begin skip taking innovation build strong pursue good science medicine heritage longterm commitment innovation strategy continue meet consult doctor meeting patient need schizophrenia present future patient need recommend change say husseini k manji md frcpc solution future require intramuscular injection risperdal global therapeutic area head small large molecule device consta risperidone neuroscience johnson johnson diagnostic say dr manji grant approval japanese ministry pharmaceutical research development piece plus willingness health early llc continue build strong collaborate expert inside available june risperdal consta program treat disorder outside company johnson johnson annual reportthe treatment moderate riding painfree doug benson carpenter elko minn severe rheumatoid arthritis enjoy outdoor activity begin treatment promise medicine simponi s able work pain log mile snowmobile year methotrexate active psoriatic relief arthritis disease affect application submit methotrexate active estimate million people fda tapentadol ankylosing spondylitis worldwide present extend release er regulatory authority form range tablet management canada europe unite mild severe disable moderate severe state simponi marketing approval chronic pain administer subcutaneously europe united fda approve steady pace regulatory skin month state brazil mexico australia invega sustenna milestone mark novel autoinjector singapore stelara paliperidone palmitate productive rd effort prefille syringe efficacy approve country oncemonthly critical future growth safety simponi food drug atypical antipsychotic meeting need show phase iii administration fda treatment schizophrenia doctor nurse patient development program approve nucynta feature johnson johnson patients tapentadol immediate pharmaceutical operating stelara ustekinumab release tablet new pipeline robust company launch multiple firstinclass biologic molecule analgesia expect file new new product treatment moderate year relief moderate compound world include severe plaque psoriasis severe acute pain patient expand core address significant administer subcutaneously age old nucynta product new indication unmet medical need week follow single molecule different pharmaceutical simponi golimumab starter dose psoriasis approach pain relief pipeline chart approve chronic immunerelate december new drug wwwinvestorjnjcom johnson johnson annual reportpharmaceutical touch prezista application pipeline product early european submit country remicade infliximab commission approve continue meet health oncedaily dose mg intelence care need patient patient prezista darunavir nonnucleoside reverse number inflammatory protease inhibitor transcriptase inhibitor disease involve lowdose ritonavir nnrti intelence immune system combination therapy etravirine medica include chronic severe treatmentnaive adult tion class demonstrate plaque psoriasis moderate previously take antiviral activity severe rheumatoid global growth market hiv medication approval nnrtiresistant virus nineteen arthritis active psoriatic expansion core brand broaden previous additional country approve arthritis moderate severe prove successful indication darunavir use intelence crohns disease adult pharmaceutical business treatmentexperience treatmentexperience child moderate severe driver hiv patient patient include brazil ulcerative colitis active core brand follow food china croatia israel chile ankylosing spondylitis franchise area drug administration intelence approve remicade available infectious disease december approval country europe country immunology prezista coadministere middle east africa emea achieve approval neuroscience story ritonavir americas asiapacific indication worldwide achieve regula antiretroviral agent remicade tory milestone broaden treatment hiv infection remicade treat million patient population pediatric patient age impressive example patient benefit include lowerdose mg formula strategy address unmet grow immunology prezista darunavir tion prezista pediatric need investigate portfolio include intelence etravirine hiv patient introduce seek approval additional potentially versatile remicade infliximab february indicationsbuilde compound pursue ment commercialization new oncedaily fix good dose antiretroviral product june tibotec inc science announce collaboration global alliance tb drug development breakthrough solution accelerate discovery come source development new drug significant scientific fight tuberculosis collaboration acquisition infectious disease tb evidence pursuit good second common cause science uncover adult death worldwide solution improve tibotecvirco odd success product virology bvba siemen patient area high healthcare diagnostics inc unmet need story biomarker offer insight researcher johnson johnson announce licensing tianjin medical university cancer hospital china pursue agreement allow good science identify biomarker help personalize example relate rd tibotecvirco virology bvba medicine advance cancer treatment effort oncology develop new research infectious disease allow scientist identify cancer disease account technology platform assist biomarker help percent cancerrelate development johnson johnson personalize medicine death united states antiviral treatment tianjin medical university advance cancer treatment related feature hepatitis c virus hcv cancer hospital china johnson johnson acquire july tibotec million establish partnership cougar biotechnology inc pharmaceutical enter people worldwide infect february hospital july clinical trial license collaboration hcv virus tumor specimen collect way compound agreement gilead lead fatal patient catalogue treatment prostate sciences inc develop disease liver johnson johnson annual report citizenship commitment conservation worldwide effort reduce water use eliminate water waste result stand river water flow natural decline india social music today rare find religious tradition foster foothills himalayas say careful use sincere reverence water source northern india achal gupta water thoughtfully protect life part country supply future generation waterscarce area world recall simple time allow world waterone achal manager environment different kind closeness earth critical resourcesis health safety ehs threat scarcity increase demand johnson johnson consumer nature vital resource inequitable access lack quality manufacturing facility baddi nature achal foothills himalayas short drive johnson johnson consumer facility work moral responsible corporate citizen india commit conserve water lead example say johnson johnson annual reporthimachal pradesh water management effort oversee include zerodischarge wastewater treatment facilityevery drop treat water reuse irrigation toilet flush rain harvesting begin water collect rooftop recharge ground harvest pit huge water monsoon season go directly storm drain waste say achal decide use water management effort contribute enterprisewide water reduction goal place year company healthy planet goal water use percent absolute reduc tion baseline thank numerous effort local level johnson johnson target reach goal end new goal effect january enterpriselevel goal demand say radhakrishnan manager environment health safety johnson johnson ltd keep child mulund india careful review local effort ensure compliance enterprise standard free infection community need effort region share good practice understand context combine impact local initiative additional effort way include treat wastewater maintain lawn fernanda jinotepe nicaragua medication mebendazole donate consumer manufacturing research get intestinal worm athletic fourth johnson johnson approximately development center mulund grader play sport feel listless million world atrisk northeastern mumbai stomach ache feel tired child treat represent nurture tree plant property not want eat say fernanda large health care company donation ethicon facility aurangabad miss school day vomit target sth cww create western india water storage tank fernanda million child million heal thy active kid instal piping modification worldwide age risk infection program child reduced water pressure cut soiltransmitte helminth sth worms fernanda learn way overall consumption small step roundworm whipworm hookworm prevent infection sth remind like instal autoclose tap sink find tropical subtropical mother chlorinate water help training area sth cause lack clean run brother luis scrub lecture water conservation water sanitation intestinal worm hand soap luis drop organize employee especially harmful child mango fernanda wash treat responsibility maintain lead malnutrition anemia stunt water take bite environment perform growth impair cognitive development fernanda physically healthy business effort meet customer poor school attendance s knowledgeable not need say achal develop performance reinfect say mother way future fernanda school participate grissell child generation feel proud child worms cww wormfree laugh active commitment action program provide deworme eat lot not stop johnson johnson annual report citizenship johnson johnson link conservation health partnership task force global health program focus solely global treatment prevention sth terai arc forest nepal provide resource nearly cww partner million people vital survival endanger specie government world wildlife fund wwf partnership johnson johnson united states organization agency international development promote community conservation improve health country stop reinfection family service family household biogas plant build provide hygiene education clean cooking fuel reduce wood use metric ton carbon dioxide emission access improve ton annually sanitation clean water help people understand link conservation health livelihood prevention community say shubash lohani wwf deputy director eastern himalayas project component child way kenya democratic republic congo continuously reinfected say kim koporc cww acting director prevention component break cycle johnson johnson begin donation mebendazole cww bangladesh cameroon uganda zambia cww expand cambodia cape verde lao people democratic republic nicaragua result country greatly expand deworme outreach cameroon reach million school child nicaragua expand program reach child make difference company support johnson johnson young live legacy give fundamental improve health guide child increase employee help difference live credo responsibility performance school say dr martha reyes director young people johnson johnson communities national immunization bridge employment bte program program nicaragua work ministry health mentor like deborah coburn program enriche live hundred partner ultimately cww aim manager sale operation young people eliminate intestinal worm planning lifescan inc share experience worldwide country currently encourage high school student different individual work expand pursue high education bte partnership lifechange long donation country introduce academy term difference vision rid world career opportunity educational development child intestinal worms health care reach human health grow play student work alongside student learn say william lin business colleagues active colombia learn www director corporate develop critical skill ireland scotland jnjcomourgive contribution help college expand brazil czech johnson johnson say deborah republic spain johnson johnson annual report modgnik detinufwwetihwyert ed nomisfirst row committee board william c weldon board chairman board director director chief executive officer audit audit committee second row leave right comprise entirely mary sue coleman phd independent director president university michigan help board oversee james g cullen company account retire president chief reporting practice recom operating officer bell atlantic mend independent public corporation accountant appointment board review row leave right performance monitor michael e johns md adequacy internal chancellor emory university accounting practice arnold g langbo procedure control retire chairman review significant change chief executive officer accounting policy kellogg company fourth row leave right james g cullen chairman susan l lindquist phd mary sue coleman phd member director leo f mullin whitehead institute biomedical research professor biology massachusetts compensation benefits institute technology compensation benefit anne mulcahy committee comprise chairman retire entirely independent chief executive officer director establish xerox corporation company executive compensation philosophy fifth row leave right principle approve leo f mullin annual compensation retire chairman longterm incentive chief executive officer company director delta air lines inc executive officer william perez committee review senior advisor greenhill co philosophy policy inc retire president nonboard management chief executive officer compensation committee wm wrigley jr company determine manage sixth row leave right ment compensation charles prince establishes perquisite chairman sconset group llc compensation policy senior counselor albright nonexecutive employee stonebridge group retire additionally committee chairman chief executive oversee management officer citigroup inc retirement david satcher md phd pension longterm incentive director center excellence saving health welfare health disparity plans cover director satcher health company employee leadership institute poussaintsatchercosby chair arnold g langbo chairman mental health morehouse michael e johns md school medicine william perez surgeon general charles prince johnson johnson annual report finance general counsel vice corporate officer executive committee finance committee president corporate affairs william c weldon executive committee exercise management government affair policy chairman board directors johnson johnson authority board worldwide operation chief executive officer principal management interval board chairman executive committee group responsible meeting finance leo f mullin chairman operation allocation committee comprise susan l lindquist phd dominic j caruso resources company chairman board william perez vice president finance committee oversee preside director david satcher md phd chief financial officer coordinate activity executive committee russell c deyo consumer pharmaceutical william c weldon chairman clifford e holland stephen j cosgrove medical device james g cullen brian perkin corporate controller diagnostic business segment ajit shetty phd subsidiary laverne h council business segment vice president nominate corporate exception manage chief information officer governance science technology citizen country nominate corporate science technology russell c deyo locate governance committee advisory committee comprise vice president general counsel comprise entirely independent director executive committee independent director company vice president company group responsible overseeing science technology advise colleen goggin chairman corporate governance matter board scientific worldwide chairman review possible candidate matter include major consumer group roberto de marques board membership internal project interaction executive committee michael j f del prado recommend nominee academic outside alex gorsky election committee research organization worldwide chairman joaquin duato responsible overseeing acquisition technolo medical device seth h z fischer process performance gy product diagnostic group evaluation board executive committee guy j lebeau md committees additionally david satcher md phd karen licitra committee review chairman raymond c jordan companys executive vice president public affairs michael f mahoney mary sue coleman phd succession plan corporate communication michael e johns md patrick mutchler executive resource susan l lindquist phd sherilyn mccoy david norton garry neil md worldwide chairman charles prince chairman pharmaceuticals group michel paul james g cullen executive committee arnold g langbo jacques peeters john papa gary j pruden treasurer public policy marc e robinson brian perkin public policy advisory vice president michael e sneed committee review corporate affair company policy program pericle p stamatiade practice public health steven rosenberg kim taylor issue environ secretary ment health safety associate general counsel nicholas j valeriani employees committee jesse j wu review company governmental affair policy public policy issue face company committee advise make recommendation board issue appropriate public policy advisory committee comprise independent director company johnson johnson annual reportcorporategovernanceandmanagementsresponsibility johnsonjohnsonisguidedbythevaluessetforthinourcredo pricewaterhousecoopersllpanindependentregisteredpublic createdbygeneralrobertwoodjohnsonintheseprinciple accountingfirmisengagedtoperformanintegratedauditofour haveguidedusovertheyearsandcontinuetosetthetoneof consolidatedfinancialstatementsandinternalcontroloverfinancial integrityfortheentirecompanyatalllevelstheemployeesof reportingthereportofindependentregisteredpublicaccounte johnsonjohnsonarecommittedtotheethicalprinciplesembod firmisonpage iedinourcredoandtheseprincipleshavebeenwovenintothe theauditcommitteeofourboardofdirectorsiscompose fabricofthecompany solelyofindependentdirectorswiththefinancialknowledgeand thevaluesarticulatedinourcredoextendtoouraccounte experiencetoprovideappropriateoversightwereviewinternal andfinancialresponsibilitiestojohnsonjohnsonshareholder controlmattersandkeyaccountingandfinancialreportingissue andinvestorswethemanagementofjohnsonjohnsonare withtheauditcommitteeonaregularbasisinadditiontheinde responsiblefortheintegrityandobjectivityoftheaccompanye pendentauditorsthegeneralcounselandthevicepresidentof financialstatementsandrelatedinformationwearealsoresponsi internalauditregularlymeetinprivatesessionswithouraudit bleforensuringthatfinancialdataisreportedaccuratelyandina committeetodiscusstheresultsoftheirworkincludingobserva mannerthatfacilitatestheunderstandingofthisdata tionsontheadequacyofinternalfinancialcontrolsthequality asevidenceofourcommitmenttothisresponsibilitywe offinancialreportingandconfirmationthattheyareproperly maintainawelldesignedsystemofinternalaccountingcontrol dischargingtheirresponsibilitiesandotherrelevantmatter encouragestrongandeffectivecorporategovernancefromour ourexecutivecommitteeiscontinuouslyinvolvedinthe boardofdirectorscontinuouslyreviewourbusinessresultsand reviewoffinancialresultsaswellasdevelopingandunderstande strategicchoicesandfocusonfinancialstewardship strategiesandkeyinitiativesforlongtermgrowthourintentisto ourcorporatestaffofprofessionallytrainedinternalauditors ensurethatwemaintainobjectivityinourbusinessassessment whotravelworldwidemonitoroursystemofinternalaccounte constructivelychallengetheapproachtobusinessopportunitiesand controlsdesignedtoprovidereasonableassurancethatassetsare issuesandmonitorourbusinessresultsandtherelatedcontrol safeguardedandthattransactionsandeventsarerecordedproperly ourconsolidatedfinancialstatementsandfinancialdatathat ourinternalcontrolsincludeselfassessmentsandinternalreview followhavebeenpreparedinconformitywithaccountingprinciple ofouroperatingcompanie generallyacceptedintheunitedstatesofamericaandinclude duringthecompanycontinuedtoinvestsignificanttime amountsthatarebaseduponourbestjudgmentswearecommit andresourcesinordertoensurecompliancewithsectionof tedtopresentanddiscussresultsofoperationsinaclearand thesarbanesoxleyactofbasedontheworkperformedwe transparentmannerinordertoprovidetimelycomprehensiveand haveconcludedthatourinternalcontroloverfinancialreporting understandableinformationtoourshareholder waseffectiveasofjanuarywereferyoutomanagement reportoninternalcontroloverfinancialreportingonpage werequirethemanagementteamsofouroperatingcompa niestocertifytheircompliancewithourpolicyonbusinessconduct whichsetsforththecompanyscommitmenttoconductitsbusi nessaffairswithintegrityandcomplywiththegoverninglaw andregulationswehaveasystematicprogramdesignedto ensurecompliancewiththesepoliciesandprovidemeansof williamcweldon dominicjcaruso reportinganyconcernsaboutviolationsofthepolicytoview chairmanboardof vicepresidentfinance ourpolicyonbusinessconductpleasevisitourwebsiteat directorsandchief andchieffinancialofficer wwwinvestorjnjcomgovernanceconductcfm executiveofficer tableofcontent managementsdiscussionandanalysis auditedconsolidatedfinancialstatement organizationandbusinesssegment consolidatedbalancesheet resultsofoperation consolidatedstatementsofearning analysisofsalesbybusinesssegment consolidatedstatementsofequity analysisofconsolidatedearningsbeforeprovisionfor consolidatedstatementsofcashflow taxesonincome notestoconsolidatedfinancialstatement liquidityandcapitalresource reportofindependentregisteredpublicaccountingfirm otherinformation managementsreportoninternalcontrolover cautionaryfactorsthatmayaffectfutureresult financialreporte supportingschedule summaryofoperationsandstatisticaldata shareholderreturnperformancegraph reconciliationofnongaapfinancialmeasure johnson johnson annual report managementsdiscussionandanalysisofresultsofoperationsandfinancialcondition organizationandbusinesssegment managementsobjective aprimaryobjectiveofthecompanyistoachievesuperiorlevelsof descriptionofthecompanyandbusinesssegment capitalefficientprofitablegrowthtoaccomplishthisthecom johnsonjohnsonanditssubsidiariesthecompanyhave panysmanagementoperatesthebusinessconsistentwithcertain approximatelyemployeesworldwideengagedinthe strategicprinciplesthathaveprovensuccessfulovertimetothis researchanddevelopmentmanufactureandsaleofabroadrangeof endthecompanyparticipatesingrowthareasinhumanhealthcare productsinthehealthcarefieldthecompanyconductsbusinessin andiscommittedtoattainingleadershippositionsinthesegrowth virtuallyallcountriesoftheworldwiththeprimaryfocusonproduct areasthroughthedevelopmentofinnovativeproductsandservice relatedtohumanhealthandwellbee newproductsintroducedwithinthepastfiveyearsaccountedfor thecompanyisorganizedintothreebusinesssegment approximatelyofsalesinbillionorof consumerpharmaceuticalandmedicaldevicesanddiagnostic saleswasinvestedinresearchanddevelopmentthisinvestment theconsumersegmentincludesabroadrangeofproductsusedin reflectsmanagementscommitmenttotheimportanceofongoe thebabycareskincareoralcarewoundcareandwomenshealth developmentofnewanddifferentiatedproductsandservicesto carefieldsaswellasnutritionalandoverthecounterpharmaceuti sustainlongtermgrowth calproductstheseproductsaremarketedtothegeneralpublic withmorethanoperatingcompanieslocatedin andsoldbothtoretailoutletsanddistributorsthroughouttheworld countriesthecompanyviewsitsprincipleofdecentralizedman thepharmaceuticalsegmentincludesproductsinthefollowing agementasanassetandfundamentaltothesuccessofabroadly therapeuticareasantiinfectiveantipsychoticcardiovascularcon basedbusinessitalsofostersanentrepreneurialspiritcombine traceptivedermatologygastrointestinalhematologyimmunology theextensiveresourcesofalargeorganizationwiththeabilityto neurologyoncologypainmanagementurologyandvirologythese reactquicklytolocalmarketchangesandchallenge productsaredistributeddirectlytoretailerswholesalersandhealth thecompanyiscommittedtodevelopingglobalbusinesslead careprofessionalsforprescriptionusethemedicaldevicesand erswhocandrivegrowthobjectivesbusinessesaremanagedforthe diagnosticssegmentincludesabroadrangeofproductsusedprin longterminordertosustainleadershippositionsandachievegrowth cipallyintheprofessionalfieldsbyphysiciansnursestherapist thatprovidesanenduringsourceofvaluetoourshareholder hospitalsdiagnosticlaboratoriesandclinicstheseproduct unifyingthemanagementteamandthecompanysdedicate includecordiscirculatorydiseasemanagementproductsdepuy employeesinachievingtheseobjectivesisourcredoourcredo orthopaedicjointreconstructionspinalcareandsportsmedicine providesacommonsetofvaluesandservesasaconstantreminder productsethiconssurgicalcareaestheticsandwomenshealth ofthecompanysresponsibilitiestoitscustomersemployeescom productsethiconendosurgerysminimallyinvasivesurgicalprod munitiesandshareholdersthecompanybelievesthatthesebasic uctslifescansbloodglucosemonitoringandinsulindelivery principlesalongwithitsoverallmissionofimprovingthequality productsorthoclinicaldiagnosticsprofessionaldiagnostic oflifeforpeopleeverywherewillenablejohnsonjohnsonto productsandvistakonsdisposablecontactlenses continuetobeamongtheleadersinthehealthcareindustry thecompanysstructureisbasedupontheprincipleof decentralizedmanagementtheexecutivecommitteeof resultsofoperation johnsonjohnsonistheprincipalmanagementgroupresponsible fortheoperationsandallocationoftheresourcesofthecompany analysisofconsolidatedsale thiscommitteeoverseesandcoordinatestheactivitiesofthe inworldwidesalesdecreasedtobillioncompare consumerpharmaceuticalandmedicaldevicesanddiagnostic toincreasesofinandinthesesale businesssegment changesconsistedofthefollowing inallofitsproductlinesthecompanycompeteswithcompa niesbothlocalandgloballocatedthroughouttheworldcompeti salesdecreaseincreasedueto volume tionexistsinallproductlineswithoutregardtothenumberandsize ofthecompetingcompaniesinvolvedcompetitioninresearch price involvingthedevelopmentandtheimprovementofnewandexiste currency productsandprocessesisparticularlysignificantthedevelopment total ofnewandinnovativeproductsisimportanttothecompanyssuc cessinallareasofitsbusinessthisalsoincludesprotectingthe salesbyuscompanieswerebillioninbillionin companysportfolioofintellectualpropertythecompetitiveenvi andbillioninthisrepresentsadecreaseof ronmentrequiressubstantialinvestmentsincontinuingresearchand inadecreaseofinandanincreaseofin inmaintainingsalesforcesinadditionthedevelopmentandmain salesbyinternationalcompanieswerebillionin tenanceofcustomerdemandforthecompanysconsumerproduct billioninandbillioninthisrepresentsa involvessignificantexpendituresforadvertisingandpromotion decreaseofinandincreasesofandin andrespectively johnson johnson annual reportusand salesby internationalsale segment foryear inbillionsofdollar inbillionsofdollar consumer pharmaceutical international medicaldevice anddiagnostic thefiveyearcompoundannualgrowthratesforworldwide analysisofsalesbybusinesssegment usandinternationalsaleswereandrespec consumersegment tivelythetenyearcompoundannualgrowthratesforworldwide consumersegmentsalesinwerebillionadecreaseof usandinternationalsaleswereandrespectively fromwithofthischangeduetooperationalgrowth andnegativecurrencyimpactofusconsumersegment salesby saleswerebillionadecreaseofinternationalsaleswere geographic billionadecreaseofwithgrowthofachievedby region operationsandadecreaseofresultingfromthenegative inbillionsofdollar impactofcurrencyfluctuation theoverthecounterotcpharmaceuticalsandnutritional europe franchisesaleswerebillionadecreaseoffrom westernhemisphere thiswasprimarilyduetothenegativeimpactofcurrencyandlower excludingus asiapacificafrica salesoftheoverthecounterzyrtecallergyproductlinerelate totheinitialbuildofinventorybythetradeduringthelaunch yearthiswaspartiallyoffsetbysalesgrowthinthesplenda sweetenerproductlinetheusfoodanddrugadministration fdaiscurrentlyconsideringcertainrecommendationsmadeby itsadvisorycommitteeforreducingthepotentialforoverdosewith salesineuropeexperiencedadeclineofincludingopera acetaminophentheactiveingredientintylenolbrandproduct tionalgrowthofandanegativeimpactfromcurrencyof thecompanyhasprovidedthefdawithitsownrecommendation salesinthewesternhemisphereexcludingtheusexperienceda andwillcontinuetobeactivelyengagedwiththefdaonthistopic declineofincludingoperationalgrowthofandanegative indecemberthecompanyannouncedavoluntaryrecall impactfromcurrencyofsalesintheasiapacificafricaregion ofalllotsoftylenolarthritispaincountwithezopencap achievedgrowthofincludingoperationalgrowthofand followingreportsofanuncharacteristicsmellhowevertherewa anincreaseofrelatedtothepositiveimpactofcurrency aninsignificantimpactonsalesinjanuarythecompanyha inandthecompanydidnothaveacus undertakenabroadervoluntaryrecalloftylenolandcertain tomerthatrepresentedormoreoftotalconsolidatedrevenue otcproductsasaprecautionaryaction resultsbenefitedfromtheinclusionofardweek theskincarefranchisesalesgrewbytobillionin seenotetotheconsolidatedfinancialstatementsforannual thesalesgrowthwasprimarilyduetotheaveeno closingdatedetailsthecompanyestimatedthatthefiscalyear neutrogenaanddabaoskincarelinesthebabycarefranchise growthratewasenhancedbyapproximatelywhile saleswerebillionadecreaseofprimarilyduetothe theadditionalweekaddedafewdaystosalesitalsoaddedafull negativeimpactofcurrencyandlowersalesforbabycentercomasa weeksworthofoperatingcoststhereforethenetearningsimpact resultofexitingtheonlineretailbusinesspartiallyoffsetbygrowth wasnegligible inthehaircareproductlinethewomenshealthfranchisesale werebillionadecreaseofprimarilyduetothenegative impactofcurrencypartiallyoffsetbyincreasedsalesassociate withtheacquisitionofajointventurepartnerinfranceinthefiscal majorconsumerfranchisesale change dollarsinmillion vs vs otcpharmaceuticalsnutritional skincare babycare womenshealth oralcare woundcareother total management discussion analysis result operation financial condition firstquarterofpriortotheacquisitionofthejointventure risperdalconstainjapanearlierintheyear partnersalesbythejointventurewerenotrecordedaspartofthe concertamethylphenidatehclaproductforthetreat companyssalestocustomerstheoralcarefranchisesaleswere mentofattentiondeficithyperactivitydisorderadhdachieve billionadecreaseofduetosoftnessinthecategoryinthe salesofbillioninrepresentinganincreaseofover uspartiallyoffsetbygrowthoflisterinemouthwashoutside salesresultsinwerefavorablyimpactedbyapproxi theusthewoundcareotherfranchisesalesgrewbyto matelymillionrelatedtoachangeintheestimateofaccrued billionprimarilyduetotherecentacquisitionsinthewellness salesreservesrelatedtosalesoutsidetheusalthoughtheoriginal andpreventionplatformandstrongsalesofpurellhandsanitizer concertapatentexpiredinthefdahasnotapprovedany consumersegmentsalesinwerebillionan genericversionthatissubstitutableforconcertapartieshave increaseofoverwithofthischangedueto filedabbreviatednewdrugapplicationsandasforgenericver operationalgrowthandtheremainingduetopositivecurrency sionsofconcertawhicharependingandmaybeapprovedat fluctuationsusconsumersegmentsaleswerebillionan anytimeanapprovalwouldleadtoalossofexclusivityandislikely increaseofinternationalsaleswerebillionanincreaseof toresultinasignificantreductioninsale withasaresultofoperationsandduetocurrency topamaxtopiramaterisperdalrisperidoneand fluctuationsover duragesicfentanyltransdermalfentanyltransdermalsystem experiencedsalesdeclinesinofand pharmaceuticalsegment respectivelyversustheprioryearduetogenericcompetitionmar pharmaceuticalsegmentsalesinwerebilliona ketexclusivityintheusexpiredfortopamaxtopiramatein decreaseoffromwithanoperationaldeclineof marchrisperdaloralinjuneandduragesicin andtheremainingduetothenegativeimpactofcurrencyfluc january tuationsussaleswerebillionadecreaseofinterna aciphexparietrabeprazolesodiumexperienceda tionalsaleswerebillionadecreaseofwhichinclude salesdeclineofduetocompetitioninthecategory operationalgrowthandadecreaseofresultingfromthe inotherpharmaceuticalsaleswerebillionrepre negativeimpactofcurrencyfluctuations sentingagrowthofovertheprioryearcontributorstothe remicadeinfliximababiologicapprovedforthetreat increaseweresalesofvelcadebortezomibaproductforthe mentofanumberofimmunemediatedinflammatorydiseases treatmentofmultiplemyelomaprezistadarunavirforthe achievedsalesofbillioninwithgrowthofover treatmentofhivaidspatientsintelenceetravirineforhiv theprioryearprimarilyattributabletostrongoverallmarketgrowth combinationtherapyandinvegapaliperidoneaoncedaily remicadeiscompetinginamarketwhichisexperience atypicalantipsychoticthegrowthwaspartiallyoffsetbytheimpact increasedcompetitionduetonewentrantsandtheexpansionof ofagenericversionoforthotricyclenloshippedbya indicationsforexistingcompetitor competitorsubsequentlythegenericmanufacturerrecognize procritepoetinalfaandeprexepoetinalfahadcom thevalidityofthepatentpaiddamagesforitsinfringingsalesand binedsalesofbillioninadeclineofcomparedto ceasedfurthershipmentsoftheproduct theprioryearlowersalesofprocritandeprexweredueto duringthecompanyreceivedregulatoryapprovalfor thedecliningmarketsforerythropoiesisstimulatingagentsesa severalnewmolecularentitiesnmesincludingstelara levaquinlevofloxacinfloxinofloxacinsaleswere ustekinumabintheusandeuropeanunioneuforthetreat billionadeclineofversustheprioryearduetocompeti mentofmoderatetosevereplaquepsoriasisinvega tioninthecategorythepatentforlevaquinlevofloxacinin sustennapaliperidonepalmitateextendedreleaseinjectable theuswillexpireindecemberapediatricextensionwa suspensionintheusfortheacuteandmaintenancetreatmentof grantedbythefdawhichextendsmarketexclusivityintheus schizophreniasimponigolimumabintheusandeuforthe throughjunetheexpirationoftheproductpatentorlossof treatmentofmoderatetosevereactiverheumatoidarthritisra marketexclusivityislikelytoresultinasignificantreductioninsale activeandprogressivepsoriaticarthritispsaandsevereactive risperdalconstarisperidonealongactinginjectable ankylosingspondylitisasandpriligydapoxetineinseveral forthetreatmentofschizophreniaachievedsalesofbillionin countriesfortheondemandtreatmentofprematureejaculation representinganincreaseofascomparedtotheprior nucyntatapentadolimmediatereleasetabletsforrelief yearthegrowthwasduetoapositiveshiftfromdailytherapiesto ofmoderatetosevereacutepainwasalsolaunchedintheus longeractingrisperdalconstaandthelaunchof majorpharmaceuticalproductrevenue change dollarsinmillion vs vs remicadeinfliximab procriteprexepoetinalfa levaquinfloxinlevofloxacinofloxacin risperdalconstarisperidone concertamethylphenidatehcl topamaxtopiramate aciphexparietrabeprazolesodium risperdalrisperidone duragesicfentanyltransdermalfentanyltransdermalsystem otherpharmaceutical total johnson johnson annual reportthecompanyalsoreceivedapprovalsexpandingtheindica salesinthecordisfranchisewerebillionadeclineof tionsforseveralkeyproductsincludinginvegapaliperidone versustheprioryearthedeclinereflectslowersalesofthe extendedreleasetabletsintheusfortheacutetreatmentof cyphersirolimuselutingcoronarystentduetoincreasedglobal schizoaffectivedisorderrisperdalconstarisperidone competitionthedeclinewaspartiallyoffsetbygrowthofthe longactingtreatmentintheusasbothmonotherapyandadjunc biosensewebsterbusiness tivetherapytolithiumorvalproateinthemaintenancetreatmentof thevisioncarefranchiseachievedsalesofbillionin bipolaridisorderaswellasforthetreatmentofschizophreniain aincreaseoverprioryearprimarilyrelatedtogrowth japanprezistadarunavirintheeuwithlowdoseritonaviras intheastigmaticcontactlensproductlineoffsetbythenegative partofcombinationtherapyintreatmentnaveadultsaswellasfor impactofcurrency treatmentexperiencedpediatricpatientswithhiv salesinthediabetescarefranchisewerebillionin thecompanysubmittedanewdrugapplicationndatothe adeclineofversustheprioryeardeclinesinthelifescan fdafortapentadolextendedreleaseertabletsaninvestigational productlinewerepartiallyoffsetbygrowthoftheanimasinsulin oralanalgesicforthemanagementofmoderatetoseverechronic deliverybusinessresultingfromnewproductlaunchesand paininpatientsyearsofageorolderinadditionthecompany continueddevelopmentininternationalmarket alsoinvestedinanumberofnewplatformsforgrowthinoncology theorthoclinicaldiagnosticsfranchiseachievedsalesof alzheimersdiseaseandvaccinesforthetreatmentandprevention billioninaincreaseovertheprioryearprimarilyattrib ofinfluenzaandotherinfectiousandnoninfectiousdisease utabletotherecentlaunchofthevitrosandanalyzers pharmaceuticalsegmentsalesinwerebilliona themedicaldevicesanddiagnosticssegmentachievedsale decreaseoffromwithanoperationaldeclineofand ofbillioninrepresentinganincreaseofoverthe increaseduetothepositiveimpactofcurrencyfluctuation prioryearwithoperationalgrowthofandduetoaposi uspharmaceuticalsegmentsaleswerebillionadecreaseof tiveimpactfromcurrencyfluctuationsussaleswerebillion internationalpharmaceuticalsegmentsaleswerebillion anincreaseofinternationalsaleswerebillionan anincreaseofwhichincludedofoperationalgrowthand increaseofwithfromoperationsandapositive relatedtothepositiveimpactofcurrencyfluctuation currencyimpactof medicaldevicesanddiagnosticssegment analysisofconsolidatedearning themedicaldevicesanddiagnosticssegmentachievedsalesof beforeprovisionfortaxesonincome billioninrepresentinganincreaseofovertheprior yearwithoperationalgrowthofandanegativecurrency consolidatedearningsbeforeprovisionfortaxesonincome impactofussaleswerebillionanincreaseof decreasedbybilliontobillioninascomparedtothe overtheprioryearinternationalsaleswerebillionadecrease billionearnedinadecreaseofthedecreasewa ofwithgrowthoffromoperationsandadecreaseof primarilyrelatedtolowersalesthenegativeimpactofproduct resultingfromthenegativeimpactofcurrencyfluctuation mixlowerinterestincomeduetolowerratesofinterestearnedand thedepuyfranchiseachievedsalesofbillionina restructuringchargesofbillionthiswaspartiallyoffsetby increaseovertheprioryearthiswasprimarilyduetogrowth lowersellingmarketingandadministrativeexpensesduetocost inthespinehipandkneeproductlinesadditionallynewproduct containmenteffortsacrossallthebusinessesincludedpur launchesinthemiteksportsmedicineproductlinecontributedto chasedinprocessresearchanddevelopmentiprdchargesof thegrowth billionandincreasedinvestmentspendinginsellingmarkete theethiconendosurgeryfranchiseachievedsalesofbil andadministrativeexpensesutilizedfromtheproceedsassociate lioninaincreaseovertheprioryearthiswasattributable withthedivestitureoftheprofessionalwoundcarebusinessof togrowthintheendoscopyharmonicensealandadvance ethiconinctheincreaseinofoverthebillion sterilizationproductline inwasprimarilyduetoloweriprdchargesofbil theethiconfranchiseachievedsalesofbillionina liongainsfromdivestituresofbillionandhigherlitigation increaseovertheprioryearthiswasattributabletogrowthin gainsofbillionversusrestructuringchargesofbillion thesuturesbiosurgicalandmeshproductlinesinadditiontosale andthewritedownofthenatrecorintangibleassetof ofnewlyacquiredproductsfromtheacquisitionsofomrixbiophar billionrecordedinasapercenttosalesconsolidate maceuticalsincandmentorcorporationthegrowthwaspartially earningsbeforeprovisionfortaxesonincomeinwas offsetbythedivestitureoftheprofessionalwoundcarebusinessof versusin ethiconincinthefiscalfourthquarterof majormedicaldevicesanddiagnosticsfranchisesales change dollarsinmillion vs vs depuy ethiconendosurgery ethicon cordis visioncare diabetescare orthoclinicaldiagnostic total prioryearamountshavebeenreclassifiedtoconformtocurrentpresentation management discussion analysis result operation financial condition thesectionsthatfollowhighlightthesignificantcomponent incostofproductssoldasapercenttosalesremaine ofthechangesinconsolidatedearningsbeforeprovisionfortaxe flattotheprioryearthechangeinthemixofbusinesseswith onincome highersalesgrowthintheconsumerbusinessandaslightsales declineinthepharmaceuticalbusinesshadanegativeimpacton costofproductssoldandsellingmarketingandadministrative thecostofproductssoldasapercenttosalesinthiswasoff expensescostofproductssoldandsellingmarketingand setbymanufacturingefficienciesandnonrecurringpositiveitem administrativeexpensesasapercenttosaleswereasfollow inandnegativeitemsintherewasanincreaseinthe ofsales percenttosalesofsellingmarketingandadministrativeexpensesin costofproductssold primarilyduetothechangeinthemixofbusinesseswhereby percentpointincreaseovertheprioryear agreaterproportionofsaleswereattributabletotheconsumer segmentwhichhashighersellingmarketingandadministrative sellingmarketingandadministrativeexpense spendingadditionallyinthecompanyutilizedthegainasso percentpointdecreaseincreaseoverthe ciatedwiththedivestitureoftheprofessionalwoundcarebusiness prioryear ofethiconinctofundincreasedinvestmentspendingthiswa incostofproductssoldasapercenttosalesincreased partiallyoffsetbyongoingcostcontainmenteffort primarilyduetothecontinuednegativeimpactofproductmixand intherewasanincreaseinthepercenttosalesofcostof inventorywriteoffsassociatedwiththerestructuringactivityaddi productssoldprimarilyduetotheimpactofnewlyacquiredcon tionallyincludedsomenonrecurringpositiveitemstherewa sumerbrandstherewasanincreaseinthepercenttosalesofsell adecreaseinthepercenttosalesofsellingmarketingandadminis ingmarketingandadministrativeexpensesinprimarilydueto trativeexpensesinprimarilyduetocostcontainmenteffort theimpactofnewlyacquiredconsumerbrandspartiallyoffsetby acrossallthebusinessesandtheannualizedsavingsrecognizedfrom costcontainmentefforts therestructuringprogramadditionallyutilizedthe proceedsassociatedwiththedivestitureoftheprofessionalwound carebusinessofethiconinctofundincreasedinvestmentspende researchanddevelopmentexpenseexcludingpurchasedinprocessresearchanddevelopmentchargesbysegment ofbusinesswasasfollow dollarsinmillion ofsale ofsale ofsale consumer pharmaceutical medicaldevicesanddiagnostic totalresearchanddevelopmentexpense percentdecreaseincreaseovertheprioryear asapercenttosegmentsale researchanddevelopmentexpenseresearchanddevelopment capitalizedandtestedforimpairmentthecompanycapitalized activitiesrepresentasignificantpartofthecompanysbusiness billionofiprdinprimarilyassociatedwiththeacquisi theseexpendituresrelatetothedevelopmentofnewproduct tionsofcougarbiotechnologyincandsubstantiallyalloftheasset improvementofexistingproductstechnicalsupportofproduct andrightsofelansimmunotherapyprogram andcompliancewithgovernmentalregulationsfortheprotection inthecompanyrecordedachargeforiprdofmil ofconsumersandpatients lionbeforeandaftertaxrelatedtotheacquisitionsofamicab inandthereductioninthepharmaceutical surgrxinchealthmediaincandomrixbiopharmaceuticalsinc researchanddevelopmentspendingwasprimarilyduetoincrease healthmediaincaprivatelyheldcompanythatcreateswebbased efficienciesinpharmaceuticalresearchanddevelopmentactivitie behaviorchangeinterventionsaccountedformillionbeforetax oftheiprdchargesandwasincludedintheoperatingprofitof restructuringinthecompanyannouncedglobalrestruc theconsumersegmenttheiprdchargesforallofthefollowe turinginitiativesthatareexpectedtogeneratepretaxannualcost acquisitionswereincludedintheoperatingprofitofthemedical savingsofbillionwhenfullyimplementedinwith devicesanddiagnosticssegmentamicabaswedishdeveloper billionexpectedtobeachievedintheassociate ofinvitrodiagnostictechnologiesforuseinpointofcareand savingswillprovideadditionalresourcestoinvestinnewgrowth nearpatientsettingsoutsidethephysicalfacilitiesoftheclinical platformsensurethesuccessfullaunchofthecompanysmany laboratoryaccountedformillionbeforetaxoftheiprd newproductsandcontinuedgrowthofthecorebusinessesand chargessurgrxincaprivatelyhelddeveloperoftheadvance provideflexibilitytoadjusttothechangedandevolvingglobalenvi bipolartissuesealingsystemusedintheensealfamilyofdevice ronmentinthefiscalfourthquarterofthecompanyrecorde accountedformillionbeforetaxoftheiprdchargesomrixbio apretaxchargeofbillionofwhichmillionisincludedin pharmaceuticalsincafullyintegratedbiopharmaceuticalcompany costofproductssold thatdevelopsandmarketsbiosurgicalandimmunotherapyprod therestructuringprogramannouncedinhasbeencom uctsaccountedformillionbeforetaxoftheiprdcharge pletedseenotetotheconsolidatedfinancialstatementsfor inthecompanyrecordedachargeforiprdof additionaldetailsrelatedtotherestructuring millionbeforeandaftertaxrelatedtotheacquisitionofconor purchasedinprocessresearchanddevelopmentinin medsystemsinctheiprdchargewasincludedintheoperate accordancewithusgaapforbusinesscombinationspurchasedin profitofthemedicaldevicesanddiagnosticssegment processresearchanddevelopmentiprdisnolongerexpensedbut johnson johnson annual reportotherincomeexpensenetotherincomeexpensenet chargesofmillionandmillionforthenatrecor includesgainsandlossesrelatedtothesaleandwritedownofcer intangibleassetwritedownrecordedin taininvestmentsinequitysecuritiesheldbyjohnsonjohnson medicaldevicesanddiagnosticssegmentintheoperate developmentcorporationgainsandlossesonthedisposalof profitinthemedicaldevicesanddiagnosticssegmentincrease propertyplantandequipmentcurrencygainsandlossesnon fromtheimprovedoperatingprofitwasdueto controllinginterestslitigationsettlementsandliabilitiesandroyalty milliongainfromnetlitigationsettlementsfavorableproductmix incometheunfavorablechangeofbillioninotherincome manufacturingefficienciesandcostcontainmentinitiativesrelate expensenetfromtowasprimarilyduetoagainof tosellingmarketingandadministrativeexpensesthiswaspartially billionfromthedivestitureoftheprofessionalwoundcare offsetbymillioninrestructuringchargesintheoperat businessofethiconincin ingprofitinthemedicaldevicesanddiagnosticssegmentincrease inotherincomeexpensenetincludedincomefrom fromtheimprovedoperatingprofitwastheresultof netlitigationsettlementsandawardsofbillionandagainof themilliongainfromnetlitigationsettlementsfavorableprod billionfromthedivestitureoftheprofessionalwoundcare uctmixmanufacturingefficienciesandloweriprdchargesof businessofethiconincinotherincomeexpensenet millioninversusmillioninadditionally includedachargeofbillionbeforetaxrelatedtothe millionofrestructuringchargeswererecordedin natrecorintangibleassetwritedown interestincomeexpenseinterestincomeindecreasedby operatingprofitbysegment millionduetolowerratesofinterestearneddespitehigher operatingprofitsbysegmentofbusinesswereasfollow averagecashbalancesthecashbalanceincludingmarketable securitieswasbillionattheendofandaverage percentof billionascomparedtothebillionaveragecashbalance segmentsale intheincreaseintheaveragecashbalancewasprimarily dollarsinmillion duetocashgeneratedfromoperatingactivitie consumer interestexpenseinincreasedbymillionduetoahigher pharmaceutical debtbalancethenetdebtbalanceattheendofwasbil meddevicesanddiagnostic lionascomparedtobillionattheendofthehigheraver total agedebtbalanceofbillioninversusbillionin lessexpensesnotallocate wasprimarilyrelatedtofundingacquisitionsandinvestmentsand tosegment thepurchaseofthecompanyscommonstockundertheongoing earningsbeforeprovision commonstockrepurchaseprogramannouncedonjuly fortaxesonincome interestincomeindecreasedbymillionduetolower seenotetotheconsolidatedfinancialstatementsformoredetail ratesofinterestearneddespitehigheraveragecashbalancesthe amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrolle cashbalanceincludingmarketablesecuritieswasbillionat interestsandgeneralcorporateincomeexpense theendofandaveragedbillionascomparedtothe billionaveragecashbalanceintheincreaseinthe averagecashbalancewasprimarilyduetocashgeneratedfrom operatingactivitie interestexpenseinincreasedbymillionduetoa higherdebtbalanceinthesecondhalfofthecompanycon vertedsomeofitsshorttermdebttofixedlongtermdebtathigher interestratesthenetdebtbalanceattheendofwasbil lionascomparedtobillionattheendofthehigherdebt balanceinwasprimarilyduetothepurchaseofthecompany commonstockundertheongoingcommonstockrepurchase programannouncedonjulyandtofundacquisition interestincomeindecreasedbymilliondueto loweraveragecashbalancesthedeclineintheaveragecash balancewasprimarilyduetotheacquisitionoftheconsumer consumersegmentinconsumersegmentoperatingprofit healthcarebusinessofpfizerincondecember decreasedfromtheprimaryreasonsforthedecreasein interestexpenseinincreasedbymillionascom operatingprofitwasmillionofrestructuringchargespartially paredtoprioryearduetoahigheraveragedebtbalancethenet offsetbycostcontainmentinitiativesininconsumer debtbalanceattheendofwasbillionascomparedto segmentoperatingprofitincreasedfromcostsyner billionattheendofthehigherdebtbalancein gieslowerintegrationcostsinrelatedtotheacquisitionofthe wasduetothedebtassociatedwiththeacquisitionofthecon consumerhealthcarebusinessofpfizerincandothercostcon sumerhealthcarebusinessofpfizerincandthecommonstock tainmentinitiativescontributedtotheincreasedoperatingprofit repurchaseprogramannouncedin provisionfortaxesonincometheworldwideeffectiveincometax pharmaceuticalsegmentinpharmaceuticalsegmentoper ratewasininandinthe atingprofitdecreasedfromtheprimaryreasonsfor taxratedecreasedascomparedtoduetoincreasesin thedecreaseinoperatingprofitweremillionofrestructure taxableincomeinlowertaxjurisdictionsrelativetotaxableincome chargesmillionoflitigationexpenseandnegativeproduct inhighertaxjurisdictionsthetaxrateincreasedascompare mixduetothelossofmarketexclusivityfortopamaxand toduetoincreasesintaxableincomeinhighertaxjurisdic risperdaloralinpharmaceuticalsegmentoperate tionsrelativetotaxableincomeinlowerjurisdictionsinadditionthe profitincreasedfromtheprimarydriverofthe improvedoperatingprofitinwasduetotherestructure management discussion analysis result operation financial condition taxratebenefitedfromaonetimegainofmillionrelate swapcontractsbyapproximatelymillionineitherscenario toabusinessrestructuringofcertaininternationalsubsidiarie atmaturitythegainorlossontheswapcontractwouldbeoffsetby thegainorlossontheunderlyingtransactionandthereforewould liquidityandcapitalresource havenoimpactonfutureanticipatedcashflow thecompanydoesnotenterintofinancialinstrumentsfor liquiditycashflow tradingorspeculativepurposesfurtherthecompanyhasapolicy cashandcashequivalentswerebillionattheendof ofonlyenteringintocontractswithpartiesthathaveatleastana ascomparedwithbillionattheendoftheprimary orequivalentcreditratingthecounterpartiestothesecontract sourcesofcashthatcontributedtothebillionincreaseversus aremajorfinancialinstitutionsandthereisnosignificantconcentra prioryearwerebillionofcashgeneratedfromoperatingactivi tionofexposurewithanyonecounterpartymanagementbelieve tiesandbillionnetproceedsfromlongandshorttermdebtthe theriskoflossisremote majorusesofcashwerecapitalspendingofbillionacquisition thecompanyhasaccesstosubstantialsourcesoffundsat ofbillionnetinvestmentpurchasesofbilliondividendsto numerousbanksworldwideinseptemberthecompany shareholdersofbillionandtherepurchaseofcommonstocknet securedanewdaycreditfacilitytotalcreditavailabletothe ofproceedsfromtheexerciseofoptionsofbillion companyapproximatesbillionwhichexpiresseptember cashflowsfromoperationswerebillioninthe interestchargedonborrowingsunderthecreditlineagree majorsourcesofcashflowwerenetincomeofbillionadjuste mentsisbasedoneitherbidsprovidedbybankstheprimerateor fornoncashchargesfordepreciationamortizationandstockbase londoninterbankofferedratesliborplusapplicablemargin compensationofbillionrestructuringreservesofbillionand commitmentfeesundertheagreementarenotmaterial accountsreceivableandinventoriesofbillion theremaine totalborrowingsattheendofandwerebil changestooperatingcashflowwereauseoffundsofbillion lionandbillionrespectivelytheincreaseinborrowing relatedtopensionplancontributionsand decreasesinaccount betweenandwasaresultoffinancinggeneralcorporate payablepartiallyoffsetbydecreasesinotherreceivablesprepaid purposesandthecontinuationofthecommonstockrepurchase expensesanddeferredtaxe programannouncedininnetcashcashandcurrent inthecompanycontinuedtohaveaccesstoliquidity marketablesecuritiesnetofdebtwasbillioncomparedtonet throughthecommercialpapermarketforadditionaldetailson cashofbillionintotaldebtrepresentedoftotal borrowingsseenotetotheconsolidatedfinancialstatements capitalshareholdersequityandtotaldebtinandof thecompanyanticipatesthatoperatingcashflowsexisting totalcapitalinshareholdersequitypershareattheendof creditfacilitiesandaccesstothecommercialpapermarketswill wascomparedwithatyearendan providesufficientresourcestofundoperatingneedsin increaseof johnsonjohnsoncontinuestobeoneofafewindustrial companieswithatripleacreditratingasummaryofborrowing canbefoundinnotetotheconsolidatedfinancialstatement contractualobligationsandcommitment thecompanyhascontractualobligationsprimarilyleasedebtand unfundedretirementplanswithnoothersignificantobligation tosatisfytheseobligationsthecompanywillusecashfromopera tionsthefollowingtablesummarizesthecompanyscontractual obligationsandtheiraggregatematuritiesasofjanuary seenotesandtotheconsolidatedfinancialstatementsfor furtherdetail longterm intereston unfunded financingandmarketrisk debt debt retirement operating thecompanyusesfinancialinstrumentstomanagetheimpactof dollarsinmillion obligation obligation plan lease total foreignexchangeratechangesoncashflowsaccordinglythecompany entersintoforwardforeignexchangecontractstoprotectthevalueof certainforeigncurrencyassetsandliabilitiesandtohedgefutureforeign currencytransactionsprimarilyrelatedtoproductcostsgainsorlosse onthesecontractsareoffsetbythegainsorlossesontheunderlye transactionsaappreciationoftheusdollarfromthejanuary marketrateswouldincreasetheunrealizedvalueofthecompany total forwardcontractsbymillionconverselyadepreciationof theusdollarfromthejanuarymarketrateswoulddecrease fortaxmattersseenotetotheconsolidatedfinancialstatement theunrealizedvalueofthecompanysforwardcontractsbymillion ineitherscenariothegainorlossontheforwardcontractwouldbeoff sharerepurchaseanddividend setbythegainorlossontheunderlyingtransactionandtherefore onjulythecompanyannouncedthatitsboardofdirector wouldhavenoimpactonfutureanticipatedearningsandcashflow approvedastockrepurchaseprogramauthorizingthecompanyto thecompanyhedgestheexposuretofluctuationsincurrency buybackuptobillionofthecompanyscommonstockthe exchangeratesandtheeffectoncertainassetsandliabilitiesin repurchaseprogramhasnotimelimitandmaybesuspendedfor foreigncurrencybyenteringintocurrencyswapcontractsa periodsordiscontinuedatanytimeanysharesacquiredwillbe changeinthespreadbetweenusandforeigninterestratesonthe availableforgeneralcorporatepurposesthecompanyfundsthe companysinterestratesensitivefinancialinstrumentswould sharerepurchaseprogramthroughacombinationofavailablecash eitherincreaseordecreasetheunrealizedvalueofthecompany anddebtasofjanuarythecompanyrepurchasedan johnson johnson annual reportaggregateofmillionsharesofjohnsonjohnsoncommon thecompanyssalesreturnreservesareaccountedforinaccor stockunderthecurrentrepurchaseprogramatacostofbillion dancewiththeusgaapguidanceforrevenuerecognitionwhen inadditionthecompanyhasanannualprogramtorepurchase rightofreturnexistssalesreturnreservesarerecordedatfullsale sharesforuseinemployeestockandincentiveplan valuesalesreturnsintheconsumerandpharmaceuticalsegment thecompanyincreaseditsdividendinforthethcon arealmostexclusivelynotresalablesalesreturnsforcertainfran secutiveyearcashdividendspaidwerepersharein chisesinthemedicaldevicesanddiagnosticssegmentaretypically comparedwithdividendsofpershareinand resalablebutarenotmaterialthecompanyrarelyexchange pershareinthedividendsweredistributedasfollow productsfrominventoryforreturnedproductsthesalesreturn reserveforthetotalcompanyhasrangedbetweenandof annualnettradesalesduringthepriorthreefiscalreportingyear firstquarter secondquarter promotionalprogramssuchasproductlistingallowancesand thirdquarter cooperativeadvertisingarrangementsarerecordedintheyear fourthquarter incurredcontinuingpromotionalprogramsincludecouponsand total volumebasedsalesincentiveprogramstheredemptioncostof consumercouponsisbasedonhistoricalredemptionexperienceby onjanuarytheboardofdirectorsdeclaredaregularquar productandvaluevolumebasedincentiveprogramsarebasedon terlycashdividendofpersharepayableonmarch estimatedsalesvolumesfortheincentiveperiodandarerecorde toshareholdersofrecordasoffebruarythecompany asproductsaresoldthecompanyalsoearnsservicerevenuefor expectstocontinuethepracticeofpayingregularcashdividend copromotionofcertainproductsforallyearspresentedservice revenueswerelessthanoftotalrevenuesandareincludedin otherinformation salestocustomersadditionallythesearrangementsareevaluate todeterminetheappropriateamountstobedeferre criticalaccountingpoliciesandestimate inadditionthecompanyentersintocollaborationarrangement managementsdiscussionandanalysisofresultsofoperation whichcontainmultiplerevenuegeneratingactivitiestherevenuefor andfinancialconditionarebasedonthecompanysconsolidate thesearrangementsisrecognizedaseachactivityisperformedor financialstatementsthathavebeenpreparedinaccordancewith deliveredbasedontherelativefairvalueupfrontfeesreceivedas accountingprinciplesgenerallyacceptedintheusgaapthe partofthesearrangementsaredeferredandrecognizedasrevenue preparationofthesefinancialstatementsrequiresthatmanagement earnedovertheobligationperiodseenotetotheconsolidate makeestimatesandassumptionsthataffecttheamountsreported financialstatementsforadditionaldisclosuresoncollaboration forrevenuesexpensesassetsliabilitiesandotherrelateddisclo reasonablylikelychangestoassumptionsusedtocalculate suresactualresultsmayormaynotdifferfromtheseestimatesthe theaccrualsforrebatesreturnsandpromotionsarenotanticipate companybelievesthattheunderstandingofcertainkeyaccounte tohaveamaterialeffectonthefinancialstatementsthecompany policiesandestimatesareessentialinachievingmoreinsightintothe currentlydisclosestheimpactofchangestoassumptionsinthe companysoperatingresultsandfinancialconditionthesekey quarterlyorannualfilinginwhichthereisamaterialfinancial accountingpoliciesincluderevenuerecognitionincometaxeslegal statementimpact andselfinsurancecontingenciesvaluationoflonglivedasset belowaretableswhichshowtheprogressionofaccrue assumptionsusedtodeterminetheamountsrecordedforpension rebatesreturnspromotionsreservefordoubtfulaccountsand andotheremployeebenefitplansandaccountingforstockoption reserveforcashdiscountsbysegmentofbusinessforthefiscal yearsendedjanuaryanddecember revenuerecognitionthecompanyrecognizesrevenuefrom productsaleswhengoodsareshippedordeliveredandtitleand riskoflosspasstothecustomerprovisionsforcertainrebatessales consumersegment incentivestradepromotionscouponsproductreturnsanddis balanceat balanceat countstocustomersareaccountedforasreductionsinsalesinthe beginning payment end sameperiodtherelatedsalesarerecorde dollarsinmillion ofperiod accrual ofperiod productdiscountsgrantedarebasedonthetermsofarrange mentswithdirectindirectandothermarketparticipantsaswell accruedrebate asmarketconditionsincludingpriceschargedbycompetitor accruedreturn rebatesthelargestbeingthemedicaidrebateprovisionareesti accruedpromotion matedbasedoncontractualtermshistoricalexperiencetrend subtotal analysisandprojectedmarketconditionsinthevariousmarket reservefordoubtfulaccount servedthecompanyevaluatesmarketconditionsforproductsor reserveforcashdiscount groupsofproductsprimarilythroughtheanalysisofwholesalerand total otherthirdpartysellthroughandmarketresearchdataaswella internallygeneratedinformation salesreturnsaregenerallyestimatedandrecordedbasedon accruedrebate historicalsalesandreturnsinformationproductsthatexhibit accruedreturn unusualsalesorreturnpatternsduetodatingcompetitionorother accruedpromotion marketingmattersarespecificallyinvestigatedandanalyzedaspart subtotal oftheaccountingforsalesreturnaccrual reservefordoubtfulaccount salesreturnsallowancesrepresentareserveforproductsthat maybereturnedduetoexpirationdestructioninthefieldorinspe reserveforcashdiscount cificareasproductrecallthereturnsreserveisbasedonhistorical total returntrendsbyproductandbymarketasapercenttogrosssale includesreserveforcustomerrebatesofmillionatjanuaryandmillion atdecemberrecordedasacontraasset management discussion analysis result operation financial condition pharmaceuticalsegment ininaccordancewithusgaapthecompanyadopte thestandardrelatedtoaccountingforuncertaintyinincometaxe balanceat balanceat thecodificationprescribesarecognitionthresholdandmeasure beginning payment end dollarsinmillion ofperiod accrual ofperiod mentattributeforthefinancialstatementrecognitionandmeasure mentofataxpositiontakenorexpectedtobetakeninataxreturn accruedrebate thecodificationalsoprovidesguidanceonderecognitionclassifi accruedreturn cationandothermattersseenotetotheconsolidatedfinancial statementsforfurtherinformationregardingincometaxe accruedpromotion atjanuaryanddecemberthecumulative subtotal amountsofundistributedinternationalearningswereapproximately reservefordoubtfulaccount billionandbillionrespectivelythecompanyintend reserveforcashdiscount tocontinuetoreinvestitsundistributedinternationalearningsto total expanditsinternationaloperationsthereforenoustaxexpense hasbeenrecordedwithrespecttotheundistributedportionnot intendedforrepatriation accruedrebate accruedreturn legalandselfinsurancecontingenciesthecompanyrecord accruedpromotions accrualsforvariouscontingenciesincludinglegalproceedingsand subtotal productliabilitycasesastheseariseinthenormalcourseofbusi nesstheaccrualsarebasedonmanagementsjudgmentastothe reservefordoubtfulaccount probabilityoflossesandwhereapplicableactuariallydetermine reserveforcashdiscount estimatesadditionallythecompanyrecordsinsurancereceivable total amountsfromthirdpartyinsurerswhenrecoveryisprobablea includesreserveforcustomerrebatesofmillionatjanuaryand appropriatereservesagainstthesereceivablesarerecordedforesti millionatdecemberrecordedasacontraasset matedamountsthatmaynotbecollectedfromthirdpartyinsurer includesmillionadjustmentrelatedtopreviouslyestimatedaccruedsalesreserve longlivedandintangibleassetsthecompanyassesseschange medicaldevicesanddiagnosticssegment ineconomicconditionsandmakesassumptionsregardingestimated futurecashflowsinevaluatingthevalueofthecompanysproperty balanceat balanceat plantandequipmentgoodwillandintangibleassetsasthese beginning payment end dollarsinmillion ofperiod accrual ofperiod assumptionsandestimatesmaychangeovertimeitmayormaynot benecessaryforthecompanytorecordimpairmentcharge accruedrebate employeebenefitplansthecompanysponsorsvariousretirement accruedreturn andpensionplansincludingdefinedbenefitdefinedcontribution accruedpromotion andterminationindemnityplanswhichcovermostemployee subtotal worldwidetheseplansarebasedonassumptionsforthediscount reservefordoubtfulaccount rateexpectedreturnonplanassetsexpectedsalaryincreasesand reserveforcashdiscount healthcarecosttrendratesseenotetotheconsolidatedfinan cialstatementsforfurtherdetailsontheseratesandtheeffecta total ratechangewouldhaveonthecompanysresultsofoperation stockbasedcompensationthecompanyrecognizescompensa accruedrebates tionexpenseassociatedwiththeissuanceofequityinstrumentsto accruedreturn employeesfortheirservicesthefairvalueofeachawardisesti accruedpromotions matedonthedateofgrantusingtheblackscholesoptionvaluation subtotal modelandisexpensedinthefinancialstatementsovertheveste reservefordoubtfulaccount periodtheinputassumptionsusedindeterminingfairvalueare reserveforcashdiscount theexpectedlifeexpectedvolatilityriskfreerateandthedividend total yieldseenotetotheconsolidatedfinancialstatementsfor additionalinformation includesreserveforcustomerrebatesofmillionatjanuaryandmillion atdecemberrecordedasacontraasset includesmillionadjustmentrelatedtopreviouslyestimatedsalesrebatereserve newaccountingpronouncement refertonotetotheconsolidatedfinancialstatementsforrecently incometaxesincometaxesarerecordedbasedonamountsrefund adoptedaccountingpronouncementsandrecentlyissuedaccount ableorpayableforthecurrentyearandincludetheresultsofany ingpronouncementsnotyetadoptedasofjanuary differencebetweengaapaccountingandtaxreportingrecorde asdeferredtaxassetsorliabilitiesthecompanyestimatesdeferred economicandmarketfactor taxassetsandliabilitiesbasedoncurrenttaxregulationsandrate thecompanyisawarethatitsproductsareusedinanenvironment changesintaxlawsandratesmayaffectrecordeddeferredtax whereformorethanadecadepolicymakersconsumersandbusi assetsandliabilitiesinthefuturemanagementbelievesthat nesseshaveexpressedconcernsabouttherisingcostofhealthcare changesintheseestimateswouldnothaveamaterialeffectonthe inresponsetotheseconcernsthecompanyhasalongstande companysresultsofoperationscashflowsorfinancialposition policyofpricingproductsresponsiblyfortheperiodin theunitedstatestheweightedaveragecompoundannualgrowth rateofthecompanysnetpriceincreasesforhealthcareproduct johnson johnson annual reportprescriptionandoverthecounterdrugshospitalandprofessional commonstockmarketprice productswasbelowtheusconsumerpriceindexcpi thecompanyscommonstockislistedonthenewyorkstock inflationratescontinuetohaveaneffectonworldwide exchangeunderthesymboljnjthecompositemarketpricerange economiesandconsequentlyonthewaycompaniesoperate forjohnsonjohnsoncommonstockduringandwere thecompanywillaccountforoperationsinvenezuelaashighly inflationaryinasthepriorthreeyearcumulativeinflation high low high low ratehassurpassedinthefaceofincreasingcoststhecom firstquarter panystrivestomaintainitsprofitmarginsthroughcostreduction secondquarter programsproductivityimprovementsandperiodicpriceincrease thirdquarter thecompanyisexposedtofluctuationsincurrencyexchange ratesachangeinthevalueoftheusdollarascomparedto fourthquarter allforeigncurrenciesinwhichthecompanyhadsalesincomeor yearendclose expenseinwouldhaveincreasedordecreasedthetranslation offoreignsalesbymillionandincomebymillion cautionaryfactorsthatmayaffect thecompanyfacesvariousworldwidehealthcarechange futureresult thatmaycontinuetoresultinpricingpressuresthatincludehealth carecostcontainmentandgovernmentlegislationrelatingtosales thisannualreportcontainsforwardlookingstatementsforward promotionsandreimbursement lookingstatementsdonotrelatestrictlytohistoricalorcurrentfact changesinthebehaviorandspendingpatternsofpurchaser andanticipateresultsbasedonmanagementsplansthataresub ofhealthcareproductsandservicesincludingdelayingmedical jecttouncertaintyforwardlookingstatementsmaybeidentifie proceduresrationingprescriptionmedicationsreducingthefre bytheuseofwordssuchasplansexpectswillanticipate quencyofphysicianvisitsandforegoinghealthcareinsurance estimatesandotherwordsofsimilarmeaninginconjunctionwith coverageasaresultofthecurrentglobaleconomicdownturnmay amongotherthingsdiscussionsoffutureoperationsfinancial continuetoimpactthecompanysbusinesse performancethecompanysstrategyforgrowthproductdevelop thecompanyalsooperatesinanenvironmentwhichhas mentregulatoryapprovalmarketpositionandexpenditures becomeincreasinglyhostiletointellectualpropertyrightsgeneric forwardlookingstatementsarebasedoncurrentexpectation drugfirmshavefiledabbreviatednewdrugapplicationsanda offutureeventsthecompanycannotguaranteethatanyforward seekingtomarketgenericformsofmostofthecompanyskeyphar lookingstatementwillbeaccuratealthoughthecompanybelieve maceuticalproductspriortoexpirationoftheapplicablepatent thatithasbeenreasonableinitsexpectationsandassumption coveringthoseproductsintheeventthecompanyisnotsuccessful investorsshouldrealizethatifunderlyingassumptionsproveinac indefendingthepatentclaimschallengedinandafilingsthe curateorthatunknownrisksoruncertaintiesmaterializeactual genericfirmswillthenintroducegenericversionsoftheproduct resultscouldvarymateriallyfromthecompanysexpectationsand atissueresultinginthepotentialforsubstantialmarketshareand projectionsinvestorsarethereforecautionednottoplaceundue revenuelossesforthatproductforfurtherinformationseethe relianceonanyforwardlookingstatementsthecompanydoesnot discussiononlitigationagainstfilersofabbreviatednewdrug undertaketoupdateanyforwardlookingstatementsasaresultof applicationsinnotetotheconsolidatedfinancialstatement newinformationorfutureeventsordevelopment risksanduncertaintiesincludegeneralindustrycondition legalproceeding andcompetitioneconomicconditionssuchasinterestrateand thecompanyisinvolvedinnumerousproductliabilitycasesinthe currencyexchangeratefluctuationstechnologicaladvances unitedstatesmanyofwhichconcernallegedadversereactionsto newproductsandpatentsattainedbycompetitorschallenge drugsandmedicaldevicesthedamagesclaimedaresubstantial inherentinnewproductdevelopmentincludingobtainingregula andwhilethecompanyisconfidentoftheadequacyofthewarning toryapprovalschallengestopatentsusandforeignhealthcare andinstructionsforusewhichaccompanysuchproductsitisnot reformsandgovernmentallawsandregulationstrendstoward feasibletopredicttheultimateoutcomeoflitigationhoweverthe healthcarecostcontainmentincreasedscrutinyofthehealth companybelievesthatifanyliabilityresultsfromsuchcasesit careindustrybygovernmentagenciesproductefficacyorsafety willbesubstantiallycoveredbyexistingamountsaccruedinthe concernsresultinginproductrecallsorregulatoryaction companysbalancesheetunderitsselfinsuranceprogramandby thecompanysreportonformkfortheyearende thirdpartyproductliabilityinsurance januaryincludesinexhibitadiscussionofadditional thecompanyisalsoinvolvedinanumberofpatenttrademark factorsthatcouldcauseactualresultstodifferfromexpectation andotherlawsuitsaswellasinvestigationsincidentaltoitsbusi thecompanynotesthesefactorsaspermittedbytheprivate nesstheultimatelegalandfinancialliabilityofthecompanyin securitieslitigationreformactof respecttoallclaimslawsuitsandproceedingsreferredtoabove cannotbeestimatedwithanycertaintyhoweverinthecompany opinionbasedonitsexaminationofthesemattersitsexperience todateanddiscussionswithcounseltheultimateoutcomeoflegal proceedingsnetofliabilitiesalreadyaccruedinthecompany balancesheetisnotexpectedtohaveamaterialadverseeffecton thecompanysfinancialconditionalthoughtheresolutioninany reportingperiodofoneormoreofthesematterscouldhavea significantimpactonthecompanysresultsofoperationsand cashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsfor furtherinformationregardinglegalproceeding management discussion analysis result operation financial condition consolidated balance sheet johnson johnson subsidiaries january december dollar million share share datum note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note defer taxis income note prepay expense receivables total current asset property plant equipment net note intangible asset net note goodwill note defer taxis income note asset total asset liability shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue salary wages commission accrue taxis income total current liability longterm debt note defer taxis income note employee relate obligation note liability total liability shareholder equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share accumulate comprehensive income note retain earning common stock hold treasury cost note share share total shareholder equity total liability shareholder equity note consolidated financial statement johnson johnson annual reportconsolidate statement earnings johnson johnson subsidiarie dollar million share figure note sale customer cost product sell gross profit selling marketing administrative expense research expense purchase inprocess research development note interest income interest expense net portion capitalize note income expense net restructure note earning provision taxis income provision taxis income note net earning basic net earning share note dilute net earning share note cash dividend share basic average share outstanding note diluted average share outstanding note note consolidated financial statement consolidate financial statement consolidate statement equity johnson johnson subsidiaries accumulate treasury comprehensive retain comprehensive common stock stock dollar million note total income earning income issue balance december net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock adoption fin comprehensive income net tax currency translation adjustment unrealize gain security employee benefit plan loss derivative hedge reclassification adjustment total comprehensive income balance december net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security employee benefit plan gain derivative hedge reclassification adjustment total comprehensive income balance december net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security employee benefit plan gain derivative hedge total comprehensive income balance january note consolidated financial statement johnson johnson annual reportconsolidate statement cash flow johnson johnson subsidiaries dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow operating activity depreciation amortization property intangible stock base compensation purchase inprocess research development intangible asset writedown natrecor defer tax provision account receivable allowance change asset liability net effect acquisition decreaseincrease account receivable decreaseincrease inventory decreaseincrease account payable accrue liability decreaseincrease current noncurrent asset increase current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal asset acquisition net cash acquire note purchase investment sale investment primarily intangible net cash investing activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt retirement longterm debt proceed exercise stock optionsexcess tax benefit net cash financing activity effect exchange rate change cash cash equivalent increase cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed conversion debt acquisition fair value asset acquire fair value liability assume noncontrolle interest net cash pay acquisition note consolidated financial statement consolidated financial statement notestoconsolidatedfinancialstatement summaryofsignificantaccountingpolicie duringthefiscalsecondquarterofinaccordancewith principlesofconsolidation usgaapthecompanyadoptedthestandardsonsubsequent theconsolidatedfinancialstatementsincludetheaccountsof eventsthispronouncementestablishesstandardsofaccounting johnsonjohnsonandsubsidiariesthecompanyinter foranddisclosureofeventsthatoccurafterthebalancesheet companyaccountsandtransactionsareeliminate datebutbeforefinancialstatementsareissuedseenotefor relateddisclosure descriptionofthecompanyandbusinesssegment duringthefiscalfirstquarterofinaccordancewithu thecompanyhasapproximatelyemployeesworldwide gaapthecompanyadoptedthestandardsonbusinesscombina engagedintheresearchanddevelopmentmanufactureandsaleof tionsandnoncontrollinginterestsinconsolidatedfinancialstate abroadrangeofproductsinthehealthcarefieldthecompany mentsthesestandardsaimtoimprovesimplifyandconverge conductsbusinessinvirtuallyallcountriesoftheworldanditspri internationallytheaccountingforbusinesscombinationsandthe maryfocusisonproductsrelatedtohumanhealthandwellbeing reportingofnoncontrollinginterestsinconsolidatedfinancialstate thecompanyisorganizedintothreebusinesssegment mentsthesestandardshaveanimpactonthemannerinwhichthe consumerpharmaceuticalandmedicaldevicesanddiagnostics companyaccountsforacquisitionsbeginninginthefiscalyear theconsumersegmentmanufacturesandmarketsabroadrange significantchangesincludethecapitalizationofpurchase ofproductsusedinthebabycareskincareoralcarewoundcare inprocessresearchanddevelopmentiprdexpensingofacqui andwomenshealthcarefieldsaswellasnutritionalandoverthe sitionrelatedrestructuringactionsandtransactionrelatedcostsand counterpharmaceuticalproductstheseproductsaremarketedto therecognitionofcontingentpurchasepriceconsiderationatfair thegeneralpublicandsoldbothtoretailoutletsanddistributor valueattheacquisitiondateinadditionchangesinaccountingfor throughouttheworldthepharmaceuticalsegmentincludesprod deferredtaxassetvaluationallowancesandacquiredincometax uctsinthefollowingtherapeuticareasantiinfectiveantipsychotic uncertaintiesafterthemeasurementperiodwillberecognizedin cardiovascularcontraceptivedermatologygastrointestinalhema earningsratherthanasanadjustmenttothecostofacquisition tologyimmunologyneurologyoncologypainmanagementurol thisaccountingtreatmentfortaxesisapplicabletoacquisitionsthat ogyandvirologytheseproductsaredistributeddirectlytoretailer occurredbothpriorandsubsequenttotheadoptionofthestandard wholesalersandhealthcareprofessionalsforprescriptionusethe operatingprofitattributabletononcontrollinginterestsisreporte medicaldevicesanddiagnosticssegmentincludesabroadrangeof inotherincomeexpensenetandtherelatedtaximpacttothe productsusedprincipallyintheprofessionalfieldsbyphysicians provisionfortaxesadditionallyequityattributabletonon nursestherapistshospitalsdiagnosticlaboratoriesandclinics controllinginterestsisrecordedinothernoncurrentliabilitie theseproductsincludecordiscirculatorydiseasemanagement noncontrollinginterestsasrelatedtothecompanysfinancial productsdepuysorthopaedicjointreconstructionspinalcareand statementsareimmaterialandthereforenotseparatelydisclose sportsmedicineproductsethiconssurgicalcareaestheticsand duringthefiscalfirstquarterofinaccordancewithus womenshealthproductsethiconendosurgerysminimallyinva gaapthecompanyadoptedthestandardrelatedtodisclosure sivesurgicalproductslifescansbloodglucosemonitoringand aboutderivativeinstrumentsandhedgingactivitieswhich insulindeliveryproductsorthoclinicaldiagnosticsprofessional enhancedthedisclosureregardingthecompanysderivativeand diagnosticproductsandvistakonsdisposablecontactlense hedgingactivitiestheadoptionofthisstandarddidnothavea materialimpactonthecompanysresultsofoperationscashflow newaccountingpronouncement orfinancialpositionseenoteforenhanceddisclosure recentlyadoptedaccountingpronouncement duringthefiscalfirstquarterofinaccordancewithus duringthefiscalfourthquarterofinaccordancewithus gaapthecompanyadoptedthestandardoncollaborativearrange gaapthecompanyadoptedtheauthoritativeguidancefor mentsrelatedtothedevelopmentandcommercializationofintel employersdisclosuresaboutpostretirementbenefitplanassetsto lectualpropertythisstandardaddressestheincomestatement enhancethedisclosureregardingthetypesofassetsandassociate classificationofpaymentsmadebetweenpartiesinacollaborative risksinanemployersdefinedbenefitpensionorotherpostretire arrangementtheimpactoftheadoptionofthisstandardrelatedto mentplanaswellaseventsintheeconomyandmarketsthatcould allcollaborationagreementsthatexistedasofjanuaryand haveasignificanteffectonthevalueoftheplanassetstheadop decemberwasimmaterialtothecompanysresultsof tionofthisstandarddidnothaveamaterialimpactonthecom operationscashflowsorfinancialposition panysresultsofoperationscashflowsorfinancialpositionsee duringthefiscalfirstquarterofinaccordancewithus noteforenhanceddisclosure gaapthecompanyadoptedthestandardrelatedtodefensive duringthefiscalthirdquarterofthecompanyadopte intangibleassetsthisstandardappliestoacquiredintangible thefasbaccountingstandardscodificationtmascorcodification assetsinsituationsinwhichanentitydoesnotintendtoactivelyuse andthehierarchyofgenerallyacceptedaccountingprinciplesgaap theassetbutintendstoholdtheassettopreventothersfrom whichestablishesthecodificationasthesolesourceforauthorita obtainingaccesstotheassetexceptforintangibleassetsthatare tiveusgaapandwillsupersedeallaccountingstandardsinu usedinresearchanddevelopmentactivitiestheadoptionofthis gaapasidefromthoseissuedbythesectheadoptionofthecod standarddidnothaveamaterialimpactonthecompanysresultsof ificationdidnothaveanimpactonthecompanysresultsofopera operationscashflowsorfinancialposition tionscashflowsorfinancialpositionsincetheadoptionofthe accountingstandardscodificationascthecompanysnotesto recentlyissuedaccountingstandard theconsolidatedfinancialstatementswillnolongermakereference notadoptedasofjanuary tostatementoffinancialaccountingstandardssfasorotherus thefasbissuedguidanceandamendmentstothecriteriaforsepa gaappronouncement ratingconsiderationinmultipledeliverablerevenuearrangement johnson johnson annual reporttheguidanceandamendmentsareexpectedtoaprovideprinci itscarryingvalueifquotedmarketpricesarenotavailablethe plesandapplicationguidanceonwhethermultipledeliverable companywillestimatefairvalueusingadiscountedvalueof existhowthearrangementshouldbeseparatedandtheconsidera estimatedfuturecashflow tionallocatedbrequireanentitytoallocaterevenueinan arrangementusingestimatedsellingpricesofdeliverablesifaven revenuerecognition dordoesnothavevendorspecificobjectiveevidenceorthirdparty thecompanyrecognizesrevenuefromproductsaleswhenthe evidenceofsellingpriceandceliminatetheuseoftheresidual goodsareshippedordeliveredandtitleandriskoflosspasstothe methodandrequireanentitytoallocatetherevenueusingthe customerprovisionsforcertainrebatessalesincentivestradepro relativesellingpricemethodtheguidancesignificantlyexpandsthe motionscouponsproductreturnsanddiscountstocustomersare disclosurerequirementsformultipledeliverablerevenuearrange accountedforasreductionsinsalesinthesameperiodtherelate mentsthisguidanceiseffectiveprospectivelyforrevenuearrange salesarerecorde mentsenteredintoormateriallymodifiedinfiscalyearsbeginne productdiscountsgrantedarebasedonthetermsofarrange onorafterjuneearlyadoptionispermittedthecompany mentswithdirectindirectandothermarketparticipantsaswell adoptedthisguidanceinthefirstfiscalquarteroftheadop asmarketconditionsincludingpriceschargedbycompetitors tionwillnothaveamaterialimpactonthecompanysresultsof rebatesthelargestbeingthemedicaidrebateprovisionareesti operationscashflowsorfinancialpositionhoweveritwillexpand matedbasedoncontractualtermshistoricalexperiencetrend thedisclosuresforsucharrangement analysisandprojectedmarketconditionsinthevariousmarket thefasbissuedastandardtoimprovefinancialreportingby servedthecompanyevaluatesmarketconditionsforproductsor enterprisesinvolvedwithvariableinterestentitiesthisstatement groupsofproductsprimarilythroughtheanalysisofwholesalerand iseffectiveforthecompanybeginningwiththefiscalyear otherthirdpartysellthroughandmarketresearchdataaswella earlierapplicationisprohibitedtheadoptionofthisstandardwill internallygeneratedinformation nothaveamaterialimpactonthecompanysresultsofoperation salesreturnsaregenerallyestimatedandrecordedbasedon cashflowsorfinancialposition historicalsalesandreturnsinformationproductsthatexhibit unusualsalesorreturnpatternsduetodatingcompetitionorother cashequivalent marketingmattersarespecificallyinvestigatedandanalyzedaspart thecompanyconsiderssecuritieswithmaturitiesofthreemonth oftheaccountingforsalesreturnaccrualssalesreturnsallowance orlesswhenpurchasedtobecashequivalent representareserveforproductsthatmaybereturnedduetoexpira tiondestructioninthefieldorinspecificareasproductrecallthe investment returnsreserveisbasedonhistoricalreturntrendsbyproductand shorttermmarketablesecuritiesarecarriedatcostwhichapproxi bymarketasapercenttogrosssalesinaccordancewiththecom matesfairvalueinvestmentsclassifiedasavailableforsaleare panysaccountingpoliciesthecompanygenerallyissuescreditto carriedatestimatedfairvaluewithunrealizedgainsandlosse customersforreturnedgoodsthecompanyssalesreturnreserve recordedasacomponentofaccumulatedothercomprehensive areaccountedforinaccordancewithusgaapguidanceregarde incomelongtermdebtsecuritiesthatthecompanyhastheability revenuerecognitionwhenrightofreturnexistssalesreturn andintenttoholduntilmaturityarecarriedatamortizedcost reservesarerecordedatfullsalesvaluesalesreturnsinthecon managementdeterminestheappropriateclassificationofit sumerandpharmaceuticalsegmentsarealmostexclusivelynot investmentindebtandequitysecuritiesatthetimeofpurchase resalablesalesreturnsforcertainfranchisesinthemedicaldevice andreevaluatessuchdeterminationateachbalancesheetdate anddiagnosticssegmentaretypicallyresalablebutarenotmate thecompanyperiodicallyreviewsitsinvestmentsinequity rialthecompanyrarelyexchangesproductsfrominventoryfor securitiesforimpairmentandadjuststheseinvestmentstotheir returnedproductsthesalesreturnsreserveforthetotalcompany fairvaluewhenadeclineinmarketvalueisdeemedtobeother hasrangedbetweenandofannualnettradesalesdure thantemporaryiflossesonthesesecuritiesareconsideredtobe thepriorthreefiscalreportingyear otherthantemporarythelossisrecognizedinearning promotionalprogramssuchasproductlistingallowancesand cooperativeadvertisingarrangementsarerecordedintheyear propertyplantandequipmentanddepreciation incurredcontinuingpromotionalprogramsincludecouponsand propertyplantandequipmentarestatedatcostthecompany volumebasedsalesincentiveprogramstheredemptioncostof utilizesthestraightlinemethodofdepreciationovertheestimated consumercouponsisbasedonhistoricalredemptionexperienceby usefullivesoftheasset productandvaluevolumebasedincentiveprogramsarebasedon theestimatedsalesvolumesfortheincentiveperiodandare buildingandbuildingequipment year recordedasproductsaresoldthecompanyalsoearnsservicerev landandleaseholdimprovement years enueforcopromotionofcertainproductsandincludesitinsalesto machineryandequipment year customersthesearrangementsareevaluatedtodeterminethe thecompanycapitalizescertaincomputersoftwareanddevelopment appropriateamountstobedeferre costsincludedinmachineryandequipmentwhenincurred inconnectionwithdevelopingorobtainingcomputersoftwarefor shippingandhandle internalusecapitalizedsoftwarecostsareamortizedoverthe shippingandhandlingcostsincurredweremillionmil estimatedusefullivesofthesoftwarewhichgenerallyrangefromto lionandmillioninandrespectivelyand year areincludedinsellingmarketingandadministrativeexpensethe thecompanyreviewslonglivedassetstoassessrecoverability amountofrevenuereceivedforshippingandhandlingislessthan usingundiscountedcashflowswhencertaineventsorchangesin ofsalestocustomersforallperiodspresente operatingoreconomicconditionsoccuranimpairmentassessment maybeperformedontherecoverabilityofthecarryingvalueof inventory theseassetsiftheassetisdeterminedtobeimpairedthelossis inventoriesarestatedatthelowerofcostormarketdeterminedby measuredbasedonthedifferencebetweentheassetsfairvalueand thefirstinfirstoutmethod note consolidated financial statement intangibleassetsandgoodwill researchanddevelopmentexpensebecausetheperformanceof theauthoritativeliteratureonusgaaprequiresthatgoodwilland contractdevelopmentservicesisnotcentraltothecompanys intangibleassetswithindefinitelivesbeassessedannuallyfor operationsingeneraltheincomestatementpresentationfor impairmentthecompanycompletedtheannualimpairmenttest thesecollaborationsisasfollow forinthefiscalfourthquarterandnoimpairmentwasdeter minedfutureimpairmenttestswillbeperformedannuallyinthe naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproduct salestocustomer fiscalfourthquarterorsoonerifatriggeringeventoccur intangibleassetsthathavefiniteusefullivescontinuetobe royaltiesmilestonespaidto collaborativepartner amortizedovertheirusefullivesandarereviewedforimpairment postregulatoryapproval costofgoodssold whenwarrantedbyeconomicconditionsseenoteforfurther royaltiesreceivedfrom detailsonintangibleassetsandgoodwill collaborativepartner otherincomeexpensenet upfrontpaymentsmilestone financialinstrument paidtocollaborativepartner asrequiredbyusgaapallderivativeinstrumentsarerecordedon preregulatoryapproval researchexpense thebalancesheetatfairvaluechangesinthefairvalueofderivative researchanddevelopmentpayment arerecordedeachperiodincurrentearningsorothercomprehensive tocollaborativepartner researchexpense incomedependingonwhetherthederivativeisdesignatedaspartof researchanddevelopmentpayment ahedgetransactionandifsothetypeofhedgetransaction receivedfromcollaborativepartner reductionofresearchexpense thecompanydocumentsallrelationshipsbetweenhedgeditem andderivativestheoverallriskmanagementstrategyincludesrea milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldover theusefullife sonsforundertakinghedgetransactionsandenteringintoderivative theobjectivesofthisstrategyareminimizeforeigncurrencyexpo advertising suresimpactonthecompanysfinancialperformanceprotectthe costsassociatedwithadvertisingareexpensedintheyearincurre companyscashflowfromadversemovementsinforeignexchange andareincludedinthesellingmarketingandadministrative ratesensuretheappropriatenessoffinancialinstrumentsand expensesadvertisingexpensesworldwidewhicharecomprisedof managetheenterpriseriskassociatedwithfinancialinstitution televisionradioprintmediaandinternetadvertisingwerebil seenoteforadditionalinformationonfinancialinstrument lioninbillioninandbillionin productliability incometaxe accrualsforproductliabilityclaimsarerecordedonanundis thecompanyintendstocontinuetoreinvestitsundistribute countedbasiswhenitisprobablethataliabilityhasbeenincurre internationalearningstoexpanditsinternationaloperationsthere andtheamountoftheliabilitycanbereasonablyestimatedbase forenoustaxexpensehasbeenrecordedwithrespecttothe onexistinginformationtheaccrualsareadjustedperiodicallyas undistributedportionnotintendedforrepatriationatjanuary additionalinformationbecomesavailableasaresultofcostand anddecemberthecumulativeamountofundistrib availabilityfactorseffectivenovemberthecompany utedinternationalearningswereapproximatelybillionand ceasedpurchasingthirdpartyproductliabilityinsurancebasedon billionrespectively theavailabilityofpriorcoveragereceivablesforinsurancerecover deferredincometaxesarerecognizedfortaxconsequence iesrelatedtoproductliabilityclaimsarerecordedonanundis oftemporarydifferencesbyapplyingenactedstatutorytaxrate countedbasiswhenitisprobablethatarecoverywillberealized applicabletofutureyearstodifferencesbetweenthefinancial reportingandthetaxbasisofexistingassetsandliabilitie researchanddevelopment researchanddevelopmentexpensesareexpensedasincurred netearningspershare upfrontandmilestonepaymentsmadetothirdpartiesinconnec basicearningspershareiscomputedbydividingnetearningsavail tionwithresearchanddevelopmentcollaborationsareexpensedas abletocommonshareholdersbytheweightedaveragenumberof incurreduptothepointofregulatoryapprovalpaymentsmadeto commonsharesoutstandingfortheperioddilutedearningsper thirdpartiessubsequenttoregulatoryapprovalarecapitalizedand sharereflectsthepotentialdilutionthatcouldoccurifsecuritie amortizedovertheremainingusefullifeoftherelatedproduct wereexercisedorconvertedintocommonstockusingthetreasury amountscapitalizedforsuchpaymentsareincludedinother stockmethod intangiblesnetofaccumulatedamortization thecompanyentersintocollaborativearrangementstypically useofestimate withotherpharmaceuticalorbiotechnologycompaniestodevelop thepreparationofconsolidatedfinancialstatementsinconformity andcommercializedrugcandidatesorintellectualpropertythese withaccountingprinciplesgenerallyacceptedintheusrequire arrangementstypicallyinvolvetwoormorepartieswhoareactive managementtomakeestimatesandassumptionsthataffectthe participantsinthecollaborationandareexposedtosignificantrisk amountsreportedestimatesareusedwhenaccountingforsale andrewardsdependentonthecommercialsuccessoftheactivitie discountsrebatesallowancesandincentivesproductliabilitie thesecollaborationsusuallyinvolvevariousactivitiesbyoneor incometaxesdepreciationamortizationemployeebenefitscon morepartiesincludingresearchanddevelopmentmarketingand tingenciesandintangibleassetandliabilityvaluationsforinstance sellinganddistributionoftenthesecollaborationsrequireupfront indeterminingannualpensionandpostemploymentbenefitcost milestoneandroyaltyorprofitsharepaymentscontingentuponthe thecompanyestimatestherateofreturnonplanassetsandthe occurrenceofcertainfutureeventslinkedtothesuccessoftheasset costoffuturehealthcarebenefitsactualresultsmayormaynot indevelopmentamountsduefromcollaborativepartnersrelatedto differfromthoseestimate developmentactivitiesaregenerallyreflectedasareductionof johnson johnson annual reportannualclosingdate reclassification thecompanyfollowstheconceptofafiscalyearwhichendson certainpriorperiodamountshavebeenreclassifiedtoconformto thesundaynearesttotheendofthemonthofdecembernormally currentyearpresentation eachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthe fiscalyearconsistsofweeksaswasthecaseinandwill bethecaseagainin cashcashequivalentsandcurrentmarketablesecuritie january december amortize unrealized estimate amortize unrealized estimate dollarsinmillion cost gainslosse fairvalue cost gainslosse fairvalue currentinvestment cash governmentsecuritiesandobligation corporatedebtsecuritie moneymarketfund timedeposit totalcashcashequivalentsandcurrentmarketablesecuritie asofjanuarycurrentmarketablesecuritiesconsistof thecompanycapitalizesinterestexpenseaspartofthecostof millionandmillionofgovernmentsecuritiesandobliga constructionoffacilitiesandequipmentinterestexpensecapital tionsandcorporatedebtsecuritiesrespectively izedinandwasmillionmillionand asofdecembercurrentmarketablesecuritiescon millionrespectively sistofmillionmillionandmillionofgovernment depreciationexpenseincludingtheamortizationofcapitalize securitiesandobligationscorporatedebtsecuritiesandtime interestinandwasbillionbillionand depositsrespectively billionrespectively fairvalueofgovernmentsecuritiesandobligationsand uponretirementorotherdisposalofpropertyplantandequip corporatedebtsecuritieswereestimatedusingquotedbroker mentthecostsandrelatedamountsofaccumulateddepreciation pricesinactivemarket oramortizationareeliminatedfromtheassetandaccumulate thecompanyinvestsitsexcesscashinbothdepositswith depreciationaccountsrespectivelythedifferenceifanybetween majorbanksthroughouttheworldandotherhighqualitymoney thenetassetvalueandtheproceedsarerecordedinearning marketinstrumentsthecompanyhasapolicyofmakinginvest mentsonlywithcommercialinstitutionsthathaveatleastana intangibleassetsandgoodwill orequivalentcreditrate attheendofandthegrossandnetamountsofintangi bleassetswere inventory dollarsinmillion attheendofandinventorieswerecomprisedof intangibleassetswithdefinitelive dollarsinmillion patentsandtrademarksgross rawmaterialsandsupplie lessaccumulatedamortization goodsinprocess patentsandtrademarksnet finishedgood otherintangiblesgross lessaccumulatedamortization otherintangiblesnet propertyplantandequipment totalintangibleassetswithdefinitelivesgross attheendofandpropertyplantandequipmentatcost lessaccumulatedamortization andaccumulateddepreciationwere totalintangibleassetswithdefinitelivesnet intangibleassetswithindefinitelive dollarsinmillion landandlandimprovement trademark buildingsandbuildingequipment purchasedinprocessresearchanddevelopment machineryandequipment totalintangibleassetswithindefinitelive constructioninprogress totalintangibleassetsnet purchasedinprocessresearchanddevelopmentwillbeaccountedforasanindefinite lessaccumulateddepreciation livedintangibleassetuntiltheunderlyingprojectiscompletedorabandone note consolidated financial statement goodwillasofjanuaryanddecembera asrequiredbyusgaapforderivativeinstrumentsandhedg allocatedbysegmentofbusinessisasfollow ingactivitiesallderivativeinstrumentsaretoberecordedonthe balancesheetatfairvaluechangesinthefairvalueofderivatives meddev arerecordedeachperiodincurrentearningsorothercomprehen dollarsinmillion consumer pharm anddiag total siveincomedependingonwhetherthederivativeisdesignatedas goodwillatdecember partofahedgetransactionandifsothetypeofhedgetransaction acquisition thedesignationasacashflowhedgeismadeattheentrance currencytranslationother dateintothederivativecontractatinceptionallderivativesare goodwillatdecember expectedtobehighlyeffectivechangesinthefairvalueofa acquisition derivativethatisdesignatedasacashflowhedgeandishighly currencytranslationother effectivearerecordedinaccumulatedothercomprehensiveincome goodwillatjanuary untiltheunderlyingtransactionaffectsearningsandarethen reclassifiedtoearningsinthesameaccountasthehedgedtransac includesreclassificationbetweensegment tiongainslossesonnetinvestmenthedgesareaccountedfor theweightedaverageamortizationperiodsforpatentsand throughthecurrencytranslationaccountandareinsignificant trademarksandotherintangibleassetsareyearsandyear onanongoingbasisthecompanyassesseswhethereachderiva respectivelytheamortizationexpenseofamortizableassetsfor tivecontinuestobehighlyeffectiveinoffsettingchangesinthe thefiscalyearsendedjanuarydecemberand cashflowsofhedgeditemsifandwhenaderivativeisnolonger decemberwasmillionmillionandmil expectedtobehighlyeffectivehedgeaccountingisdiscontinue lionbeforetaxrespectivelycertainpatentsandintangibleasset hedgeineffectivenessifanyisincludedincurrentperiodearning werewrittendowntofairvalueduringfiscalyearsand inotherincomeandexpensenetandwasinsignificantforthe withtheresultingchargeincludedinamortizationexpense fiscalyearendedjanuaryanddecemberrefer theestimatedamortizationexpenseforthefivesucceede tonotefordisclosuresofmovementsinaccumulatedother yearsapproximatesmillionbeforetaxperyearsubstantially comprehensiveincome alloftheamortizationexpenseisincludedincostofproductssold asofjanuarythebalanceofdeferrednetgainson derivativesincludedinaccumulatedothercomprehensiveincome wasmillionaftertaxforadditionalinformationseenote fairvaluemeasurement thecompanyexpectsthatsubstantiallyalloftheamountrelate duringthefiscalfirstquarterofinaccordancewithus toforeignexchangecontractswillbereclassifiedintoearningsover gaapthecompanyadoptedthestandardrelatedtodisclosure thenextmonthsasaresultoftransactionsthatareexpectedto aboutderivativeinstrumentsandhedgingactivitiesthisstandard occuroverthatperiodthemaximumlengthoftimeoverwhichthe requiresqualitativedisclosuresaboutobjectivesandstrategiesfor companyishedgingtransactionexposureismonthsexclude usingderivativesquantitativedisclosuresaboutfairvalueamount interestrateswapstheamountultimatelyrealizedinearningswill ofgainandlossesonderivativeinstrumentsanddisclosuresabout differasforeignexchangerateschangerealizedgainsandlosse creditriskrelatedcontingentfeaturesinderivativeagreement areultimatelydeterminedbyactualexchangeratesatmaturityof thecompanyusesforwardexchangecontractstomanageits thederivative exposuretothevariabilityofcashflowsprimarilyrelatedtothefor thefollowingtableisasummaryoftheactivityforthefiscal eignexchangeratechangesoffutureintercompanyproductand yearendedjanuaryrelatedtodesignatedderivativesas thirdpartypurchasesofrawmaterialsdenominatedinforeigncur definedinthecodification rencythecompanyalsousescrosscurrencyinterestrateswapsto managecurrencyriskprimarilyrelatedtoborrowingsbothtypesof gainloss gainloss gainloss reclassedfrom recognize derivativesaredesignatedascashflowhedgesthecompanyalso recognizedin accumulated inother usesforwardexchangecontractstomanageitsexposuretothe cashflowhedge accumulate ociinto income dollarsinmillion oci income expense variabilityofcashflowsforrepatriationofforeigndividendsthese foreignexchangecontract contractsaredesignatedasnetinvestmenthedgesadditionally thecompanyusesforwardexchangecontractstooffsetitsexpo foreignexchangecontract b suretocertainforeigncurrencyassetsandliabilitiestheseforward foreignexchangecontract c exchangecontractsarenotdesignatedashedgesandtherefore crosscurrencyinterestrateswap changesinthefairvaluesofthesederivativesarerecognizedin foreignexchangecontract e earningstherebyoffsettingthecurrentearningseffectofthe total relatedforeigncurrencyassetsandliabilitiesthecompanydoe effectiveportion notenterintoderivativefinancialinstrumentsfortradingorspecu ineffectiveportion lativepurposesorcontaincreditriskrelatedcontingentfeaturesor aincludedinsalestocustomer requirementstopostcollateralonanongoingbasisthecompany bincludedincostofproductssold monitorscounterpartycreditratingsthecompanyconsiderscredit cincludedinresearchexpense nonperformancerisktobelowbecausethecompanyentersinto dincludedininterestincomeinterestexpensenet agreementswithcommercialinstitutionsthathaveatleastana eincludedinotherincomeexpensenet orequivalentcreditratingasofjanuarythecompany hadnotionalamountsoutstandingforforwardforeignexchange forthefiscalyearendedjanuaryagainofmillionwa contractsandcrosscurrencyinterestrateswapsofbillionand recognizedinotherincomeexpensenetrelatingtoforeign billionrespectively exchangecontractsnotdesignatedashedginginstrumentsunder thecodification johnson johnson annual reportduringthefiscalfirstquarterofinaccordancewithus duringthecompanyacquiredsubstantiallyalloftheasset gaapthecompanyadoptedthestandardrelatedtofairvaluemeas andrightsofelansalzheimersimmunotherapyprogramthrougha urementsexceptfornonfinancialassetsandliabilitiesrecognizedor newlyformedcompanyjanssenalzheimerimmunotherapyjai disclosedatfairvalueonanonrecurringbasiswhichbecameeffec ofwhichthecompanyownsandelanownsinaddi tiveduringthefirstfiscalquarteroftheeffectofadoptionon tionthecompanypurchasedapproximatelymillionnewly decemberofthisstandardfornonfinancialassetsandlia issuedamericandepositaryreceiptsadrsofelanrepresente bilitiesrecordedatfairvalueonanonrecurringbasisdidnothavea ofelansoutstandingordinarysharesaspartofthistransac materialimpactonthecompanysfinancialpositionandresultsof tionthecompanypaidmilliontoelanandcommittedtofund operationsthisstandarddefinesfairvalueestablishesaframework uptomillionofelansshareofresearchanddevelopment formeasuringfairvalueandexpandsdisclosuresaboutfairvalue spendingbyjaiofthistotalconsiderationofmillion measurementsduringthefiscalfirstquarterofthecompany millionrepresentsthefairvalueoftheinvestmentinelan adoptedthestandardrelatedtofairvalueoptionforfinancialasset basedonelanssharepriceinanactivelytradedmarketasofthe andfinancialliabilitiesthisstandardpermitsthecompanytomeas dateofthistransactiontheiprdrelatedtothistransactionwa urecertainfinancialassetsandfinancialliabilitiesatfairvaluethe millionandisassociatedwithbapineuzumabapotentialfirst companyassessedthefairvalueoptionmadeavailableuponadopte inclasstreatmentthatisbeingevaluatedforslowingtheprogre thisstandardandhaselectednottoapplythefairvalueoptiontoany sionofalzheimersdiseasethevalueoftheiprdwascalculate financialinstrumentsthatwerenotalreadyrecognizedatfairvalue usingcashflowprojectionsdiscountedfortheriskinherentinsuch usgaapdefinesfairvalueastheexitpricethatwouldbe projectsprobabilityofsuccessfactorsrangingfromwere receivedtosellanassetorpaidtotransferaliabilityfairvalueisa usedtoreflectinherentclinicalandregulatoryriskthediscount marketbasedmeasurementthatshouldbedetermineduse rateappliedwasthenoncontrollinginterestrelatedtothis assumptionsthatmarketparticipantswoulduseinpricinganasset transactionwasmillionwhichthecompanyhasrecordedin orliabilitytheauthoritativeliteratureestablishesathreelevelhi othernoncurrentliabilitie archytoprioritizetheinputsusedinmeasuringfairvaluethelevel duringthecompanyenteredintoastrategiccollabora withinthehierarchyaredescribedinthetablebelowwithlevel tionwithcrucellnvwhichwillfocusonthediscoverydevelop havingthehighestpriorityandlevelhavingthelow mentandcommercializationofmonoclonalantibodiesandvaccine thefairvalueofaderivativefinancialinstrumentieforward forthetreatmentandpreventionofinfluenzaandotherinfectious exchangecontractcurrencyswapistheaggregationbycurrencyof andnoninfectiousdiseasesinadditionthecompanythroughit allfuturecashflowsdiscountedtoitspresentvalueattheprevaile affiliatepurchasedapproximatelyofcrucellsoutstande marketinterestratesandsubsequentlyconvertedtotheusdollarat ordinarysharesforanaggregatepurchasepriceofmillion thecurrentspotforeignexchangeratethecompanydoesnot ofthetotalconsiderationpaidmillionrepresentsthefair believethatfairvaluesofthesederivativeinstrumentsmateriallydif valueoftheinvestmentbasedoncrucellssharepriceinanactively ferfromtheamountsthatcouldberealizeduponsettlementormatu tradedmarketasofthedateofthetransactionwiththeexcess rityorthatthechangesinfairvaluewillhaveamaterialeffectonthe recordedtoresearchanddevelopmentexpensein companysresultsofoperationscashflowsorfinancialposition thecompanydidnothaveanyothersignificantfinancial thecompanyalsoholdsequityinvestmentswhichareclassi assetsorliabilitieswhichwouldrequirerevisedvaluationsunder fiedaslevelsincetheyaretradedinanactiveexchangemarket thisstandardthatarerecognizedatfairvalue thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofjanuaryanddecemberwereasfollow significant quotedpricesin significant activemarketsfor observable unobservable identicalasset input input dollarsinmillion level level level total total derivativesdesignatedashedginginstrument asset foreignexchangecontract crosscurrencyinterestrateswap total liability foreignexchangecontract crosscurrencyinterestrateswap total derivativesnotdesignatedashedginginstrument asset foreignexchangecontract liability foreignexchangecontract otherinvestment assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofotherinvestmentsofmillionwhichareclassifiedaslevel includesmillionofnoncurrentasset includesmillionofnoncurrentliabilitie seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet note consolidated financial statement borrowing thecompanyfiledashelfregistrationwiththesecuritiesand thecomponentsoflongtermdebtareasfollow exchangecommissionthatbecameeffectivemarchwhich enablesthecompanytoissueanunlimitedaggregateprincipal effective effective amountindebtsecuritiesandwarrantstopurchasedebtsecuritie dollarsinmillion rate rate aggregatematuritiesoflongtermobligationscommencingin notesdue debenturesdue debenturesdue dollarsinmillion debenturesdue debenturesdue notesdue beurobeuro incometaxe zerocouponconvertible theprovisionfortaxesonincomeconsistsof subordinateddebenturesdue debenturesdue dollarsinmillion currentlypayable notesdue mmgbp ustaxes mmgbp internationaltaxe notesdue debenturedue defer notesdue ustaxe debenturesdue internationaltaxe otherincludesindustrial revenuebond lesscurrentportion acomparisonofincometaxexpenseattheusstatutoryrateof inandtothecompanyseffectivetaxrate weightedaverageeffectiverate isasfollow translationrateatjanuary translationrateatdecember dollarsinmillion theexcessofthefairvalueoverthecarryingvalueofdebtwasbillioninand billionin international fairvalueofthenoncurrentdebtwasestimatedusingmarket earningsbeforetaxesonincome priceswhichwerecorroboratedbyquotedbrokerpricesin taxrate activemarket usstatutoryrate thecompanyhasaccesstosubstantialsourcesoffundsat irelandandpuertoricooperation numerousbanksworldwideinseptemberthecompany researchandorphandrugtaxcredit securedanewdaycreditfacilitytotalcreditavailabletothe usstateandlocal companyapproximatesbillionwhichexpiresseptember internationalsubsidiariesexcludingireland interestchargedonborrowingsunderthecreditlineagree usmanufacturingdeduction mentsisbasedoneitherbidsprovidedbybankstheprimerateor londoninterbankofferedratesliborplusapplicablemargin inprocessresearchand developmentiprd commitmentfeesundertheagreementsarenotmaterial onjulyalzacorporationasubsidiaryofthe ustaxinternationalincome companycompletedaprivateofferingofthezerocoupon allother convertiblesubordinateddebentureswhichwereissuedata effectivetaxrate priceofperprincipalamountatmaturityunder thetermsofthedebenturesholdersareentitledtoconvert thecompanyhassubsidiariesmanufacturinginirelandunderan theirdebenturesintoapproximatelymillionsharesof incentivetaxrateinadditionthecompanyhassubsidiariesoperat johnsonjohnsonstockatapriceofpershareapproxi inginpuertoricoundervarioustaxincentivegrantsthedecrease matelymillionshareshavebeenissuedasofjanuary inthetaxratewasprimarilyduetoincreasesintaxable duetovoluntaryconversionsbynoteholdersattheoption incomeinlowertaxjurisdictionsrelativetotaxableincomeinhigher oftheholderthedebenturesmayberepurchasedbythe taxjurisdictionstheincreaseinthetaxratewasmainly companyonjulyatapurchasepriceequaltotheissue attributedtoincreasesintaxableincomeinhighertaxjurisdiction priceplusaccretedoriginalissuediscounttosuchpurchasedate relativetotaxableincomeinlowerjurisdictionsaswellasabusi thecompanyatitsoptionmayalsoredeemanyorallofthe nessrestructuringofcertaininternationalsubsidiariesin debenturesafterjulyattheissuepriceplusaccrete resultinginaonetimebenefitofmillionwhichreducedthe originalissuediscount effectivetaxrateby throughoutthecompanycontinuedtohaveaccessto liquiditythroughthecommercialpapermarketshorttermborrow ingsandthecurrentportionoflongtermdebtamountedtoapproxi matelybillionattheendofofwhichbillionwas borrowedunderthecommercialpaperprogramtheremainder representsprincipallylocalborrowingbyinternationalsubsidiarie johnson johnson annual reporttemporarydifferencesandcarryforwardsforand thecompanyclassifiesliabilitiesforunrecognizedtaxbenefit areasfollow andrelatedinterestandpenaltiesaslongtermliabilitiesinter expenseandpenaltiesrelatedtounrecognizedtaxbenefitsarecla sifiedasincometaxexpenseduringthefiscalyearendedjanuary deferredtax deferredtax thecompanyrecognizedmillionofinterestexpenseand dollarsinmillion asset liability asset liability millionofinterestincomewithanaftertaximpactofmil employeerelatedobligation lionexpenseforthefiscalyearendeddecemberthe stockbasedcompensation companyrecognizedmillionofinterestexpensewithanafter depreciation taximpactofmillionforthefiscalyearendeddecember nondeductibleintangibles thecompanyrecognizedmillionofinterestexpenseand internationalrdcapitalize millionofinterestincomewithanaftertaximpactofmil fortax lionexpensethetotalamountofaccruedinterestwasmillion reservesliabilitie andmillioninandrespectively incomereportedfor taxpurpose netoperatingloss employeerelatedobligation carryforwardinternational attheendofandemployeerelatedobligation miscellaneousinternational recordedontheconsolidatedbalancesheetwere miscellaneousus dollarsinmillion totaldeferredincometaxe pensionbenefit postretirementbenefit thedifferencebetweenthenetdeferredtaxonincomeperthe postemploymentbenefit balancesheetandthenetdeferredtaxaboveisincludedintaxe deferredcompensation onincomeonthebalancesheettheanddeferre taxmiscellaneoususincludescurrentyeartaxreceivablesthe totalemployeeobligation companyhasawhollyownedinternationalsubsidiarywhichhas lesscurrentbenefitspayable cumulativenetlossesthecompanybelievesthatitismorelikely employeerelatedobligationslongterm thannotthatthesubsidiarywillrealizefuturetaxableincome sufficienttoutilizethesedeferredtaxasset prepaidemployeerelatedobligationsofmillionandmil thefollowingtablesummarizestheactivityrelatedto lionforandrespectivelyareincludedinotherassetson unrecognizedtaxbenefit theconsolidatedbalancesheet dollarsinmillion beginningofyear pensionsandotherbenefitplan increasesrelatedtocurrentyeartaxposition thecompanysponsorsvariousretirementandpensionplan increasesrelatedtopriorperiodtaxposition includingdefinedbenefitdefinedcontributionandtermination decreasesrelatedtopriorperiodtaxposition indemnityplanswhichcovermostemployeesworldwidethe settlement companyalsoprovidespostretirementbenefitsprimarilyhealth lapseofstatuteoflimitation caretoallusretiredemployeesandtheirdependent endofyear manyinternationalemployeesarecoveredbygovernment sponsoredprogramsandthecosttothecompanyisnotsignificant retirementplanbenefitsareprimarilybasedontheemployee thecompanyhadbillionandbillionofunrecognizedtax compensationduringthelastthreetofiveyearsbeforeretirement benefitsasofjanuaryanddecemberrespec andthenumberofyearsofserviceinternationalsubsidiarieshave tivelyalloftheunrecognizedtaxbenefitsofbillionatjanuary plansunderwhichfundsaredepositedwithtrusteesannuitiesare ifrecognizedwouldaffectthecompanysannualeffective purchasedundergroupcontractsorreservesareprovide taxratethecompanyconductsbusinessandfilestaxreturnsin thecompanydoesnotfundretireehealthcarebenefitsin numerouscountriesandcurrentlyhastaxauditsinprogresswitha advanceandhastherighttomodifytheseplansinthefuture numberoftaxauthoritiestheusinternalrevenueserviceirs thecompanyusesthedateofitsconsolidatedfinancialstate hascompleteditsauditforthetaxyearsthroughinother mentsjanuaryanddecemberrespectivelyas majorjurisdictionswherethecompanyconductsbusinesstheyear themeasurementdateforallusandinternationalretirementand remainopengenerallybacktotheyearwithsomejurisdiction otherbenefitplan remainingopenasfarbackasthecompanydoesnotexpect inaccordancewithusgaapthecompanyhasadopte thatthetotalamountofunrecognizedtaxbenefitswillsignificantly therecentstandardsrelatedtoemployersaccountingfordefine changeoverthenexttwelvemonthsthecompanybelievesthatitis benefitpensionandotherpostretirementplan possiblethatwithinthenexttwelvemonthstheirsmaycomplete itsauditofthetaxyearsthecloseoftheauditmay resultinthereductionofunrecognizedtaxbenefitsthecompanyis notabletoprovideareasonablyreliableestimateofthetimingof anyotherfuturetaxpaymentsrelatingtouncertaintaxposition note consolidated financial statement netperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponent retirementplan otherbenefitplan dollarsinmillion servicecost interestcost expectedreturnonplanasset amortizationofpriorservicecost amortizationofnettransitionasset recognizedactuariallosse curtailmentsandsettlement netperiodicbenefitcost thenetperiodicbenefitcostattributabletousretirementplanswasmillionmillionandmillioninand respectively amountsexpectedtoberecognizedinnetperiodicbenefitcost lifeexpectancytheamortizationofgainsandlossesfortheother inthecomingyearforthecompanysdefinedbenefitretirement usbenefitplansisdeterminedbyusingacorridorofthe plansandotherpostretirementplan greaterofthemarketvalueofassetsortheprojectedbenefitobliga tiontotalunamortizedgainsandlossesinexcessofthecorridorare dollarsinmillion amortizedovertheaverageremainingfutureservice amortizationofnettransitionobligation priorservicecostsbenefitsfortheuspensionplansare amortizationofnetactuariallosse amortizedovertheremainingfutureserviceofplanparticipantsat amortizationofpriorservicecost thetimeoftheplanamendmentpriorservicecostbenefitforthe otherusbenefitplansisamortizedovertheaverageremaine unrecognizedgainsandlossesfortheuspensionplansareamor servicetofulleligibilityageofplanparticipantsatthetimeofthe tizedovertheaverageremainingfutureserviceforeachplanfor planamendment planswithnoactiveemployeestheyareamortizedovertheaverage theweightedaverageassumptionsinthefollowingtablerepresenttheratesusedtodeveloptheactuarialpresentvalueofprojecte benefitobligationfortheyearlistedandalsothenetperiodicbenefitcostforthefollowingyear retirementplan otherbenefitplan dollarsinmillion usbenefitplan discountrate expectedlongtermrateofreturnonplanasset rateofincreaseincompensationlevel internationalbenefitplans discountrate expectedlongtermrateofreturnonplanasset rateofincreaseincompensationlevel thecompanysdiscountratesaredeterminedbyconsidere thefollowingtabledisplaystheassumedhealthcarecosttrend currentyieldcurvesrepresentinghighqualitylongtermfixe ratesforallindividual incomeinstrumentstheresultingdiscountratesareconsistent healthcareplan withthedurationofplanliabilitie healthcarecosttrendrateassumedfornextyear theexpectedlongtermrateofreturnonplanassetsassump ratetowhichthecosttrendrateisassume tionisdeterminedusingabuildingblockapproachconsidering todeclineultimatetrend historicalaveragesandrealreturnsofeachassetclassincertain yeartheratereachestheultimatetrendrate countrieswherehistoricalreturnsarenotmeaningfulconsidera tionisgiventolocalmarketexpectationsoflongtermreturns aonepercentagepointchangeinassumedhealthcarecosttrend rateswouldhavethefollowingeffect onepercentage onepercentage dollarsinmillion pointincrease pointdecrease healthcareplan totalinterestandservicecost postretirementbenefitobligation johnson johnson annual reportthefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyearendandfor thecompanysdefinedbenefitretirementplansandotherpostretirementplans retirementplan otherbenefitplan dollarsinmillion changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontribution amendment actuariallossesgain divestituresacquisition curtailmentssettlementsrestructure benefitspaidfromplan effectofexchangerate projectedbenefitobligationendofyear changeinplanasset planassetsatfairvaluebeginningofyear actualreturnlossonplanasset companycontribution planparticipantcontribution settlement benefitspaidfromplanasset effectofexchangerate planassetsatfairvalueendofyear fundedstatusatendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowe noncurrentasset currentliabilitie noncurrentliabilitie totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistofthefollowe netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffect accumulatedbenefitobligationsendofyear changesinplanassetsandbenefitobligationsrecognizedinothercomprehensiveincome netperiodicbenefitcost netactuarialgainloss amortizationofnetactuarialloss priorservicecost amortizationofpriorservicecost effectofexchangerate totalrecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanydoesnotfundcertainplansasfundingisnotrequiredbillionoftheprojecte benefitobligationandbillionoftheunderfundedstatusforeachofthefiscalyearsand relatestotheunfundedpensionplansbillionandbillionoftheaccumulatedbenefit obligationforthefiscalyearsandrespectivelyrelatetotheseunfundedpensionplan planswithaccumulatedbenefitobligationsinexcessofplanassetsconsistofthefollowe retirementplan dollarsinmillion accumulatedbenefitobligation projectedbenefitobligation planassetsatfairvalue note consolidated financial statement thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplan dollarsinmillion projectedfuturebenefitpayment retirementplan otherbenefitplansgross medicarerebate otherbenefitplansnet inthecompanycontributedmillionandmillion thecompanyplanstocontinuetofunditsusdefinedbenefit toitsusandinternationalpensionplansrespectivelyinaddition planstocomplywiththeact thecompanyfundedmilliontoitsusplansinthefirstmonth internationalplansarefundedinaccordancewithlocal regulationsadditionaldiscretionarycontributionsaremadewhen incongresspassedthepensionprotectionactof deemedappropriatetomeetthelongtermobligationsoftheplan theactamendedtheemployeeretirementincomesecurityact forcertainplansfundingisnotacommonpracticeasfunde erisaforplanyearsbeginningafterandestablishednew providesnoeconomicbenefitconsequentlythecompanyhas minimumfundingstandardsforusemployerdefinedbenefitplans severalpensionplansthatarenotfunde thefollowingtabledisplaystheprojectedfutureminimumcontributionstothecompanysusandinternationalunfundedretirement planstheseamountsdonotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillion projectedfuturecontribution unfundedusretirementplan unfundedinternationalretirementplan eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationandinvestmentofthepension plansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboardconsidersfactorsincludinglocalpensionrulesand regulationslocaltaxregulationsavailabilityofinvestmentvehiclesseparateaccountscommingledaccountsinsurancefundsetc fundedstatusoftheplansratioofactivestoretireesdurationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityof localmarketsandliquidityofbasecurrencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobe ongoingplanspermittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefundsanassetallocationofequitiesandfixedincomeisgenerallypursuedunlesslocalregulationsandilliquidity requireotherwise thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareasfollow percentof target planasset allocation usretirementplan equitysecuritie debtsecuritie totalplanasset internationalretirementplan equitysecuritie debtsecuritie realestateandoth totalplanasset thecompanysotherbenefitplansareunfundedexceptforuslife determinationoffairvalue insurancecontractassetsofmillionandmillionatjanuary theplanhasanestablishedandwelldocumentedprocessfor anddecemberrespectively determiningfairvaluesfairvalueisbaseduponquotedmarket thefairvalueofjohnsonjohnsoncommonstockdirectly priceswhereavailableiflistedpricesorquotesarenotavailable heldinplanassetswasmillionoftotalplanassetsat fairvalueisbaseduponmodelsthatprimarilyuseasinput januaryandmillionoftotalplanassetsat marketbasedorindependentlysourcedmarketparameter december includingyieldcurvesinterestratesvolatilitiesequityordebt pricesforeignexchangeratesandcreditcurve whiletheplanbelievesitsvaluationmethodsareappropriate andconsistentwithothermarketparticipantstheuseofdifferent methodologiesorassumptionstodeterminethefairvalueofcertain financialinstrumentscouldresultinadifferentestimateoffairvalue atthereportingdate johnson johnson annual reportvaluationhierarchy ifquotedmarketpricesarenotavailableforthespecificsecurity theauthoritativeliteratureestablishesathreelevelhierarchytopri thenfairvaluesareestimatedbyusingpricingmodelsquote oritizetheinputsusedinmeasuringfairvaluethelevelswithinthe pricesofsecuritieswithsimilarcharacteristicsordiscountedcash hierarchyaredescribedinthetablebelowwithlevelhavingthe flowsandareclassifiedaslevelleveldebtinstrumentsare highestpriorityandlevelhavingthelowest pricedbasedonunobservableinputs afinancialinstrumentscategorizationwithinthevaluationhierar equitysecuritiescommonstocksarevaluedattheclosing chyisbaseduponthelowestlevelofinputthatissignificanttothe pricereportedonthemajormarketonwhichtheindividualsecuri fairvaluemeasurement tiesaretradedsubstantiallyallcommonstockisclassifiedwithin followingisadescriptionofthevaluationmethodologiesuse levelofthevaluationhierarchy fortheinvestmentsmeasuredatfairvalue commingledfundstheinvestmentsarepublicinvestment shortterminvestmentscashandquotedshortterminstru vehiclesvaluedusingthenavprovidedbythefundadministrator mentsarevaluedattheclosingpriceortheamountheldondeposit thenavisbasedonthevalueoftheunderlyingassetsownedby bythecustodianbankotherinvestmentsarethroughinvestment thefundminusitsliabilitiesandthendividedbythenumberof vehiclesvaluedusingthenetassetvaluenavprovidedbythe sharesoutstandingassetsinthelevelcategoryhaveaquote administratorofthefundthenavisbasedonthevalueofthe marketpriceinamarketthatisnotactive underlyingassetsownedbythefundminusitsliabilitiesandthen insurancecontractstheinstrumentsareissuedbyinsurance dividedbythenumberofsharesoutstandingthenavisaquote companiesthefairvalueisbasedonnegotiatedvalueandthe priceinamarketthatisnotactiveandclassifiedaslevel underlyinginvestmentsheldinseparateaccountportfoliosaswell governmentandagencysecuritiesalimitednumberofthese asconsideringthecreditworthinessoftheissuertheunderlye investmentsarevaluedattheclosingpricereportedonthemajor investmentsaregovernmentassetbackedandfixedincome marketonwhichtheindividualsecuritiesaretradedwherequote securitiesingeneralinsurancecontractsareclassifiedaslevelas pricesareavailableinanactivemarkettheinvestmentsareclassified therearenoquotedpricesnorotherobservableinputsforpricing withinlevelofthevaluationhierarchyifquotedmarketpricesare otherassetsotherassetsarerepresentedprimarilybylimite notavailableforthespecificsecuritythenfairvaluesareestimated partnershipsandrealestateinvestmentsaswellascommercial byusingpricingmodelsquotedpricesofsecuritieswithsimilar loansandcommercialmortgagesthatarenotclassifiedascorporate characteristicsordiscountedcashflowswhenquotedmarketprice debtotherassetsthatareexchangelistedandactivelytradedare forasecurityarenotavailableinanactivemarkettheyareclassifie classifiedaslevelwhileinactivelytradedassetsareclassifiedas aslevel levelmostlimitedpartnershipsrepresentinvestmentsinprivate debtinstrumentsalimitednumberoftheseinvestmentsare equityandsimilarfundsthatarevaluedbythegeneralpartner valuedattheclosingpricereportedonthemajormarketonwhich theseaswellasanyotherassetsvaluedusingunobservableinputs theindividualsecuritiesaretradedwherequotedpricesareavail areclassifiedaslevel ableinanactivemarkettheinvestmentsareclassifiedaslevel thefollowingtablesetsforththetrustinvestmentsmeasuredatfairvalueasofjanuary quotedprice significant inactive significant marketsfor observable unobservable identicalasset input input dollarsinmillion level level level totalasset shortterminvestmentfund governmentandagencysecuritie debtinstrument equitysecuritie commingledfund insurancecontract otherasset trustinvestmentsatfairvalue levelgainsandlosse thetablebelowsetsforthasummaryofchangesinthefairvalueoftheplanslevelassetsfortheyearendedjanuary debt equity commingle insurance total dollarsinmillion instrument security fund contract asset level balancedecember realizedgainslosse unrealizedgainslosse purchasessalesissuancesandsettlementsnet balancejanuary note consolidated financial statement savingsplan accumulatedothercomprehensiveincome thecompanyhasvoluntaryksavingsplansdesignedto componentsofothercomprehensiveincomelossconsistof enhancetheexistingretirementprogramscoveringeligibleemploy thefollowing eesthecompanymatchesapercentageofeachemployeescontri total butionsconsistentwiththeprovisionsoftheplanforwhichheshe gain accumulate iseligibletotalcompanymatchingcontributionstotheplanswere foreign gain losseson millionmillionandmillioninand currency losseson employee derivative comprehensive dollarsinmillion translation security benefitplan hedge incomeloss respectively december change capitalandtreasurystock unrealizedgainloss changesintreasurystockwere netamountreclassed tonetearning amountsinmillionsexcepttreasurystock treasurystock netchange numberofsharesinthousand share december balanceatdecember change employeecompensationandstockoptionplans unrealizedgainloss conversionofsubordinateddebenture netamountreclasse repurchaseofcommonstock tonetearning balanceatdecember netchange employeecompensationandstockoptionplans december conversionofsubordinateddebenture change repurchaseofcommonstock unrealizedgainloss balanceatdecember netamountreclassed employeecompensationandstockoptionplans tonetearning conversionofsubordinateddebenture netchange repurchaseofcommonstock january balanceatjanuary thetaxeffectontheunrealizedgainslossesontheequitysecuri aggregatesharesofcommonstockissuedwereapproximately tieswasincomeofmillioninandexpenseofmillion millionsharesattheendofand andmillioninandrespectivelythetaxeffect cashdividendspaidwerepershareincompare relatedtoemployeebenefitplanswasmillionmillion withdividendsofpershareinandpershare andmillioninandrespectivelythetax effectonthegainslossesonderivativesandhedgeswasexpense ofmillionandmillioninandrespectivelyand incomeofmillioninseenoteforadditionalinformation relatingtoderivativesandhedging thecurrencytranslationadjustmentsarenotadjustedfor incometaxesastheyrelatetopermanentinvestmentsin internationalsubsidiaries johnson johnson annual reportinternationalcurrencytranslation rentalexpenseandleasecommitment fortranslationofitssubsidiariesoperatinginnonusdollarcur rentalsofspacevehiclesmanufacturingequipmentandofficeand renciesthecompanyhasdeterminedthatthelocalcurrenciesof dataprocessingequipmentunderoperatingleaseswereapproxi itsinternationalsubsidiariesarethefunctionalcurrenciesexcept matelymillioninmillioninandmillion thoseinhighlyinflationaryeconomieswhicharedefinedasthose whichhavehadcompoundcumulativeratesofinflationof theapproximateminimumrentalpaymentsrequiredunder ormoreduringthepastthreeyearsorwhereasubstantialportion operatingleasesthathaveinitialorremainingnoncancelablelease ofitscashflowsarenotinthelocalcurrency termsinexcessofoneyearatjanuaryare inconsolidatinginternationalsubsidiariesbalancesheetcur dollarsinmillion rencyeffectsarerecordedasacomponentofaccumulatedother total comprehensiveincomethisequityaccountincludestheresult oftranslatingallbalancesheetassetsandliabilitiesatcurrent exchangeratesexceptforthoselocatedinhighlyinflationary commitmentsundercapitalleasesarenotsignificant economiesthetranslationofbalancesheetaccountsforhighly inflationaryeconomiesarereflectedintheoperatingresult ananalysisofthechangesduringandfor commonstockstockoptionplansandstock foreigncurrencytranslationadjustmentsisincludedinnote compensationagreement netcurrencytransactionandtranslationgainsandlosse stockoption includedinotherincomeexpensewerelossesofmillion atjanuarythecompanyhadstockbasedcompen millionandmillioninandrespectively sationplansthesharesoutstandingareforcontractsunderthe companysandstockoptionplansthelong termincentiveplanthenonemployeedirectorsplanand earningspershare thealzainvernessandsciosstockoptionplansdure thefollowingisareconciliationofbasicnetearningspershareto nooptionsorrestrictedsharesweregrantedunderanyofthese dilutednetearningspershareforthefiscalyearsendedjanuary plansexceptunderthelongtermincentiveplan decemberanddecember thecompensationcostthathasbeenchargedagainstincome fortheseplanswasmillionmillionandmillionfor sharesinmillionsexceptpersharedata andrespectivelythetotalincometaxbenefit basicnetearningspershare recognizedintheincomestatementforsharebasedcompensation averageshare costswasmillionmillionandmillionfor outstandingbasic andrespectivelysharebasedcompensationcost potentialsharesexercisable capitalizedaspartofinventorywereinsignificantinallperiod understockoptionplan stockoptionsexpireyearsfromthedateofgrantandvest lesssharesrepurchase overserviceperiodsthatrangefromsixmonthstofiveyearsall undertreasurystockmethod optionsaregrantedattheaverageofthehighandlowpricesofthe convertibledebtshare companyscommonstockonthenewyorkstockexchangeon adjustedaverageshare thedateofgrantunderthelongtermincentiveplanthe outstandingdilute companymayissueuptomillionsharesofcommonstock dilutednetearningspershare sharesavailableforfuturegrantsunderthelongterm incentiveplanweremillionattheendof thedilutednetearningspersharecalculationincludesthedilutive thecompanysettlesemployeestockoptionexerciseswith effectofconvertibledebtthatisoffsetbytherelatedreduction treasurysharestreasurysharesarereplenishedthroughoutthe ininterestexpenseofmillionaftertaxforyear yearforthenumberofsharesusedtosettleemployeestock optionexercise dilutednetearningspershareexcludesmillionmillion thefairvalueofeachoptionawardwasestimatedonthedate andmillionsharesunderlyingstockoptionsforand ofgrantusingtheblackscholesoptionvaluationmodelthatuse respectivelyastheexercisepriceoftheseoptionswa theassumptionsnotedinthefollowingtableexpectedvolatility greaterthantheiraveragemarketvaluewhichwouldresultinan representsablendedrateofyeardailyhistoricalaveragevolatility antidilutiveeffectondilutedearningspershare rateandaweekaverageimpliedvolatilityratebasedonatthe moneytradedjohnsonjohnsonoptionswithalifeofyears historicaldataisusedtodeterminetheexpectedlifeoftheoption theriskfreeratewasbasedontheustreasuryyieldcurvein effectatthetimeofgrant note consolidated financial statement theaveragefairvalueofoptionsgrantedwasand stockoptionsexercisableatdecemberanddecember inandrespectivelythefairvaluewa wereatanaveragepriceofandanaverage estimatedbasedontheweightedaverageassumptionsof lifeofyearsandatanaveragepriceofandan averagelifeofyearsrespectively riskfreerate restrictedshareunit expectedvolatility thecompanygrantsrestrictedshareunitswithavestingperiod expectedlife yrs yrs yrs ofthreeyearsthecompanysettlesemployeestockissuancewith dividendyield treasurysharestreasurysharesarereplenishedthroughoutthe yearforthenumberofsharesusedforemployeestockissuance asummaryofoptionactivityundertheplanasofjanuary asummaryofshareactivityundertheplanasofjanuary decemberanddecemberandchangesduring theyearsendingonthosedatesispresentedbelow outstanding sharesinthousand share aggregate sharesatdecember weight intrinsic sharesgrante outstanding average value sharesinthousand share exerciseprice dollarsinmillion sharesissue sharesatdecember sharescanceledforfeited optionsgrante sharesatdecember optionsexercise sharesgrante optionscanceledforfeited sharesissue sharesatdecember sharescanceledforfeited sharesatdecember optionsgrante sharesgrante optionsexercised sharesissue optionscanceledforfeite sharescanceledforfeited sharesatdecember sharesatjanuary optionsgrante optionsexercised theaveragefairvalueoftherestrictedshareunitsgrantedwa optionscanceledforfeite andinandrespectively sharesatjanuary usingthefairmarketvalueatthedateofgrantthefairvalueof restrictedshareunitswasdiscountedfordividendswhicharenot thetotalintrinsicvalueofoptionsexercisedwasmillion paidontherestrictedshareunitsduringthevestingperiodthefair millionandmillioninandrespectivelythe valueofrestrictedshareunitssettledwasmillionmil totalunrecognizedcompensationcostwasmillionasofjanu lionandmillioninandrespectively arymillionasofdecemberandmil lionasofdecembertheweightedaverageperiodforthis costtoberecognizedwasyearsyearsandyearsfor andrespectively thefollowingtablesummarizesstockoptionsoutstandingand exercisableatjanuary sharesinthousandsoutstande exercisable average average exercise average exercise exercise pricerange option life price option price averagecontractualliferemaininginyear johnson johnson annual reportsegmentsofbusinessandgeographicarea salestocustomer dollarsinmillion consumer unitedstate international total pharmaceutical unitedstate international total medicaldevicesanddiagnostic unitedstate international total worldwidetotal operatingprofit identifiableasset dollarsinmillion consumer pharmaceutical medicaldevicesanddiagnostic total lessexpensenotallocatedtosegment generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillion consumer pharmaceutical medicaldevicesanddiagnostic segmentstotal generalcorporate worldwidetotal salestocustomer longlivedasset dollarsinmillion unitedstate europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedasset worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperate exportsalesarenotsignificantinandthecompanydidnothaveacustomerthatrepresentedoftotalrevenue amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrollinginterestsandgeneralcorporateincomeexpense generalcorporateincludescashandmarketablesecuritie includesmillionofrestructuringexpensecomprisedofmillionmillionandmillionfortheconsumerpharmaceuticalandmedicaldevicesanddiagnostic segmentsrespectivelyincludesmillionoffourthquarternetlitigationgaincomprisedofamillionexpenseinthepharmaceuticalsegmentandagainofmillioninthe medicaldevicesanddiagnosticssegment includesmillionandmillionofiprdfortheconsumerandmedicaldevicesanddiagnosticssegmentsrespectivelyincludesmillionoffourthquarternetlitigationgain comprisedofamillionexpenseintheconsumersegmentandagainofmillioninthemedicaldevicesanddiagnosticssegmentthemedicaldevicesanddiagnosticssegment alsoincludesmilliongainonthedivestitureoftheprofessionalwoundcarebusinessofethiconinc includesmillionofrestructuringexpensecomprisedofmillionmillionandmillionfortheconsumerpharmaceuticalandmedicaldevicesanddiagnosticssegment respectivelythemedicaldevicesanddiagnosticssegmentincludesmillionofiprdthepharmaceuticalsegmentalsoincludesmillionforthewritedownofthenatrecor intangibleasset longlivedassetsincludepropertyplantandequipmentnetforandofandrespectivelyandintangibleassetsandgoodwillnetfor andofandrespectively note consolidated financial statement selectedquarterlyfinancialdataunaudite selectedunauditedquarterlyfinancialdatafortheyearsandaresummarizedbelow second fourth second fourth dollarsinmillionsexceptpersharedata quarter quarter quarter quarter quarter quarter quarter quarter segmentsalestocustomer consumer pharmaceutical meddevicesdiagnostic totalsale grossprofit earningsbeforeprovisionfortaxesonincome netearning basicnetearningspershare dilutednetearningspershare thefourthquarterofincludesanaftertaxchargeofmillionforrestructuringandmillionaftertaxofincomefromnetlitigation thesecondquarterofincludesanaftertaxchargeofmillionforiprd thefourthquarterofincludesanaftertaxchargeofmillionforiprdmillionaftertaxofincomefromnetlitigationandmillionaftertaxgainonthedivestitureof theprofessionalwoundcarebusinessofethiconincthegainfromthedivestitureoftheprofessionalwoundcarebusinessofethiconincwasreinvestedinthebusiness businesscombinationsanddivestiture certainbusinesseswereacquiredformillionincashand certainbusinesseswereacquiredformillionincashand millionofliabilitiesassumedduringtheseacquisition millionofliabilitiesassumedandnoncontrollinginterest wereaccountedforbythepurchasemethodandaccordingly duringtheseacquisitionswereaccountedforbythepur resultsofoperationshavebeenincludedinthefinancialstatement chasemethodandaccordinglyresultsofoperationshavebeen fromtheirrespectivedatesofacquisition includedinthefinancialstatementsfromtheirrespectivedate theacquisitionsincludedamicabaprivatelyheld ofacquisition swedishdeveloperofinvitrodiagnostictechnologiesforusein theacquisitionsincludedmentorcorporationaleading pointofcareandnearpatientsettingsbeijingdabaocosmetic supplierofmedicalproductsfortheglobalaestheticsmarket coltdacompanythatsellspersonalcarebrandsinchina cougarbiotechnologyincadevelopmentstagebiopharmaceutical surgrxincaprivatelyhelddeveloperoftheadvancedbipolar companywithaspecificfocusononcologyfinsburyorthopaedic tissuesealingsystemusedintheensealfamilyofdevice limitedaprivatelyheldukbasedmanufacturerandglobaldistrib healthmediaincaprivatelyheldcompanythatcreateswebbase utoroforthopaedicimplantsglostereuropeaprivatelyhelddevel behaviorchangeinterventionslgeperformancesystemsinca operofinnovativedisinfectionprocessesandtechnologiesto privatelyheldcompanyknownashumanperformanceinstitute preventhealthcareacquiredinfectionsandsubstantiallyallofthe whichdevelopssciencebasedtrainingprogramstoimprove assetsandrightsofelansalzheimersimmunotherapyprogram employeeengagementandproductivityandomrixbiopharmaceu throughanewlyformedcompanyofwhichthecompanyown ticalsincafullyintegratedbiopharmaceuticalcompanythat andelanown developsandmarketsbiosurgicalandimmunotherapyproduct theexcessofpurchasepriceovertheestimatedfairvalueof theexcessofpurchasepriceovertheestimatedfairvalueof tangibleassetsacquiredamountedtomillionandhasbeen tangibleassetsacquiredamountedtomillionandhasbeen assignedtoidentifiableintangibleassetswithanyresidualrecorde assignedtoidentifiableintangibleassetswithanyresidualrecorde togoodwillofthisamountapproximatelymillionhasbeen togoodwillapproximatelymillionhasbeenidentifiedasthe identifiedasthevalueofiprdprimarilyassociatedwiththeacqui valueofiprdassociatedwiththeacquisitionsofomrixbiophar sitionsofcougarbiotechnologyincandsubstantiallyallofthe maceuticalsincamicabsurgrxincandhealthmediainc assetsandrightsofelansalzheimersimmunotherapyprogram theiprdchargerelatedtotheacquisitionofomrixbiophar additionallyapproximatelymillionhasbeenidentifiedasthe maceuticalsincwasmillionandisassociatedwithstand valueofotherintangibleassetsincludingpatentstechnologyand aloneandcombinationbiosurgicaltechnologiesusedtoachieve customerrelationshipsprimarilyassociatedwiththeacquisitionof hemostasisthevalueoftheiprdwascalculatedusingcash mentorcorporation flowprojectionsdiscountedfortheriskinherentinsuchproject theiprdrelatedtotheacquisitionofcougarbiotechnology probabilityofsuccessfactorsrangingfromwereuse incwasmillionandisassociatedwithabirateroneacetatea toreflectinherentclinicalandregulatoryriskthediscountrate latestagefirstinclasscompoundforthetreatmentofprostatecan appliedwasasoftheendofthefiscalyearofthe certhevalueoftheiprdwascalculatedusingcashflowprojec outstandingsharesofcommonstockofomrixbiopharmaceutical tionsdiscountedfortheriskinherentinsuchprojectsprobabilityof successfactorsrangingfromwereusedtoreflectinherent clinicalandregulatoryriskthediscountrateappliedwas refertonoteforinformationrelatedtotheelantransaction johnson johnson annual reportinchadbeentenderedbystockholdersexcludingsharesthat notelegalproceeding weretenderedsubjecttoguaranteeddeliveryprocedure productliability oftheoutstandingsharesofcommonstockhadbeentendere thecompanyssubsidiariesareinvolvedinnumerousproduct ondecemberthecompanycompletedtheacquisition liabilitycasesintheunitedstatesmanyofwhichconcernallege ofomrixbiopharmaceuticalsinc adversereactionstodrugsandmedicaldevicesthedamage theiprdchargerelatedtotheacquisitionofamicabwa claimedaresubstantialandwhilethecompanyisconfidentofthe millionandisassociatedwithpointofcaredeviceandcast adequacyofthewarningsandinstructionsforusethataccompany chiptechnologiesthevalueoftheiprdwascalculateduse suchproductsitisnotfeasibletopredicttheultimateoutcomeof cashflowprojectionsdiscountedfortheriskinherentinsuch litigationhoweverthecompanybelievesthatifanyproductliabil projectsthediscountrateappliedwa ityresultsfromsuchcasesitwillbesubstantiallycoveredbyexist theiprdchargerelatedtotheacquisitionofsurgrxincwa ingamountsaccruedinthecompanysbalancesheetandwhere millionandisassociatedwithvesselcuttingandsealingsurgical availablebythirdpartyproductliabilityinsurance devicesthevalueoftheiprdwascalculatedusingcashflowpro multipleproductsofjohnsonjohnsonsubsidiarie jectionsdiscountedfortheriskinherentinsuchprojectsprobability aresubjecttonumerousproductliabilityclaimsandlawsuit ofsuccessfactorsrangingfromwereusedtoreflectinher thereareasignificantnumberofclaimantswhohavepende entclinicalandregulatoryriskthediscountrateappliedwas lawsuitsorclaimsregardinginjuriesallegedlyduetoortho theiprdchargerelatedtotheacquisitionofhealthmedia evrarisperdallevaquinduragesicthecharit incwasmillionandisassociatedprimarilywithprocess artificialdiscandcypherstenttheseclaimantsseeksub enhancementstosoftwaretechnologythevalueoftheiprdwa stantialcompensatoryandwhereavailablepunitivedamage calculatedusingcashflowprojectionsdiscountedfortheriskinher withrespecttorisperdaltheattorneysgeneralofeight entinsuchprojectsaprobabilityofsuccessfactorofwa statesandtheofficeofgeneralcounselofthecommonwealthof usedtoreflectinherentriskthediscountrateappliedwas pennsylvaniahavefiledactionsseekingreimbursementofmedicaid certainbusinesseswereacquiredformillionincashand orotherpublicfundsforrisperdalprescriptionswrittenfor millionofliabilitiesassumedduringtheseacquisition offlabelusecompensationfortreatingtheircitizensforallege wereaccountedforbythepurchasemethodandaccordingly adversereactionstorisperdalcivilfinesorpenaltiespunitive resultsofoperationshavebeenincludedinthefinancialstatement damagesorotherrelieftheattorneygeneraloftexashasjoineda fromtheirrespectivedatesofacquisition quitamactioninthatstateseekingsimilarreliefcertainofthese theacquisitionsincludedconormedsystemsinca actionsalsoseekinjunctivereliefrelatingtothepromotionof cardiovasculardevicecompanywithnewdrugdeliverytechnology risperdaltheattorneysgeneralofmorethanotherstate robertreidincajapaneseorthopedicproductdistributorand haveindicatedapotentialinterestinpursuingsimilarlitigation mayasmomincasocialmediacompany againstthecompanyssubsidiaryjanssenpharmaceuticainc theexcessofpurchasepriceovertheestimatedfairvalue janssennoworthomcneiljanssenpharmaceuticalsinc oftangibleassetsacquiredamountedtomillionandhas omjpiandhaveobtainedatollingagreementstayingtherun beenassignedtoidentifiableintangibleassetswithanyresidual ningofthestatuteoflimitationswhiletheyinquireintotheissue recordedtogoodwillapproximatelymillionhasbeenidenti inadditiontherearesixcasesfiledbyunionhealthplansseeke fiedasthevalueofiprdassociatedwiththeacquisitionofconor damagesforallegedoverpaymentsforrisperdalseveralof medsystemsinc whichseekcertificationasclassactionsinthecasebroughtbythe theiprdchargerelatedtotheacquisitionofconor attorneygeneralofwestvirginiabasedonclaimsforallegedcon medsystemsincwasmillionandisassociatedwithresearch sumerfraudastoduragesicaswellasrisperdaljanssen relatedtothediscoveryandapplicationofthestenttechnology nowomjpiwasfoundliableanddamageswereassessedat thevalueoftheiprdwascalculatedusingcashflowprojection millionomjpihasfiledanappeal discountedfortheriskinherentinsuchprojectsthediscountrate numerousclaimsandlawsuitsintheunitedstatesrelating appliedwa tothedrugpropulsidwithdrawnfromgeneralsalebythe supplementalproformainformationforand companysjanssennowomjpisubsidiaryinhavebeen inaccordancewithusgaapstandardsrelatedtobusinesscombi resolvedorarecurrentlyenrolledinsettlementprogramswithan nationsandgoodwillandotherintangibleassetsisnotprovideda aggregatecapbelowmillionsimilarlitigationconcerne theimpactoftheaforementionedacquisitionsdidnothaveamate propulsidispendingincanadawhereanationalclassactionof rialeffectonthecompanysresultsofoperationscashflowsor personsallegingadversereactionstothedrughasbeencertifie financialposition andasettlementprograminstitutedwithanaggregatecapbelow withtheexceptionofthedivestitureoftheprofessional million woundcarebusinessofethiconincwhichresultedinagainof millionbeforetaxandisrecordedinotherincomeexpense affirmativestentpatentlitigation netindivestituresinanddidnothavea inpatentinfringementactionstriedindelawarefederaldistrict materialeffectonthecompanysresultsofoperationscashflows courtinlatecordiscorporationcordisasubsidiaryof orfinancialposition johnsonjohnsonobtainedverdictsofinfringementandpatent validityanddamageawardsagainstbostonscientificcorporation bostonscientificandmedtronicaveincmedtronicbasedon anumberofcordisvascularstentpatentsindecemberthe juryinthedamageactionagainstbostonscientificreturnedaver dictofmillionandthejuryinthemedtronicactionreturneda verdictofmillionthecourtofappealsforthefederalcircuit hasupheldliabilityinthesecasesandonseptemberthe districtcourtenteredjudgmentsincludinginterestintheamount ofmillionandmillionagainstbostonscientificand note consolidated financial statement medtronicrespectivelymedtronicpaidmillioninoctober appealsforthefederalcircuitheldthedingpatentinvalidanda representingthejudgmentnetofamountsexchangedinset judgmentinfavorofcordisinthatcasehasbeenenteredinmarch tlementofanumberofotherlitigationsbetweenthecompanie thecourtofappealsforthefederalcircuitupheldthejudg thenetsettlementofmillionwasrecordedasacredittoother mentthatcordiscypherstentinfringedbostonscientificsjang incomeexpensenetintheconsolidatedstatementofearn patentthecasehasbeenremandedforatrialontheissuesofdam ingsinseptembercordissettledthiscasewithbostonscien agesandwillfulnessthejangcasehasbeendismissedaspartof tifictogetherwiththekasenthoferfontirrocheanddingcase thejanuarysettlementdescribedintheparagraphabove describedbelowforanetpaymentofmillionaspartofthat relatingtotheexpresstaxusandlibertestent settlementbostonscientificreceivedapaiduplicensetothe ingermanybostonscientifichadseveralactionsbasedonit fontirrochefamilyofpatentsworldwideandcordisreceivedapaid dingpatentspendingagainstthecordiscypherstentboston licensetothekastenhoferanddingfamiliesofpatentsworldwide scientificalsohadbroughtactionsinbelgiumthenetherland andthepartiessettledallpendinglawsuitsworldwiderelatingto germanyfranceanditalyunderitskastenhoferpatentwhich thesepatentsthereceiptofmillionlesstheimpactofother purportstocovertwolayercatheterssuchasthoseusedtodeliver litigationmattersresultedinacredittootherincomeexpensenet thecypherstentthesecaseshavebeensettledaspartofthe ofmillioninthefiscalfourthquarterofinadditionin septembersettlementdescribedabove maymedtronicpaidmilliontosettleadditionalpatent trialinbostonscientificsuscasebasedonthekastenhofer infringementclaimsassertedbycordisbasedonitsvascularstent patentinfederaldistrictcourtincaliforniaconcludedinoctober patentswhichwasrecordedasacredittootherincomeexpense withajuryfindingthatthepatentwasinvalidthejuryalso netinthefiscalsecondquarterof foundforcordisonitscounterclaimthatsalebybostonscientificof injanuarycordisfiledapatentinfringementaction itsballooncathetersandstentdeliverysystemsinfringecordis againstbostonscientificindelawarefederaldistrictcourtaccus fontirrochepatentthecourthasdeniedbostonscientificspost ingitsexpresstaxusandlibertestentsofinfringingthepal trialmotionsthiscasewassettledaspartoftheseptember mazpatentthatexpiredinnovemberthelibertestentwas settlementdescribedabove alsoaccusedofinfringingcordisgraypatentthatexpiresin inmaycentocorinccentocornowcentocorortho injuneajuryfoundthattheexpresstaxusandliberte biotechinccobifiledalawsuitagainstgenentechincgenen stentsinfringedthepalmazpatentandthatthelibertestentalso techinusdistrictcourtforthecentraldistrictofcaliforniaseek infringedthegraypatentonmarchtheuscourtof ingtoinvalidatethecabillyiipatentpriortofilingsuitcentocor appealsforthefederalcircuitaffirmedthisjudgmentthecase hadasublicenseunderthispatentfromcelltechwhowaslicensed wasremandedtothedistrictcourtforatrialondamagesandwill bygenentechforremicadeandhadbeenpayingroyaltiesto fulnesscordisalsofiledalawsuitindelawarefederaldistrictcourt celltechcentocorhasterminatedthatsublicenseandstoppe inoctoberofallegingthatbostonscientificssalesoftaxus payingroyaltiesgenentechhasfiledacounterclaimallegingthat andliberteafterjuneofinfringescordisgraypatenton remicadeinfringesitscabillyiipatentsandthatthemanufacture januarythesecasestogetherwiththejangcasereferre ofremicadestelarasimponiandreoproalsoinfringe tointheparagraphbelowweresettledunderthetermsoftheset oneofitsotherpatentsrelatingtothepurificationofantibodiesmade tlementbostonscientificpaidcordisbilliononfebruary throughrecombinantdnatechniquesthecourthasscheduleda andwillpaycordisanadditionalmillionplusintereston hearingforsummaryjudgmentmotionsinaugust januarycordisgrantedbostonscientificapaidupworld inaprilabenchtrialwasheldbeforethefederaldistrict widelicenseunderthepalmazandgraypatentsandbostonscien courtforthemiddledistrictoffloridaontheliabilityphaseof tificgrantedcordisapaidupworldwidelicenseunderthejang cibaspatentinfringementlawsuitallegingthatjohnsonjohnson patentsforallstentssoldbycordisexceptthemmsizecypher visioncareincsjjvcacuvueoasyslensesinfringethree cordishasseveralpendinglawsuitsinnewjerseyand oftheirnicholsonpatentsinaugustthedistrictcourtfound delawarefederaldistrictcourtagainstguidantcorporation twoofthesepatentsvalidandinfringedandenteredjudgment guidantabbottlaboratoriesincabbottbostonscientificand againstjjvcjjvchasappealedthatjudgmenttothecourtof medtronicallegingthatthexiencevabbottpromusboston appealsforthefederalcircuitonmarchthedistrict scientificandendeavormedtronicdrugelutingstentsinfringe courtwillholdahearingoncibasmotionforapermanentinjunc severalpatentsownedbyorlicensedtocordisinoneofthecase tionifthejudgmentisupheldonappealthecourtwillschedule againstbostonscientificallegingthatsalesoftheirpromusstent anothertrialtodeterminedamagesandwillfulness infringedwrightandfaloticopatentsonjanuarythe inmayabbottbiotechnologyltdfiledapatentinfringe districtcourtindelawarefoundthewrightfaloticopatentinvalid mentlawsuitagainstcentocornowcobiintheunitedstatesdis forlackofwrittendescriptionandorlackofenablementcordi trictcourtforthedistrictofmassachusettsthesuitallegesthat intendstoappealthisrule centocorssimponiproductahumanantitnfalphaantibody infringesabbottspatentthesalfeldpatentthecaseha patentlitigationagainstvarious beenstayedpendingtheresolutionofanarbitrationfiledbycento johnsonjohnsonsubsidiaries cordirectedtoitsclaimthatitislicensedunderthepatentthe theproductsofvariousjohnsonjohnsonsubsidiariesarethe arbitrationisscheduledformarch subjectofvariouspatentlawsuitstheoutcomesofwhichcould inaugustabbottgmbhcoabbottgmbhand potentiallyadverselyaffecttheabilityofthosesubsidiariestosell abbottbioresearchcenterfiledapatentinfringementlawsuit thoseproductsorrequirethepaymentofpastdamagesand againstcobiintheunitedstatesdistrictcourtforthedistrictof futureroyaltie massachusettsthesuitallegesthatcobisstelaraproduct injulyajuryinfederaldistrictcourtindelawarefound infringestwouspatentsassignedtoabbottgmbhinaugust thatthecordiscypherstentinfringedbostonscientificsding cobifiledacomplaintforadeclaratoryjudgmentofnon patentandthatthecordiscypherandbxvelocity infringementandinvalidityoftheabbottgmbhpatentsinthe stentsalsoinfringedbostonscientificsjangpatentthejury unitedstatesdistrictcourtforthedistrictofcolumbiaonthe alsofoundbothofthosepatentsvalidinjanuarythecourtof samedatealsointheunitedstatesdistrictcourtforthedistrictof johnson johnson annual reportcolumbiacobifiledacomplaintforreviewofapatentinterfer texasonjuneajuryreturnedaverdictfindingthepatent encedecisiongrantingpriorityofinventionononeofthetwo validandwillfullyinfringedandawardedcentocordamagesof assertedpatentstoabbottgmbhinaugustabbottgmbh approximatelybillionabenchtrialonabbottsdefensesof andabbottlaboratorieslimitedbroughtapatentinfringementsuit inequitableconductandprosecutionlacheswasheldinaugust incanadaallegingthatstelarainfringesabbottgmbhscana andthedistrictcourtdecidedtheseissuesinfavorofcento dianpatentthecasesfiledbycobiinthedistrictofcolumbiahave corallofabbottsposttrialmotionshavebeendeniedexceptthat beentransferredtothedistrictofmassachusetts thedistrictcourtgrantedabbottsmotiontooverturnthejuryfind inaugustbayerhealthcarellcfiledsuitagainstcobi ingofwillfulnessjudgmentintheamountofbillionwa inmassachusettsdistrictcourtalleginginfringementbycobis enteredinfavorofcentocorindecemberandabbottha simponiproductofitspatentrelatingtohumanantitnfanti filedanappealtothecourtofappealsforthefederalcircuitthe bodiesbayerhasalsofiledsuitunderitseuropeancounterpartto companyhasnotreflectedanyofthebillioninitsconsolidate thesepatentsingermanyandthenetherland financialstatementscentocorhasalsofiledanewlawsuitinthe injunecentocorsnowcobilawsuitallegingthat easterndistrictoftexasseekingdamagesforinfringementofthe abbottshumiraantitnfalphaproductinfringescentocor patentattributabletosalesofhumirasubsequenttothejury patentwenttotrialinfederaldistrictcourtintheeasterndistrictof verdictinjune thefollowingchartsummarizesvariouspatentlawsuitsconcerningproductsofthecompanyssubsidiariesthathaveyettoproceed totrial jj plaintiff product company patent patentholder court trialdate datefile cypherstent cordis wall wall edtx q cypherstent cordis saffran saffran edtx q bloodglucosemetersandstrip lifescan wilsey rochediagnostics dde remicadeustekinumab centocorcobi cabillyii genentech cdca golimumabreopro simponi centocorcobi salfeld abbottlaboratorie simponi centocorcobi boyle bayerhealthcare stelara centocorcobi salfeld abbottgmbh madc trialdatetobeschedule qreflectsthecompanysfiscalquarter litigationagainstfilersofabbreviatednewdrug noninfringementinvalidityandunenforceabilityofthesepatent applicationsanda intheeventthesubsidiaryofthecompanyinvolvedisnotsuccess thefollowingchartindicateslawsuitspendingagainstgenericfirm fulintheseactionsorthestatutorymonthstayexpiresbeforea thatfiledabbreviatednewdrugapplicationsandasseekingto rulingfromthedistrictcourtisobtainedthefirmsinvolvedwillhave marketgenericformsofproductssoldbyvarioussubsidiariesof theabilityuponfdaapprovaltointroducegenericversionsofthe thecompanypriortoexpirationoftheapplicablepatentscovere productatissueresultinginverysubstantialmarketshareand thoseproductstheseandastypicallyincludeallegationsof revenuelossesfortheproductofthecompanyssubsidiary asnotedinthefollowingchartmonthstaysexpiredduringandwillexpireinandwithrespecttoanda challengesregardingvariousproduct brandname patentnda generic trial date month product holder challenger court date file stayexpiration concerta mcneilppc andrx dde q andmgcontrolle alza kudco dde releasetablet levaquinmgtablet orthomcneil lupin dnj orthotricyclenlo orthomcneil watson dnj mgmgmgmg sandoz dnj andmgmg dnj ultramermgtablet orthomcneilbiovail par dde q ultramermgtablet orthomcneilbiovail impax dde q ultramermgtablet orthomcneilbiovail paddock ddrdminn ultramermgtablet orthomcneilbiovail cipher dde ultramermgtablet orthomcneilbiovail lupin dde trialdatetobeschedule qreflectsthecompanysfiscalquarter note consolidated financial statement intheactionagainstbarrpharmaceuticalsincbarrnowa thedelawaredecisioninvalidatingtherazadyneusepatent whollyownedsubsidiaryoftevapharmaceuticalindustriesltd asaresultthiscasewillnotbereopene regardingorthotricyclenloinjanuarythecom intheactionagainstlupinpharmaceuticalsinclupin panyssubsidiaryorthowomenshealthurologyadivisionof regardingitsandaconcerninglevaquinlupincontendsthat orthomcneiljanssenpharmaceuticalsincomjpiandbarr theuspatentandtrademarkofficeimproperlygrantedapatent agreedtoanonbindingtermsheettosettlethelitigationwhich termextensiontothepatentthatorthomcneilnowortho settlementdiscussionsarestillunderwaythetrialcourtpostpone mcneiljanssenpharmaceuticalsincomjpilicensesfrom thejanuarytrialwithoutsettinganewtrialdateinjune daiichipharmaceuticalsincdaiichilupinallegesthattheactive barrlauncheditsgenericproductatriskbeforetrialomjpi ingredientinlevaquinwasthesubjectofpriormarketingand soughtapreliminaryinjunctionandrecallofbarrproductwhichthe thereforewasnoteligibleforthepatenttermextensionlupincon courtgrantedinjulyinjulythepartiesenteredintoa cedesvalidityandthatitsproductwouldviolatethepatentifmar definitiveagreementtosettlethelawsuitunderthetermsofthe ketedpriortotheexpirationoftheoriginalpatenttermsummary settlementbarrobtainedareleaseforitssalesofitsgenericproduct judgmentagainstlupinwasgrantedinmayandlupin inexchangeforanundisclosedroyaltypaymentbarralsoobtaineda appealedoralargumentwasheldinseptemberadecision nonexclusiveroyaltybearinglicensetoreenterthemarketon ispende decemberorearlierincertainlimitedcircumstance intheultrameractionsorthomcneilpharmaceutical inoctoberthecompanyssubsidiaryomjpifiledsuitin incorthomcneilnowomjpifiledlawsuitseachfordifferent federaldistrictcourtinnewjerseyagainstwatsonlaboratorie dosagesagainstparpharmaceuticalsincandparpharmaceutical incwatsoninresponsetowatsonsandaregardingortho companiesincparinmayjuneandoctoberontwo tricyclenloinjunethecompanyssubsidiaryomjpi tramadolerformulationpatentsownedbypurduepharma filedsuitinfederaldistrictcourtinnewjerseyagainstsandoz productslppurdueandnapppharmaceuticalgroupltdnapp laboratoriesincsandozinresponsetosandozsandaregarde omjpialsofiledlawsuitseachfordifferentdosagesagainstimpax orthotricyclenlothesandozandwatsoncaseshave laboratoriesincimpaxonatramadolerformulationpatent beenconsolidate ownedbypurdueandnappinaugustandnovemberpurdue injanuarythecompanyssubsidiaryomjpifiledsuitin nappandbiovaillaboratoriesinternationalsrlbiovailthenda federaldistrictcourtinnewjerseyagainstlupinltdandlupin holderjoinedascoplaintiffsinthelawsuitsagainstparandimpax pharmaceuticalsinccollectivelylupininresponsetolupin butbiovailandomjpiweresubsequentlydismissedforlackof andaregardingorthotricyclenlo standingthetrialagainstpartookplaceinaprilinaugust intheactionagainstbarrandalphapharmwithrespecttotheir thecourtissuedadecisionfindingthepatentsinsuitinvalid andachallengestotherazadynepatentthatjanssennow purduehasappealedthatdecisionthetrialagainstimpaxissche omjpilicensesfromsynaptechincsynaptechafourdaynon uledforjuneinnovemberthecaseagainstimpaxwa jurytrialwasheldinthefederaldistrictcourtindelawareinmay stayedwiththeconsentofallpartiesinseptemberandoctober inaugustthecourtheldthatthepatentwasinvalid respectivelypurduefiledsuitsagainstpaddocklaboratorie becauseitwasnotenabledjanssenomjpiandsynaptechhave incpaddockandcipherpharmaceuticalsinccipheronits appealedthedecisionsincethecourtsdecisionmultiplegeneric tramadolerformulationpatents companieshavereceivedfinalapprovalsfortheirproductsandhave injanuarypurduefiledasuitagainstlupinltdlupin launchedatriskpendingappealadditionalgenericapprovalsand onitstramadolerformulationpatent launchescouldoccuratanytimeinseptemberthecourtof inseptembercentocororthobiotechproductslp appealsaffirmedthejudgmentthatthepatentisinvalid cobilpintervenedinaninventorshipdisputebetweenkansas intheactionbymcneilppcincmcneilppcandalza universitycenterforresearchkucrinvolvingcertainus corporationalzaagainstandrxcorporationandrxwith governmentownedvelcadeformulationpatentskucrbrought respecttoitsandachallengetotheconcertapatentsafive thisactionagainsttheusgovernmentinthedistrictofkansas daynonjurytrialwasheldinthefederaldistrictcourtindelaware seekingtoaddtwokansasuniversityscientiststothepatent indecemberinmarchthecourtruledthatone theusgovernmentlicensedthepatentsandtheirforeigncoun concertapatentwouldnotbeinfringedbyandrxspropose terpartstomillenniumpharmaceuticalsincwhointurnsubli genericproductandthatthepatentwasinvalidbecauseitwasnot censedthepatentsandtheirforeigncounterpartstocobilp enabledthecourtdismissedwithoutprejudiceandrxsdeclaratory forcommercialmarketingoutsidetheusifkucrsucceedsinits judgmentsuitonasecondpatentforlackofjurisdictionmcneil coinventorshipclaimandestablishescoownershipintheus ppcandalzafiledanappealinmaytheappealscourt velcadeformulationpatentsweanticipatethatkucrwilliniti heardargumentonfebruaryadecisionispende ateactionstoestablishcoinventorshipandcoownershipwith alzaandomjpifiledasecondsuitinfederaldistrictcourtin respecttotheforeigncounterpartpatentsinthecountrieswhere delawareagainstkremersurbanllcandkudcoirelandltd cobilphascommercialmarketingrightsifkucrinkansasis kudcoinjanuaryinresponsetokudcosandachal successfulthismayadverselyaffectcobilpslicenserightsin lengeregardingconcertatabletsinitsnoticeletterkudco thosecountries contendsthattwoalzapatentsforconcertaareinvalidand notinfringedbyakudcogeneric averagewholesalepriceawplitigation intherazadyneercasesalawsuitwasfiledagainstbarr johnsonjohnsonandseveralofitspharmaceuticalsubsidiarie ontherazadyneusepatentthatjanssennowomjpilicense alongwithnumerousotherpharmaceuticalcompaniesaredefen fromsynaptechinjuneinseptembertheabove dantsinaseriesoflawsuitsinstateandfederalcourtsinvolvingalle discusseddelawaredecisioninvalidatingtherazadyneuse gationsthatthepricingandmarketingofcertainpharmaceutical patentresultedinentryofjudgmentforbarronthatpatentbutthe productsamountedtofraudulentandotherwiseactionableconduct casewillbereopenedifjanssennowomjpiandsynaptechwin becauseamongotherthingsthecompaniesallegedlyreportedan onappealbarrhasreceivedfdaapprovalofitsproductandhas inflatedaveragewholesalepriceawpforthedrugsatissue launchedatriskinseptemberthefederalcircuitaffirme manyofthesecasesbothfederalactionsandstateaction johnson johnson annual reportremovedtofederalcourthavebeenconsolidatedforpretrialpur inseptemberplaintiffsinanemploymentdiscrimination posesinamultidistrictlitigationmdlinfederaldistrictcourt litigationinitiatedagainstthecompanyininfederaldistrict inbostonmassachusettstheplaintiffsinthesecasesinclude courtinnewjerseymovedtocertifyaclassofallafricanamerican classesofprivatepersonsorentitiesthatpaidforanyportionofthe andhispanicsalariedemployeesofthecompanyanditsaffiliatesin purchaseofthedrugsatissuebasedonawpandstategovernment theuswhowereemployedatanytimefromnovemberto entitiesthatmademedicaidpaymentsforthedrugsatissuebase thepresentplaintiffsseekmonetarydamagesfortheperiod onawp throughthepresentincludingpunitivedamagesandequitable themdlcourtidentifiedclassesofmassachusettsonlypri reliefthecourtdeniedplaintiffsclasscertificationmotionin vateinsurersprovidingmedigapinsurancecoverageandprivate decemberandtheirmotionforreconsiderationinapril payersforphysicianadministereddrugswherepaymentswere plaintiffssoughttoappealthesedecisionsandinaprilthe basedonawpclassandclassandanationalclassof courtofappealsruledthatplaintiffsappealofthedenialofclass individualswhomadecopaymentsforphysicianadministere certificationwasuntimelyinjulyplaintiffsfiledamotionfor drugscoveredbymedicareclassatrialofthetwomassachu certificationofamodifiedclasswhichthecompanyisoppose settsonlyclassactionsconcludedbeforethemdlcourtindecem plaintiffsareengagedinfurtherdiscoveryofindividualplaintiff berinjunethemdlcourtissuedposttrialruling claimsthehearingonplaintiffsmotionforclasscertificationi dismissingthejohnsonjohnsondefendantsfromthecaseregard scheduledforjuly ingallclaimsofclassesandandsubsequentlyofclassaswell inmarchdepuyorthopaedicsincdepuyajohnson plaintiffsappealedtheclassjudgmentandinseptember johnsonsubsidiaryreceivedasubpoenafromtheusattorneys thecourtofappealsvacatedthejudgmentandremandedfor officedistrictofnewjerseyseekingrecordsconcerningcontrac furtherproceedingsinthedistrictcourtawpcasesbroughtby tualrelationshipsbetweendepuyandsurgeonsorsurgeonsin variousattorneysgeneralhaveproceededtotrialagainstother traininginvolvedinhipandkneereplacementandreconstructive manufacturersonestatecaseagainstcertainofthecompany surgerythisinvestigationwasresolvedbydepuyandthefourother subsidiarieshasbeensetfortrialinlateandotherstatecase leadingsuppliersofhipandkneeimplantsinlateseptember arelikelytobesetfortrialthereafter byagreementswiththeusattorneysofficeforthedistrictof newjerseythesettlementsincludedanmonthdeferredprose cutionagreementdpaacceptancebyeachcompanyofamoni injulycentocornowcobiajohnsonjohnsonsub tortoassurecompliancewiththedpaandwithrespecttofourof sidiaryreceivedarequestthatitvoluntarilyprovidedocumentsand thefivecompaniespaymentofsettlementmoniesandentryinto informationtothecriminaldivisionoftheusattorneysoffice fiveyearcorporateintegrityagreementsdepuypaidmilliona districtofnewjerseyinconnectionwithitsinvestigationintovari itssettlementthetermofthemonitorshipunderthedeferre ouscentocormarketingpracticessubsequentrequestsfordocu prosecutionagreementconcludedonmarchandanorder mentshavebeenreceivedfromtheusattorneysofficeboththe dismissingallchargeswasenteredonmarch companyandcentocorhaverespondedtotheserequestsfor innovembertheattorneygeneralofthecommon documentsandinformation wealthofmassachusettsissuedacivilinvestigativedemandto indecemberorthomcneilnowomjpireceiveda depuyseekinginformationregardingfinancialrelationships subpoenafromtheusattorneysofficeinbostonmassachusett betweenanumberofmassachusettsbasedorthopedicsurgeon seekingdocumentsrelatingtothemarketingincludingallegedoff andprovidersanddepuydepuyisrespondingtomassachusett labelmarketingofthedrugtopamaxtopiramateadditional additionalrequest subpoenasfordocumentshavebeenreceivedandcurrentandfor injulysciosincsciosajohnsonjohnsonsubsidiary meremployeeshavetestifiedbeforeagrandjurydiscussionsare receivedasubpoenafromtheusattorneysofficedistrictofmas underwayinanefforttoresolvethismatterbutwhetheragreement sachusettsseekingdocumentsrelatedtothesalesandmarketingof canbereachedandonwhattermsisuncertain natrecorsciosrespondedtothesubpoenainearlyaugust injanuaryjanssennowomjpireceivedasubpoena scioswasadvisedthattheinvestigationwouldbehandledby fromtheofficeoftheinspectorgeneraloftheusofficeofperson theusattorneysofficeforthenortherndistrictofcaliforniain nelmanagementseekingdocumentsconcerningsalesandmarket sanfranciscoadditionalrequestsfordocumentshavebeenreceive ingofanyandallpaymentstophysiciansinconnectionwithsales andrespondedtoandformersciosemployeeshavetestifiedbeforea andmarketingofandclinicaltrialsforrisperdalrisperidone grandjuryinsanfranciscothequitamcomplaintswereunseale fromtodocumentssubsequenttohavealsobeen onfebruarytheusgovernmenthasintervenedinoneof requestedanadditionalsubpoenaseekinginformationaboutmar thequitamactionsandfiledacomplaintagainstsciosandthecom ketingofandadversereactionstorisperdalwasreceivedfrom panyinjunesciosandjohnsonjohnsonhavefiledamotion theusattorneysofficefortheeasterndistrictofpennsylvaniain todismissthequitamcomplaintfiledbythegovernmentandthat novembersubpoenasseekingtestimonyfromvariouswit motionwasdeniedthecriminalinvestigationiscontinuinganddis nessesbeforeagrandjuryhavealsobeenreceivedjanssenis cussionsareunderwayinanefforttosettlethismatterwhethera cooperatinginrespondingtoongoingrequestsfordocument settlementcanbereachedandonwhattermsisuncertain andwitnessesthegovernmentiscontinuingtoactivelyinvestigate inseptemberthecompanyreceivedasubpoenafrom thismatterinfebruarythegovernmentservedcivilinvestiga theusattorneysofficedistrictofmassachusettsseekingdocu tivedemandsseekingadditionalinformationrelatingtosalesand mentsrelatedtosalesandmarketingofeightdrugstoomnicare marketingofrisperdalandsalesandmarketingofinvega incamanagerofpharmaceuticalbenefitsforlongtermcarefacili inseptemberorthobiotechincorthobiotechnow tiesthejohnsonjohnsonsubsidiariesinvolvedrespondedtothe cobireceivedasubpoenafromtheusofficeofinspectorgen subpoenaseveralemployeesofthecompanyspharmaceutical eralsdenvercoloradofieldofficeseekingdocumentsdirectedto subsidiarieshavebeensubpoenaedtotestifybeforeagrandjury thesalesandmarketingofprocritepoetinalfafrom inconnectionwiththisinvestigationinaprilthecompany tothepresentaswellastodealingswithusoncologyinca wasservedwiththecomplaintsintwocivilquitamcasesrelatedto healthcareservicesnetworkforoncologistsorthobiotechnow marketingofprescriptiondrugstoomnicareinconjanuary cobihasrespondedtothesubpoena note consolidated financial statement thegovernmentfiledacomplaintinterveninginthecase withinthepharmaceuticalsectorbecausethisisasectorinquiry thecomplaintassertsclaimsunderthefederalfalseclaimsactand itisnotbasedonanyspecificallegationthatthecompanyha arelatedstatelawclaiminconnectionwiththemarketingofseveral violatedeccompetitionlawtheinquirybeganwithunannounce drugstoomnicare raidsofasubstantialnumberofpharmaceuticalcompanie innovemberamgenincamgenfiledsuitagainst throughouteuropeincludingjohnsonjohnsonaffiliatesinmarch hoffmannlarocheincrocheintheusdistrictcourtforthe theecissueddetailedquestionnairestoapproximately districtofmassachusettsseekingadeclarationthattheroche companiesincludingjohnsonjohnsonaffiliatesinnovember productcerawhichrochehasindicateditwouldseektointroduce theecissuedapreliminaryreportsummarizingitsfinding intotheunitedstatesinfringesanumberofamgenpatentscon thefinalreportwasissuedonjuly cerningepoamgenlicensesepoforsaleintheunitedstatesto inmarchthecompanyreceivedaletterrequestfrom orthobiotechnowcobifornondialysisindicationstrialinthis theattorneygeneralofthestateofmichigantherequestseek actionconcludedinoctoberwithaverdictinamgensfavor documentsandinformationrelatingtonominalpricetransaction findingthepatentsvalidandinfringedthejudgeissuedaprelimi thecompanyrespondedtotherequestandwillcooperatewiththe naryinjunctionblockingtheceralaunchandsubsequentlymade inquiry theinjunctionpermanentthefederalcircuitupheldtheentryofa injunethecompanyreceivedasubpoenafromthe permanentinjunctionthismatterhasbeensettledpursuanttoan unitedstatesattorneysofficeforthedistrictofmassachusetts agreementbetweenthepartie relatingtothemarketingofbiliarystentsbythecompanyscordis infebruarythecompanyreceivedasubpoenafromthe subsidiarycordisiscooperatinginrespondingtothesubpoena ussecuritiesexchangecommissionsecrequestingdocu inseptembermultilanagmultilananindirectsub mentsrelatingtotheparticipationbyseveraljohnsonjohnson sidiaryofscheringploughcorporationcommencedarbitration subsidiariesintheunitednationsiraqoilforfoodprogramthe againstjanssenpharmaceuticanvforanallegedwrongfultermina subsidiariesarecooperatingwiththesecandusdepartmentof tionofanagreementrelatingtopaymentsinconnectionwithtermi justicedojinproducingresponsivedocument nationofcertainmarketingrightsmultilanseeksdeclaratoryrelief infebruarythecompanyvoluntarilydisclosedtothe specificperformanceanddamagesthiscasewasrecentlysettle dojandthesecthatsubsidiariesoutsidetheunitedstatesare andachargewasrecordedtootherincomeexpensenetinthe believedtohavemadeimproperpaymentsinconnectionwiththe fiscalfourthquarterof saleofmedicaldevicesintwosmallmarketcountrieswhichpay infebruarybasileapharmaceuticaagbasileabrought mentsmayfallwithinthejurisdictionoftheforeigncorruptprac anarbitrationagainstthecompanyandvariousaffiliatesallege ticesactfcpainthecourseofcontinuingdialogueswiththe thatthecompanybreachedthelicenseagreementforcefto agenciesotherissuespotentiallyrisingtotheleveloffcpaviola biprolebyamongotherthingsfailingtosecurefdaapprovalofthe tionsinadditionalmarketshavebeenbroughttotheattentionofthe csssiskinindicationandallegedlyfailingtoproperlydevelopthe agenciesbythecompanythecompanyhasprovidedandwillcon pneumoniaindicationbasileaisseekingtorecoverdamagesanda tinuetoprovideadditionalinformationtothedojandsecandwill declarationthatthecompanymateriallybreachedtheagreement cooperatewiththeagenciesreviewsofthesematterslawenforce thismatterhasbeenscheduledforanarbitrationhearingcom mentagenciesofanumberofothercountriesarealsopursuing mencinginjunefollowedbyposttrialsubmission investigationsofmattersvoluntarilydisclosedbythecompanyto inaprilthecompanyreceivedahippasubpoena thedojandsecdiscussionsareunderwayinanefforttoresolve fromtheusattorneysofficeforthedistrictofmassachusett thesemattersandtheiraqoilforfoodmatterreferencedabovebut bostonseekinginformationregardingthecompanysfinancial whetheragreementcanbereachedandonwhattermsisuncertain relationshipwithseveralpsychiatriststhecompanyisresponde inmarchthecompanyreceivedseparatesubpoena tothisrequ fromtheusattorneysofficeinphiladelphiatheusattorney inaprilorthoclinicaldiagnosticsincocdreceive officeinbostonandtheusattorneysofficeinsanfranciscothe agrandjurysubpoenafromtheusdepartmentofjustice subpoenasrelatetoinvestigationsbythesethreeofficesreference antitrustdivisionrequestingdocumentsandinformationforthe aboveconcerningrespectivelysalesandmarketingofrisperdal periodbeginningseptemberthroughthepresentpertaining byjanssennowomjpitopamaxbyorthomcneilnow toaninvestigationofallegedviolationsoftheantitrustlawsinthe omjpiandnatrecorbysciosthesubpoenasrequestinforma bloodreagentsindustrythecompanyisintheprocessofcomply tionregardingthecompanyscorporatesupervisionandoversight ingwiththesubpoenaintheweeksfollowingthepublicannounce ofthesethreesubsidiariesincludingtheirsalesandmarketingof mentthatocdhadreceivedasubpoenafromtheantitrust thesedrugsthecompanyrespondedtotheserequestsinaddition divisionmultipleclassactioncomplaintswerefiledthevarious theusattorneysofficeinbostonhasissuedsubpoenasforgrand caseswereconsolidatedforpretrialpurposesintheeastern jurytestimonytoseveralemployeesofjohnsonjohnson districtofpennsylvania inmaythenewyorkstateattorneygeneralissueda inmaythenewjerseyattorneygeneralissuedasub subpoenaseekinginformationrelatingtothemarketingandsafety poenatodepuyorthopaedicsincseekinginformationregarde ofprocritthecompanyisrespondingtotheserequest thefinancialinterestofclinicalinvestigatorswhoperformedclinical inaprilthecompanyreceivedtwosubpoenasfromthe studiesfordepuyorthopaedicsincanddepuyspineincthe officeoftheattorneygeneralofthestateofdelawarethesub companyisrespondingtotheserequest poenasseekdocumentsandinformationrelatingtonominalprice inmaycobicommencedanarbitrationproceede agreementsforpurposesofthesubpoenasnominalpricingagree beforetheamericanarbitrationassociationagainstschering mentsaredefinedasagreementsunderwhichthecompanyagreed ploughcorporationanditssubsidiaryscheringploughireland toprovideapharmaceuticalproductforlessthantenpercentofthe companycollectivelyscheringploughcobiandschere averagemanufacturerpricefortheproductthecompany plougharepartiestoaseriesofagreementsthedistribution respondedtotheserequest injanuarytheeuropeancommissionecbeganan industrywideantitrustinquiryconcerningcompetitivecondition johnson johnson annual reportagreementsthatgrantscheringploughtheexclusiverighttodis ofmillionandmillionrelatedtoleaseholdandcontract tributethedrugsremicadeandsimponiworldwideexcept obligationsthemillionofassetwriteoffsrelatetoinventory withintheunitedstatesjapantaiwanindonesiaandthepeople ofmillionrecordedincostofproductssoldpropertyplant republicofchinaincludinghongkongtheterritorycobi andequipmentofmillionintangibleassetsofmillionand distributesremicadeandsimponithenextgeneration otherassetsofmillionadditionallyaspartofthisprogramthe treatmentwithintheunitedstatesinthearbitrationcobi companyplanstoeliminateapproximatelypositionsofwhich seeksadeclarationthattheagreementandmergerbetween approximatelyhavebeeneliminatedsincetherestructure merckcoincmerckandscheringploughconstitutesa wasannounce changeofcontrolunderthetermsofthedistributionagreement thefollowingtablesummarizestheseverancechargesandthe thatpermitscobitoterminatetheagreementsthetermination associatedspendingforthefiscalyearende ofthedistributionagreementswouldreturntocobitheright asset todistributeremicadeandsimponiwithintheterritory dollarsinmillion severance writeoff total scheringploughhasfiledaresponsetocobisarbitrationdemand restructuringcharge thatdeniesthatithasundergoneachangeofcontrolthearbitra currentyearactivity torshavebeenselectedandthematterwillbeproceedingto reservebalance arbitrationinlateseptember january indecemberthestateofisraelshebamedicalcenter filedalawsuitagainstthreeomrixentitiesinthelawsuitthestate cashoutlaysforseveranceareexpectedtobesubstantiallypaidoutoverthenextto monthsinaccordancewiththecompanysplansandlocallaw claimedthatanemployeeofagovernmentownedhospitalwasthe inventoronseveralpatentsrelatedtofibringluetechnologythathe foradditionalinformationontherestructuringasitrelatestothe developedwhilehewasagovernmentemployeethestateclaim segmentsseenote thathehadnorighttotransferanyintellectualpropertytoomrix inthethirdquarterofthecompanyannouncedrestruc becauseitbelongstothestatethestateisseekingdamagesplus turinginitiativesinanefforttoimproveitsoverallcoststructure royaltyonquixilandeviceloralternativelytransferofthe thisactionwastakentooffsettheanticipatednegativeimpact patentstothestate associatedwithgenericcompetitioninthepharmaceuticalsegment inrecentyearsthecompanyhasreceivednumerousrequest andchallengesinthedrugelutingstentmarketthecompanys fromavarietyofunitedstatescongressionalcommitteestopro pharmaceuticalssegmenthasreduceditscostbasebyconsolidat duceinformationrelevanttoongoingcongressionalinquiriesitis ingcertainoperationswhilecontinuingtoinvestinrecently thecompanyspolicytocooperatewiththeseinquiriesbyproduc launchedproductsanditslatestagepipelineofnewproductsthe ingtherequestedinformation cordisfranchisehasmovedtoamoreintegratedbusinessmodelto withrespecttoalltheabovemattersthecompanyandit addressthemarketchangesunderwaywithdrugelutingstentsand subsidiariesarevigorouslycontestingtheallegationsasserte tobetterservethebroadspectrumofitspatientscardiovascular againstthemandotherwisepursuingdefensestomaximizethe needswhilereducingitscostbasethecompanyacceleratedsteps prospectofsuccessthecompanyanditssubsidiariesinvolvedin tostandardizeandstreamlinecertainaspectsofitsenterprisewide thesematterscontinuallyevaluatetheirstrategiesinmanaging functionssuchashumanresourcesfinanceandinformationtech thesemattersandwhereappropriatepursuesettlementsandother nologytosupportgrowthacrossthebusinesswhilealsoleverage resolutionswherethoseareinthebestinterestofthecompany itsscalemoreeffectivelyinareassuchasprocurementtobenefitit thecompanyisalsoinvolvedinanumberofotherpatent operatingcompaniesadditionallyaspartofthisprogramthe trademarkandotherlawsuitsincidentaltoitsbusinesstheulti companyeliminatedapproximatelypositions matelegalandfinancialliabilityofthecompanyinrespecttoall thecompanyrecordedmillioninrelatedpretaxcharge claimslawsuitsandproceedingsreferredtoabovecannotbeesti duringthefiscalthirdquarterofofwhichapproximately matedwithanycertaintyhoweverinthecompanysopinionbase millionofthepretaxrestructuringchargesrequiredcashpayment onitsexaminationofthesemattersitsexperiencetodateanddis themillionofrestructuringchargesconsistsofseverancecost cussionswithcounseltheultimateoutcomeoflegalproceeding ofmillionassetwriteoffsofmillionandmillion netofliabilitiesaccruedinthecompanysbalancesheetisnot relatedtoleaseholdobligationsthemillionofassetwriteoffs expectedtohaveamaterialadverseeffectonthecompanysfinan relatetopropertyplantandequipmentofmillionintangible cialconditionalthoughtheresolutioninanyreportingperiodofone assetsofmillionandotherassetsofmilliontherestructur ormoreofthesematterscouldhaveasignificantimpactonthe inginitiativeannouncedinhasbeencomplete companysresultsofoperationsandcashflowsforthatperiod subsequentevent restructure onjanuarythecompanycompletedtheacquisitionof inthefourthquarterofthecompanyannouncedglobal acclarentincforanetpurchasepriceofapproximatelymil restructuringinitiativesdesignedtostrengthenthecompanysposi lionacclarentincisamedicaltechnologycompanydedicatedto tionasoneoftheworldsleadingglobalhealthcarecompaniesthis designingdevelopingandcommercializingdevicesthataddress programwillallowthecompanytoinvestinnewgrowthplatform conditionsaffectingtheearnoseandthroat ensurethesuccessfullaunchofitsmanynewproductsandcontin thecompanyhasperformedanevaluationofsubsequent uedgrowthofitscorebusinessesandprovideflexibilitytoadjustto eventsthroughmarchthedatethecompanyissuedthese thechangedandevolvingglobalenvironment financialstatement duringthefiscalfourthquarterofthecompany recordedbillioninrelatedpretaxchargesofwhichapproxi matelymillionofthepretaxrestructuringchargesare expectedtorequirecashpaymentsthebillionofrestructure chargesconsistsofseverancecostsofmillionassetwriteoff note consolidated financial statement reportofindependentregisteredpublicaccountingfirm totheshareholdersandboardofdirectorsofjohnsonjohnson controlbasedontheassessedriskourauditsalsoincludedper formingsuchotherproceduresasweconsiderednecessaryinthe inouropiniontheaccompanyingconsolidatedbalancesheetsand circumstanceswebelievethatourauditsprovideareasonable therelatedconsolidatedstatementsofearningsstatementsof basisforouropinion equityandstatementsofcashflowspresentfairlyinallmaterial asdiscussedinnotetotheconsolidatedfinancialstatement respectsthefinancialpositionofjohnsonjohnsonanditssub thecompanychangedthemannerinwhichitaccountsforbusiness sidiariesthecompanyatjanuaryanddecember combinationsin andtheresultsoftheiroperationsandtheircashflowsfor acompanysinternalcontroloverfinancialreportingisa eachofthethreeyearsintheperiodendedjanuaryincon processdesignedtoprovidereasonableassuranceregardingthe formitywithaccountingprinciplesgenerallyacceptedintheunite reliabilityoffinancialreportingandthepreparationoffinancial statesofamericaalsoinouropinionthecompanymaintainedin statementsforexternalpurposesinaccordancewithgenerally allmaterialrespectseffectiveinternalcontroloverfinancialreport acceptedaccountingprinciplesacompanysinternalcontrolover ingasofjanuarybasedoncriteriaestablishedininternal financialreportingincludesthosepoliciesandproceduresthati controlintegratedframeworkissuedbythecommitteeofspon pertaintothemaintenanceofrecordsthatinreasonabledetail soringorganizationsofthetreadwaycommissioncosothe accuratelyandfairlyreflectthetransactionsanddispositionsofthe companysmanagementisresponsibleforthesefinancialstate assetsofthecompanyiiprovidereasonableassurancethattrans mentsformaintainingeffectiveinternalcontroloverfinancial actionsarerecordedasnecessarytopermitpreparationoffinancial reportingandforitsassessmentoftheeffectivenessofinternalcon statementsinaccordancewithgenerallyacceptedaccountingprin troloverfinancialreportingincludedintheaccompanyingman ciplesandthatreceiptsandexpendituresofthecompanyarebee agementsreportoninternalcontroloverfinancialreportingour madeonlyinaccordancewithauthorizationsofmanagementand responsibilityistoexpressopinionsonthesefinancialstatement directorsofthecompanyandiiiprovidereasonableassurance andonthecompanysinternalcontroloverfinancialreporte regardingpreventionortimelydetectionofunauthorizedacquisi basedonourintegratedauditsweconductedourauditsinaccor tionuseordispositionofthecompanysassetsthatcouldhavea dancewiththestandardsofthepubliccompanyaccountingover materialeffectonthefinancialstatement sightboardunitedstatesthosestandardsrequirethatweplan becauseofitsinherentlimitationsinternalcontroloverfinan andperformtheauditstoobtainreasonableassuranceabout cialreportingmaynotpreventordetectmisstatementsalsopro whetherthefinancialstatementsarefreeofmaterialmisstatement jectionsofanyevaluationofeffectivenesstofutureperiodsare andwhethereffectiveinternalcontroloverfinancialreportingwa subjecttotheriskthatcontrolsmaybecomeinadequatebecauseof maintainedinallmaterialrespectsourauditsofthefinancialstate changesinconditionsorthatthedegreeofcompliancewiththe mentsincludedexaminingonatestbasisevidencesupportingthe policiesorproceduresmaydeteriorate amountsanddisclosuresinthefinancialstatementsassessingthe accountingprinciplesusedandsignificantestimatesmadebyman agementandevaluatingtheoverallfinancialstatementpresenta tionourauditofinternalcontroloverfinancialreportingincluded obtaininganunderstandingofinternalcontroloverfinancialreport ingassessingtheriskthatamaterialweaknessexistsandtesting newyorknewyork andevaluatingthedesignandoperatingeffectivenessofinternal march johnson johnson annual reportmanagementsreportoninternalcontroloverfinancialreporte undersectionofthesarbanesoxleyactofmanage establishedbythecommitteeofsponsoringorganizationsofthe mentisrequiredtoassesstheeffectivenessofthecompanysinter treadwaycommissioncosoininternalcontrolintegrate nalcontroloverfinancialreportingasoftheendofeachfiscalyear frameworkthesecriteriaareintheareasofcontrolenvironment andreportbasedonthatassessmentwhetherthecompany riskassessmentcontrolactivitiesinformationandcommunication internalcontroloverfinancialreportingiseffective andmonitoringthecompanysassessmentincludedextensive managementofthecompanyisresponsibleforestablishing documentingevaluatingandtestingthedesignandoperatingeffec andmaintainingadequateinternalcontroloverfinancialreporte tivenessofitsinternalcontrolsoverfinancialreporte thecompanysinternalcontroloverfinancialreportingisdesigne basedonthecompanysprocessesandassessmenta toprovidereasonableassuranceastothereliabilityofthecompany describedabovemanagementhasconcludedthatasofjanuary financialreportingandthepreparationofexternalfinancialstate thecompanysinternalcontroloverfinancialreporting mentsinaccordancewithgenerallyacceptedaccountingprinciple waseffective internalcontrolsoverfinancialreportingnomatterhowwell theeffectivenessofthecompanysinternalcontrolover designedhaveinherentlimitationsthereforeinternalcontrolover financialreportingasofjanuaryhasbeenauditedby financialreportingdeterminedtobeeffectivecanprovideonly pricewaterhousecoopersllpanindependentregisteredpublic reasonableassurancewithrespecttofinancialstatementprepara accountingfirmasstatedintheirreportwhichappearsherein tionandmaynotpreventordetectallmisstatementsmoreover projectionsofanyevaluationofeffectivenesstofutureperiodsare subjecttotheriskthatcontrolsmaybecomeinadequatebecause ofchangesinconditionsorthatthedegreeofcompliancewiththe policiesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessof williamcweldon dominicjcaruso thecompanysinternalcontroloverfinancialreportingasofjanuary chairmanboardofdirector vicepresidentfinance inmakingthisassessmentthecompanyusedthecriteria andchiefexecutiveofficer andchieffinancialofficer management report internal control financial reporting summaryofoperationsandstatisticaldata dollarsinmillionsexceptpersharefigure salestocustomerus salestocustomerinternational totalsale costofproductssold sellingmarketingandadministrativeexpense researchexpense purchasedinprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalize otherincomeexpensenet restructure earningsbeforeprovisionfortaxesonincome provisionfortaxesonincome netearning percentofsalestocustomer dilutednetearningspershareofcommonstock percentreturnonaverageshareholdersequity percentincreasedecreaseoverpreviousyear salestocustomer dilutednetearningspershare supplementaryexpensedata costofmaterialsandservice totalemploymentcost depreciationandamortization maintenanceandrepairs totaltaxexpense supplementarybalancesheetdata propertyplantandequipmentnet additionstopropertyplantandequipment totalasset longtermdebt operatingcashflow commonstockinformation dividendspaidpershare shareholdersequitypershare marketpricepershareyearendclose averagesharesoutstandingmillionsbasic diluted employeesthousand netofinterestandotherincome alsoincludedincostofmaterialsandservicescategory includestaxesonincomepayrollpropertyandotherbusinesstaxe summary operation statistical datashareholderreturnperformancegraph shareholoder return performance graph reconciliationofnongaapfinancialmeasure thetablesbelowareprovidedtoreconcilecertainfinancialdisclosuresinthelettertoshareholderspage vs vs dollarsinmillionsexceptpersharedata change change earningsbeforeprovisionfortaxesonincomeasreporte purchasedinprocessresearchdevelopmentiprd netgainonfourthquarterlitigation restructuringexpense natrecorintangibleassetwritedown earningsbeforeprovisionfortaxesonincomeasadjuste netearningsasreported purchasedinprocessresearchdevelopmentiprd netgainonfourthquarterlitigation restructuringexpense natrecorintangibleassetwritedown internationaltaxgainonrestructure netearningsasadjuste dilutednetearningspershareasreporte purchasedinprocessresearchdevelopmentiprd netgainonfourthquarterlitigation restructuringexpense natrecorintangibleassetwritedown internationaltaxgainonrestructuring dilutednetearningspershareasadjuste vs vs dollarsinmillion change change netcashflowsfromoperatingactivities additionstopropertyplantandequipment freecashflow thecompanybelievesinvestorsgainadditionalperspectiveofunderlyingbusinesstrendsandresultsbyprovidingfreecashflowameasure ofearningsbeforetaxnetearningsanddilutednetearningspersharethatexcludesiprdchargesandotherspecialitemsinordertoeval uateongoingbusinessoperationsthesenongaapfinancialmeasuresshouldnotbeconsideredreplacementsforandshouldberead togetherwiththemostcomparablegaapfinancialmeasure reconciliation nongaap financial measuresprincip al office company require file exhibit dividend reinvestment plan johnson johnson plaza fiscal year certifica plan allow partial new brunswick new jersey tions section sarbanesoxley dividend reinvestment additional monthly act sign chief executive officer cash investment year chief financial officer addition johnson johnson common stock annual meeting company require submit certifica brokerage commission service charge annual meeting shareholder tion sign chief executive officer stock purchase interested place april hyatt regency new york stock exchange day participate plan need authoriza new brunswick albany street new brunswick follow annual meeting shareholder tion form andor information new jersey meeting convene copy certification file previous computershare trust company na shareholder cordially invite attend year post company corporate formal notice meet proxy statement governance web site future certification outside proxy send shareholder post promptly filing hearing imp air corporate governance common stock shareholder inquiry copy company annual report list new york stock exchange stockrelate matter communicate directly quarterly report form q stock symbol jnj computershare trust company na current report form k telecommunications device tdd securities exchange commission shareholder rela tions contact telephone number service proxy statement annual report steven rosenberg available online wwwinvestorjnjcom corporate secretary outside secfilingscfm shareholder charge write request secretary register shareholder wish receive investor relation contact company principal address call electronic notice online access future louise mehrotra annual report proxy material instead vice president investor relation paper copy register online addition company corporate governance web site wwwcomputersharenacomgreen wwwinvestorjnjcomgovernancecfm beneficial johnson johnson shareholders transfer gent gistrar shareholder view company question stock holding shares broker bank principle corporate governance certificate replacementtransfer dividend register online delivery charter audit committee address change direct material go compensation benefit committee computershare trust company na httpenrollicsdeliverycomjnj nominate corporate governance royall street johnson johnson web committee policy business conduct canton company website wwwjnjcom employee code business conduct ethic member board outside online annual report director executive officer wwwcomputersharecom wwwinvestorjnjcom annualreport copy document available company blog wwwjnjbtwcom shareholder charge write paper publication johnson johnson history blog postconsumer recycle fiber request secretary companys forest stewardship council certify chain custody wwwkilmerhousecom principal address manufacture green energy credit purchase electricity generate renewableenergy source facebook follow johnson johnson wind lowimpact hydro resources network twitter jnjcomm youtube wwwyoutubecomjnjhealth johnson johnson follow trademark trade name johnson johnson affilia ted company appear report day acuvue trueye acclarent aciphexpariet active natural active naturals institute active photobarrier complex acuvue trueye aveeno biosense webster bx velocity carto cellsearch centocor ortho biotech centocor research development charit clean clear concerta cordis cougar biotechnology cypher depuy depuy institute depuy orthopaedics dabao diabetes care institute duragesic earthward enseal ethicon ethicon endosurgery evicel feverfew pfe finsbury orthopaedic flex hd gloster europe harmonic helioplex intelence invega invega sustenna janssen alzheimer immunotherapy janssencilag johnson johnson johnson johnson consumer group company johnson johnson diabetes institute johnson johnson pharmaceutical research development johnsons le petit marseillais levaquinfloxin lifescan listerine mcneil nutritionals memorygel mentor natrecor neutrogena nucynta oasys orthoclinical diagnostic ortho evra ortho tricyclen lo pinnacle complete prezista priligy procriteprex propulsid quixil razadyne reach realize remicade reopro risperdal risperdal consta roc sedasys silent simponi skin d splenda stelara sun crystal surgiflo tibotec tibotec pharmaceutical tibotecvirco virology bvba topamax truvu ultram er vania expansion veridex vision care institute xianjanssen pharmaceutical follow trademark trade name comp anie appear report academy educational development american academy dermatology american society plastic surgeon bayer healthcare ag rivaroxaban child worms cleveland clinic crucell elan forest stewardship council gilead sciences global alliance tb drug development good housekeeping grnenthal mayo clinic memorial sloankettere cancer center merck co mitsubishi tanabe pharma national childrens oral health foundation pfizer prix galien royal marsden hospital siemen healthcare diagnostic task force global health terracycle tianjin medical university cancer hospital agency international development food drug administration velcade millennium takeda oncology company world wildlife fund nucynta codevelope grnenthal gmbh centocor ortho biotech inc marketing right remicade xianjanssen pharmaceutical ltd markets product china janssencilag hong kong distribution agreement place merck co inc mitsubishi tanabe pharma corporation market world corporate shareholder informationour c r e believe responsibility doctor nurse patient mother father use product service meeting need high quality constantly strive reduce cost order maintain reasonable price customer order service promptly accurately supplier distributor opportunity fair profit responsible employee man woman work world consider individual respect dignity recognize merit sense security job compensation fair adequate working condition clean orderly safe mindful way help employee fulfill family responsibility employee feel free suggestion complaint equal opportunity employment development advancement qualified provide competent management action ethical responsible community live work world community good citizenssupport good work charity bear fair share taxis encourage civic improvement well health education maintain good order property privileged use protect environment natural resource final responsibility stockholder business sound profit experiment new idea research carry innovative program develop mistake pay new equipment purchase new facility provide new product launch reserve create provide adverse time operate accord principle stockholder realize fair return